id	sid	tid	token	lemma	pos
ajlm-939	1	1	abstract	abstract	ADJ
ajlm-939	1	2	introduction	introduction	NOUN
ajlm-939	1	3	methods	method	NOUN
ajlm-939	1	4	results	result	VERB
ajlm-939	1	5	discussion	discussion	NOUN
ajlm-939	1	6	acknowledgements	acknowledgement	NOUN
ajlm-939	1	7	references	reference	NOUN
ajlm-939	1	8	about	about	ADP
ajlm-939	1	9	the	the	DET
ajlm-939	1	10	author(s	author(s	NOUN
ajlm-939	1	11	)	)	PUNCT
ajlm-939	1	12	rodgers	rodger	VERB
ajlm-939	1	13	n.	n.	PROPN
ajlm-939	1	14	demba	demba	PROPN
ajlm-939	1	15	school	school	PROPN
ajlm-939	1	16	of	of	ADP
ajlm-939	1	17	health	health	PROPN
ajlm-939	1	18	sciences	sciences	PROPN
ajlm-939	1	19	,	,	PUNCT
ajlm-939	1	20	kisii	kisii	PROPN
ajlm-939	1	21	university	university	PROPN
ajlm-939	1	22	,	,	PUNCT
ajlm-939	1	23	kisii	kisii	PROPN
ajlm-939	1	24	,	,	PUNCT
ajlm-939	1	25	kenya	kenya	PROPN
ajlm-939	1	26	institute	institute	PROPN
ajlm-939	1	27	of	of	ADP
ajlm-939	1	28	tropical	tropical	ADJ
ajlm-939	1	29	and	and	CCONJ
ajlm-939	1	30	infectious	infectious	ADJ
ajlm-939	1	31	diseases	disease	NOUN
ajlm-939	1	32	,	,	PUNCT
ajlm-939	1	33	university	university	NOUN
ajlm-939	1	34	of	of	ADP
ajlm-939	1	35	nairobi	nairobi	PROPN
ajlm-939	1	36	,	,	PUNCT
ajlm-939	1	37	nairobi	nairobi	PROPN
ajlm-939	1	38	,	,	PUNCT
ajlm-939	1	39	kenya	kenya	PROPN
ajlm-939	1	40	sylviah	sylviah	PROPN
ajlm-939	1	41	m.	m.	PROPN
ajlm-939	1	42	aradi	aradi	PROPN
ajlm-939	1	43	department	department	PROPN
ajlm-939	1	44	of	of	ADP
ajlm-939	1	45	internal	internal	ADJ
ajlm-939	1	46	medicine	medicine	NOUN
ajlm-939	1	47	,	,	PUNCT
ajlm-939	1	48	university	university	PROPN
ajlm-939	1	49	of	of	ADP
ajlm-939	1	50	nairobi	nairobi	PROPN
ajlm-939	1	51	,	,	PUNCT
ajlm-939	1	52	nairobi	nairobi	PROPN
ajlm-939	1	53	,	,	PUNCT
ajlm-939	1	54	kenya	kenya	PROPN
ajlm-939	1	55	matilu	matilu	PROPN
ajlm-939	1	56	mwau	mwau	PROPN
ajlm-939	1	57	center	center	PROPN
ajlm-939	1	58	for	for	ADP
ajlm-939	1	59	infectious	infectious	ADJ
ajlm-939	1	60	and	and	CCONJ
ajlm-939	1	61	parasitic	parasitic	ADJ
ajlm-939	1	62	diseases	disease	NOUN
ajlm-939	1	63	control	control	PROPN
ajlm-939	1	64	research	research	PROPN
ajlm-939	1	65	,	,	PUNCT
ajlm-939	1	66	kenya	kenya	PROPN
ajlm-939	1	67	medical	medical	PROPN
ajlm-939	1	68	research	research	PROPN
ajlm-939	1	69	institute	institute	PROPN
ajlm-939	1	70	,	,	PUNCT
ajlm-939	1	71	busia	busia	PROPN
ajlm-939	1	72	,	,	PUNCT
ajlm-939	1	73	kenya	kenya	PROPN
ajlm-939	1	74	walter	walter	PROPN
ajlm-939	1	75	o.	o.	PROPN
ajlm-939	1	76	mwanda	mwanda	PROPN
ajlm-939	1	77	institute	institute	PROPN
ajlm-939	1	78	of	of	ADP
ajlm-939	1	79	tropical	tropical	ADJ
ajlm-939	1	80	and	and	CCONJ
ajlm-939	1	81	infectious	infectious	ADJ
ajlm-939	1	82	diseases	disease	NOUN
ajlm-939	1	83	,	,	PUNCT
ajlm-939	1	84	university	university	NOUN
ajlm-939	1	85	of	of	ADP
ajlm-939	1	86	nairobi	nairobi	PROPN
ajlm-939	1	87	,	,	PUNCT
ajlm-939	1	88	nairobi	nairobi	PROPN
ajlm-939	1	89	,	,	PUNCT
ajlm-939	1	90	kenya	kenya	PROPN
ajlm-939	1	91	citation	citation	PROPN
ajlm-939	1	92	demba	demba	PROPN
ajlm-939	1	93	rn	rn	PROPN
ajlm-939	1	94	,	,	PUNCT
ajlm-939	1	95	aradi	aradi	PROPN
ajlm-939	1	96	sm	sm	PROPN
ajlm-939	1	97	,	,	PUNCT
ajlm-939	1	98	mwau	mwau	PROPN
ajlm-939	1	99	m	m	PROPN
ajlm-939	1	100	,	,	PUNCT
ajlm-939	1	101	mwanda	mwanda	PROPN
ajlm-939	1	102	wo	will	AUX
ajlm-939	1	103	.	.	PUNCT
ajlm-939	2	1	kaposi	kaposi	PROPN
ajlm-939	2	2	’s	’s	PART
ajlm-939	2	3	sarcoma	sarcoma	NOUN
ajlm-939	2	4	-	-	PUNCT
ajlm-939	2	5	associated	associate	VERB
ajlm-939	2	6	herpesvirus	herpesvirus	NOUN
ajlm-939	2	7	protein	protein	NOUN
ajlm-939	2	8	orf75	orf75	ADJ
ajlm-939	2	9	among	among	ADP
ajlm-939	2	10	hiv-1	hiv-1	X
ajlm-939	2	11	patients	patient	NOUN
ajlm-939	2	12	in	in	ADP
ajlm-939	2	13	kenya	kenya	PROPN
ajlm-939	2	14	.	.	PUNCT
ajlm-939	3	1	afr	afr	PROPN
ajlm-939	3	2	j	j	PROPN
ajlm-939	3	3	lab	lab	PROPN
ajlm-939	3	4	med	me	VERB
ajlm-939	3	5	.	.	PUNCT
ajlm-939	3	6	2020;9(1	2020;9(1	NUM
ajlm-939	3	7	)	)	PUNCT
ajlm-939	3	8	,	,	PUNCT
ajlm-939	3	9	a939	a939	PROPN
ajlm-939	3	10	.	.	PUNCT
ajlm-939	4	1	https://doi.org/10.4102/ajlm.v9i1.939	https://doi.org/10.4102/ajlm.v9i1.939	PROPN
ajlm-939	4	2	original	original	ADJ
ajlm-939	4	3	research	research	PROPN
ajlm-939	4	4	kaposi	kaposi	PROPN
ajlm-939	4	5	’s	’s	PART
ajlm-939	4	6	sarcoma	sarcoma	NOUN
ajlm-939	4	7	-	-	PUNCT
ajlm-939	4	8	associated	associate	VERB
ajlm-939	4	9	herpesvirus	herpesvirus	NOUN
ajlm-939	4	10	protein	protein	NOUN
ajlm-939	4	11	orf75	orf75	ADJ
ajlm-939	4	12	among	among	ADP
ajlm-939	4	13	hiv-1	hiv-1	X
ajlm-939	4	14	patients	patient	NOUN
ajlm-939	4	15	in	in	ADP
ajlm-939	4	16	kenya	kenya	PROPN
ajlm-939	4	17	rodgers	rodger	VERB
ajlm-939	4	18	n.	n.	PROPN
ajlm-939	4	19	demba	demba	PROPN
ajlm-939	4	20	,	,	PUNCT
ajlm-939	4	21	sylviah	sylviah	PROPN
ajlm-939	4	22	m.	m.	PROPN
ajlm-939	4	23	aradi	aradi	PROPN
ajlm-939	4	24	,	,	PUNCT
ajlm-939	4	25	matilu	matilu	NOUN
ajlm-939	4	26	mwau	mwau	PROPN
ajlm-939	4	27	,	,	PUNCT
ajlm-939	4	28	walter	walter	PROPN
ajlm-939	4	29	o.	o.	PROPN
ajlm-939	4	30	mwanda	mwanda	PROPN
ajlm-939	4	31	received	receive	VERB
ajlm-939	4	32	:	:	PUNCT
ajlm-939	4	33	01	01	NUM
ajlm-939	4	34	dec	dec	PROPN
ajlm-939	4	35	.	.	PROPN
ajlm-939	4	36	2018	2018	NUM
ajlm-939	4	37	;	;	PUNCT
ajlm-939	4	38	accepted	accept	VERB
ajlm-939	4	39	:	:	PUNCT
ajlm-939	4	40	15	15	NUM
ajlm-939	4	41	may	may	PROPN
ajlm-939	4	42	2020	2020	NUM
ajlm-939	4	43	;	;	PUNCT
ajlm-939	4	44	published	publish	VERB
ajlm-939	4	45	:	:	PUNCT
ajlm-939	4	46	25	25	NUM
ajlm-939	4	47	aug	aug	PROPN
ajlm-939	4	48	.	.	PROPN
ajlm-939	4	49	2020	2020	NUM
ajlm-939	5	1	copyright	copyright	NOUN
ajlm-939	5	2	:	:	PUNCT
ajlm-939	5	3	©	©	PROPN
ajlm-939	5	4	2020	2020	NUM
ajlm-939	5	5	.	.	PUNCT
ajlm-939	6	1	the	the	DET
ajlm-939	6	2	author(s	author(s	PROPN
ajlm-939	6	3	)	)	PUNCT
ajlm-939	6	4	.	.	PUNCT
ajlm-939	7	1	licensee	licensee	NOUN
ajlm-939	7	2	:	:	PUNCT
ajlm-939	7	3	aosis	aosis	NOUN
ajlm-939	7	4	.	.	PUNCT
ajlm-939	8	1	this	this	PRON
ajlm-939	8	2	is	be	AUX
ajlm-939	8	3	an	an	DET
ajlm-939	8	4	open	open	ADJ
ajlm-939	8	5	access	access	NOUN
ajlm-939	8	6	article	article	NOUN
ajlm-939	8	7	distributed	distribute	VERB
ajlm-939	8	8	under	under	ADP
ajlm-939	8	9	the	the	DET
ajlm-939	8	10	terms	term	NOUN
ajlm-939	8	11	of	of	ADP
ajlm-939	8	12	the	the	DET
ajlm-939	8	13	creative	creative	ADJ
ajlm-939	8	14	commons	common	NOUN
ajlm-939	8	15	attribution	attribution	NOUN
ajlm-939	8	16	license	license	NOUN
ajlm-939	8	17	,	,	PUNCT
ajlm-939	8	18	which	which	PRON
ajlm-939	8	19	permits	permit	VERB
ajlm-939	8	20	unrestricted	unrestricted	ADJ
ajlm-939	8	21	use	use	NOUN
ajlm-939	8	22	,	,	PUNCT
ajlm-939	8	23	distribution	distribution	NOUN
ajlm-939	8	24	,	,	PUNCT
ajlm-939	8	25	and	and	CCONJ
ajlm-939	8	26	reproduction	reproduction	NOUN
ajlm-939	8	27	in	in	ADP
ajlm-939	8	28	any	any	DET
ajlm-939	8	29	medium	medium	NOUN
ajlm-939	8	30	,	,	PUNCT
ajlm-939	8	31	provided	provide	VERB
ajlm-939	8	32	the	the	DET
ajlm-939	8	33	original	original	ADJ
ajlm-939	8	34	work	work	NOUN
ajlm-939	8	35	is	be	AUX
ajlm-939	8	36	properly	properly	ADV
ajlm-939	8	37	cited	cite	VERB
ajlm-939	8	38	.	.	PUNCT
ajlm-939	9	1	abstract	abstract	ADJ
ajlm-939	9	2	background	background	NOUN
ajlm-939	9	3	:	:	PUNCT
ajlm-939	9	4	histology	histology	NOUN
ajlm-939	9	5	is	be	AUX
ajlm-939	9	6	used	use	VERB
ajlm-939	9	7	to	to	PART
ajlm-939	9	8	identify	identify	VERB
ajlm-939	9	9	kaposi	kaposi	PROPN
ajlm-939	9	10	’s	’s	PART
ajlm-939	9	11	sarcoma	sarcoma	NOUN
ajlm-939	9	12	(	(	PUNCT
ajlm-939	9	13	ks	ks	NOUN
ajlm-939	9	14	)	)	PUNCT
ajlm-939	9	15	in	in	ADP
ajlm-939	9	16	countries	country	NOUN
ajlm-939	9	17	with	with	ADP
ajlm-939	9	18	low	low	ADJ
ajlm-939	9	19	resources	resource	NOUN
ajlm-939	9	20	to	to	PART
ajlm-939	9	21	fund	fund	VERB
ajlm-939	9	22	healthcare	healthcare	NOUN
ajlm-939	9	23	costs	cost	NOUN
ajlm-939	9	24	.	.	PUNCT
ajlm-939	10	1	approximately	approximately	ADV
ajlm-939	10	2	95	95	NUM
ajlm-939	10	3	%	%	NOUN
ajlm-939	10	4	of	of	ADP
ajlm-939	10	5	ks	ks	NOUN
ajlm-939	10	6	cases	case	NOUN
ajlm-939	10	7	can	can	AUX
ajlm-939	10	8	be	be	AUX
ajlm-939	10	9	detected	detect	VERB
ajlm-939	10	10	using	use	VERB
ajlm-939	10	11	a	a	DET
ajlm-939	10	12	polymerase	polymerase	NOUN
ajlm-939	10	13	chain	chain	NOUN
ajlm-939	10	14	reaction	reaction	NOUN
ajlm-939	10	15	.	.	PUNCT
ajlm-939	11	1	objective	objective	NOUN
ajlm-939	11	2	:	:	PUNCT
ajlm-939	11	3	to	to	PART
ajlm-939	11	4	determine	determine	VERB
ajlm-939	11	5	the	the	DET
ajlm-939	11	6	presence	presence	NOUN
ajlm-939	11	7	of	of	ADP
ajlm-939	11	8	the	the	DET
ajlm-939	11	9	open	open	ADJ
ajlm-939	11	10	reading	reading	NOUN
ajlm-939	11	11	frame	frame	NOUN
ajlm-939	11	12	75	75	NUM
ajlm-939	11	13	(	(	PUNCT
ajlm-939	11	14	orf75	orf75	ADJ
ajlm-939	11	15	)	)	PUNCT
ajlm-939	11	16	gene	gene	NOUN
ajlm-939	11	17	associated	associate	VERB
ajlm-939	11	18	with	with	ADP
ajlm-939	11	19	kaposi	kaposi	PROPN
ajlm-939	11	20	’s	’s	PART
ajlm-939	11	21	sarcoma	sarcoma	NOUN
ajlm-939	11	22	herpes	herpe	NOUN
ajlm-939	11	23	virus	virus	NOUN
ajlm-939	11	24	among	among	ADP
ajlm-939	11	25	hiv-1	hiv-1	X
ajlm-939	11	26	/	/	SYM
ajlm-939	11	27	aids	aid	NOUN
ajlm-939	11	28	patients	patient	NOUN
ajlm-939	11	29	and	and	CCONJ
ajlm-939	11	30	to	to	PART
ajlm-939	11	31	describe	describe	VERB
ajlm-939	11	32	morphological	morphological	ADJ
ajlm-939	11	33	presentations	presentation	NOUN
ajlm-939	11	34	of	of	ADP
ajlm-939	11	35	ks	ks	PROPN
ajlm-939	11	36	.	.	PROPN
ajlm-939	11	37	methods	method	NOUN
ajlm-939	11	38	:	:	PUNCT
ajlm-939	11	39	this	this	PRON
ajlm-939	11	40	was	be	AUX
ajlm-939	11	41	a	a	DET
ajlm-939	11	42	retrospective	retrospective	ADJ
ajlm-939	11	43	,	,	PUNCT
ajlm-939	11	44	descriptive	descriptive	ADJ
ajlm-939	11	45	study	study	NOUN
ajlm-939	11	46	of	of	ADP
ajlm-939	11	47	archived	archive	VERB
ajlm-939	11	48	tissue	tissue	NOUN
ajlm-939	11	49	blocks	block	NOUN
ajlm-939	11	50	collected	collect	VERB
ajlm-939	11	51	from	from	ADP
ajlm-939	11	52	2013	2013	NUM
ajlm-939	11	53	to	to	ADP
ajlm-939	11	54	2016	2016	NUM
ajlm-939	11	55	.	.	PUNCT
ajlm-939	12	1	haematoxylin	haematoxylin	NOUN
ajlm-939	12	2	and	and	CCONJ
ajlm-939	12	3	eosin	eosin	NOUN
ajlm-939	12	4	staining	stain	VERB
ajlm-939	12	5	was	be	AUX
ajlm-939	12	6	used	use	VERB
ajlm-939	12	7	to	to	PART
ajlm-939	12	8	identify	identify	VERB
ajlm-939	12	9	ks	ks	PROPN
ajlm-939	12	10	.	.	PROPN
ajlm-939	12	11	deoxyribonucleic	deoxyribonucleic	ADJ
ajlm-939	12	12	acid	acid	NOUN
ajlm-939	12	13	from	from	ADP
ajlm-939	12	14	archived	archive	VERB
ajlm-939	12	15	tissue	tissue	NOUN
ajlm-939	12	16	blocks	block	NOUN
ajlm-939	12	17	was	be	AUX
ajlm-939	12	18	extracted	extract	VERB
ajlm-939	12	19	and	and	CCONJ
ajlm-939	12	20	a	a	DET
ajlm-939	12	21	nested	nested	ADJ
ajlm-939	12	22	polymerase	polymerase	NOUN
ajlm-939	12	23	chain	chain	NOUN
ajlm-939	12	24	reaction	reaction	NOUN
ajlm-939	12	25	was	be	AUX
ajlm-939	12	26	used	use	VERB
ajlm-939	12	27	to	to	PART
ajlm-939	12	28	detect	detect	VERB
ajlm-939	12	29	the	the	DET
ajlm-939	12	30	orf75	orf75	ADJ
ajlm-939	12	31	gene	gene	NOUN
ajlm-939	12	32	.	.	PUNCT
ajlm-939	13	1	results	result	NOUN
ajlm-939	13	2	:	:	PUNCT
ajlm-939	13	3	all	all	DET
ajlm-939	13	4	81	81	NUM
ajlm-939	13	5	cases	case	NOUN
ajlm-939	13	6	in	in	ADP
ajlm-939	13	7	this	this	DET
ajlm-939	13	8	study	study	NOUN
ajlm-939	13	9	had	have	AUX
ajlm-939	13	10	been	be	AUX
ajlm-939	13	11	diagnosed	diagnose	VERB
ajlm-939	13	12	as	as	ADP
ajlm-939	13	13	hiv-1	hiv-1	PUNCT
ajlm-939	13	14	positive	positive	ADJ
ajlm-939	13	15	,	,	PUNCT
ajlm-939	13	16	of	of	ADP
ajlm-939	13	17	which	which	PRON
ajlm-939	13	18	68	68	NUM
ajlm-939	13	19	had	have	VERB
ajlm-939	13	20	hallmark	hallmark	ADJ
ajlm-939	13	21	features	feature	NOUN
ajlm-939	13	22	of	of	ADP
ajlm-939	13	23	ks	ks	PROPN
ajlm-939	13	24	in	in	ADP
ajlm-939	13	25	the	the	DET
ajlm-939	13	26	histology	histology	NOUN
ajlm-939	13	27	report	report	NOUN
ajlm-939	13	28	and	and	CCONJ
ajlm-939	13	29	13	13	NUM
ajlm-939	13	30	had	have	VERB
ajlm-939	13	31	features	feature	NOUN
ajlm-939	13	32	suggestive	suggestive	ADJ
ajlm-939	13	33	of	of	ADP
ajlm-939	13	34	ks	ks	PROPN
ajlm-939	13	35	(	(	PUNCT
ajlm-939	13	36	‘	'	PUNCT
ajlm-939	13	37	ks	ks	NOUN
ajlm-939	13	38	-	-	PUNCT
ajlm-939	13	39	like	like	ADJ
ajlm-939	13	40	’	'	PUNCT
ajlm-939	13	41	)	)	PUNCT
ajlm-939	13	42	.	.	PUNCT
ajlm-939	14	1	microscopic	microscopic	ADJ
ajlm-939	14	2	identification	identification	NOUN
ajlm-939	14	3	of	of	ADP
ajlm-939	14	4	ks	ks	PROPN
ajlm-939	14	5	by	by	ADP
ajlm-939	14	6	haematoxylin	haematoxylin	NOUN
ajlm-939	14	7	and	and	CCONJ
ajlm-939	14	8	eosin	eosin	NOUN
ajlm-939	14	9	staining	stain	VERB
ajlm-939	14	10	was	be	AUX
ajlm-939	14	11	considered	consider	VERB
ajlm-939	14	12	a	a	DET
ajlm-939	14	13	significant	significant	ADJ
ajlm-939	14	14	indicator	indicator	NOUN
ajlm-939	14	15	of	of	ADP
ajlm-939	14	16	ks	ks	PROPN
ajlm-939	14	17	herpes	herpe	NOUN
ajlm-939	14	18	virus	virus	NOUN
ajlm-939	14	19	orf75	orf75	ADJ
ajlm-939	14	20	gene	gene	NOUN
ajlm-939	14	21	positivity	positivity	NOUN
ajlm-939	14	22	(	(	PUNCT
ajlm-939	14	23	p	p	NOUN
ajlm-939	14	24	=	=	NOUN
ajlm-939	14	25	0.002	0.002	NUM
ajlm-939	14	26	)	)	PUNCT
ajlm-939	14	27	.	.	PUNCT
ajlm-939	15	1	the	the	DET
ajlm-939	15	2	orf75	orf75	ADJ
ajlm-939	15	3	gene	gene	NOUN
ajlm-939	15	4	was	be	AUX
ajlm-939	15	5	detected	detect	VERB
ajlm-939	15	6	in	in	ADP
ajlm-939	15	7	60.5	60.5	NUM
ajlm-939	15	8	%	%	NOUN
ajlm-939	15	9	(	(	PUNCT
ajlm-939	15	10	49/81	49/81	NUM
ajlm-939	15	11	)	)	PUNCT
ajlm-939	15	12	of	of	ADP
ajlm-939	15	13	tissue	tissue	NOUN
ajlm-939	15	14	blocks	block	NOUN
ajlm-939	15	15	;	;	PUNCT
ajlm-939	15	16	27.2	27.2	NUM
ajlm-939	15	17	%	%	NOUN
ajlm-939	15	18	were	be	AUX
ajlm-939	15	19	men	man	NOUN
ajlm-939	15	20	(	(	PUNCT
ajlm-939	15	21	22/81	22/81	NUM
ajlm-939	15	22	)	)	PUNCT
ajlm-939	15	23	and	and	CCONJ
ajlm-939	15	24	33.3	33.3	NUM
ajlm-939	15	25	%	%	NOUN
ajlm-939	15	26	were	be	AUX
ajlm-939	15	27	women	woman	NOUN
ajlm-939	15	28	(	(	PUNCT
ajlm-939	15	29	27/81	27/81	NUM
ajlm-939	15	30	)	)	PUNCT
ajlm-939	15	31	.	.	PUNCT
ajlm-939	16	1	the	the	DET
ajlm-939	16	2	orf75	orf75	ADJ
ajlm-939	16	3	gene	gene	NOUN
ajlm-939	16	4	was	be	AUX
ajlm-939	16	5	observed	observe	VERB
ajlm-939	16	6	to	to	PART
ajlm-939	16	7	be	be	AUX
ajlm-939	16	8	present	present	ADJ
ajlm-939	16	9	in	in	ADP
ajlm-939	16	10	up	up	ADP
ajlm-939	16	11	to	to	PART
ajlm-939	16	12	15.4	15.4	NUM
ajlm-939	16	13	%	%	NOUN
ajlm-939	16	14	(	(	PUNCT
ajlm-939	16	15	2/13	2/13	NUM
ajlm-939	16	16	)	)	PUNCT
ajlm-939	16	17	of	of	ADP
ajlm-939	16	18	the	the	DET
ajlm-939	16	19	cases	case	NOUN
ajlm-939	16	20	reported	report	VERB
ajlm-939	16	21	to	to	PART
ajlm-939	16	22	have	have	VERB
ajlm-939	16	23	ks	ks	NOUN
ajlm-939	16	24	-	-	PUNCT
ajlm-939	16	25	like	like	ADJ
ajlm-939	16	26	features	feature	NOUN
ajlm-939	16	27	.	.	PUNCT
ajlm-939	17	1	conclusion	conclusion	NOUN
ajlm-939	17	2	:	:	PUNCT
ajlm-939	17	3	following	follow	VERB
ajlm-939	17	4	the	the	DET
ajlm-939	17	5	initial	initial	ADJ
ajlm-939	17	6	diagnosis	diagnosis	NOUN
ajlm-939	17	7	of	of	ADP
ajlm-939	17	8	ks	ks	NOUN
ajlm-939	17	9	by	by	ADP
ajlm-939	17	10	histology	histology	NOUN
ajlm-939	17	11	,	,	PUNCT
ajlm-939	17	12	the	the	DET
ajlm-939	17	13	orf75	orf75	ADJ
ajlm-939	17	14	gene	gene	NOUN
ajlm-939	17	15	was	be	AUX
ajlm-939	17	16	fur	fur	NOUN
ajlm-939	17	17	-	-	PUNCT
ajlm-939	17	18	ther	ther	NOUN
ajlm-939	17	19	detected	detect	VERB
ajlm-939	17	20	from	from	ADP
ajlm-939	17	21	both	both	DET
ajlm-939	17	22	cases	case	NOUN
ajlm-939	17	23	that	that	PRON
ajlm-939	17	24	had	have	VERB
ajlm-939	17	25	hallmark	hallmark	ADJ
ajlm-939	17	26	features	feature	NOUN
ajlm-939	17	27	of	of	ADP
ajlm-939	17	28	ks	ks	PROPN
ajlm-939	17	29	as	as	ADV
ajlm-939	17	30	well	well	ADV
ajlm-939	17	31	as	as	ADP
ajlm-939	17	32	among	among	ADP
ajlm-939	17	33	cases	case	NOUN
ajlm-939	17	34	with	with	ADP
ajlm-939	17	35	ks	ks	NOUN
ajlm-939	17	36	-	-	PUNCT
ajlm-939	17	37	like	like	ADJ
ajlm-939	17	38	fea	fea	NOUN
ajlm-939	17	39	-	-	NOUN
ajlm-939	17	40	tures	ture	NOUN
ajlm-939	17	41	.	.	PUNCT
ajlm-939	18	1	keywords	keyword	NOUN
ajlm-939	18	2	:	:	PUNCT
ajlm-939	18	3	human	human	ADJ
ajlm-939	18	4	herpes	herpe	NOUN
ajlm-939	18	5	virus	virus	NOUN
ajlm-939	18	6	8	8	NUM
ajlm-939	18	7	;	;	PUNCT
ajlm-939	18	8	kaposi	kaposi	PROPN
ajlm-939	18	9	’s	’s	PART
ajlm-939	18	10	sarcoma	sarcoma	NOUN
ajlm-939	18	11	;	;	PUNCT
ajlm-939	18	12	histology	histology	NOUN
ajlm-939	18	13	;	;	PUNCT
ajlm-939	18	14	nested	nested	ADJ
ajlm-939	18	15	pcr	pcr	PROPN
ajlm-939	18	16	;	;	PUNCT
ajlm-939	18	17	orf75	orf75	ADJ
ajlm-939	18	18	gene	gene	NOUN
ajlm-939	18	19	.	.	PUNCT
ajlm-939	19	1	introduction	introduction	NOUN
ajlm-939	19	2	kaposi	kaposi	PROPN
ajlm-939	19	3	sarcoma	sarcoma	PROPN
ajlm-939	19	4	(	(	PUNCT
ajlm-939	19	5	ks	ks	NOUN
ajlm-939	19	6	)	)	PUNCT
ajlm-939	19	7	is	be	AUX
ajlm-939	19	8	a	a	DET
ajlm-939	19	9	tumor	tumor	NOUN
ajlm-939	19	10	formed	form	VERB
ajlm-939	19	11	from	from	ADP
ajlm-939	19	12	blood	blood	NOUN
ajlm-939	19	13	vessels	vessel	NOUN
ajlm-939	19	14	;	;	PUNCT
ajlm-939	19	15	it	it	PRON
ajlm-939	19	16	later	later	ADV
ajlm-939	19	17	shows	show	VERB
ajlm-939	19	18	lesions	lesion	NOUN
ajlm-939	19	19	on	on	ADP
ajlm-939	19	20	the	the	DET
ajlm-939	19	21	skin	skin	NOUN
ajlm-939	19	22	or	or	CCONJ
ajlm-939	19	23	organs	organ	NOUN
ajlm-939	19	24	of	of	ADP
ajlm-939	19	25	hiv	hiv	PROPN
ajlm-939	19	26	-	-	PUNCT
ajlm-939	19	27	positive	positive	ADJ
ajlm-939	19	28	people.1	people.1	PROPN
ajlm-939	19	29	all	all	DET
ajlm-939	19	30	forms	form	NOUN
ajlm-939	19	31	of	of	ADP
ajlm-939	19	32	ks	k	NOUN
ajlm-939	19	33	are	be	AUX
ajlm-939	19	34	caused	cause	VERB
ajlm-939	19	35	by	by	ADP
ajlm-939	19	36	kaposi	kaposi	PROPN
ajlm-939	19	37	’s	’s	PART
ajlm-939	19	38	sarcoma	sarcoma	NOUN
ajlm-939	19	39	herpesvirus	herpesvirus	NOUN
ajlm-939	19	40	(	(	PUNCT
ajlm-939	19	41	kshv	kshv	PROPN
ajlm-939	19	42	)	)	PUNCT
ajlm-939	19	43	,	,	PUNCT
ajlm-939	19	44	also	also	ADV
ajlm-939	19	45	known	know	VERB
ajlm-939	19	46	as	as	ADP
ajlm-939	19	47	human	human	ADJ
ajlm-939	19	48	herpesvirus	herpesvirus	NOUN
ajlm-939	19	49	8	8	NUM
ajlm-939	19	50	(	(	PUNCT
ajlm-939	19	51	hhv-8).2,3	hhv-8).2,3	VERB
ajlm-939	19	52	the	the	DET
ajlm-939	19	53	genome	genome	NOUN
ajlm-939	19	54	of	of	ADP
ajlm-939	19	55	hhv-8	hhv-8	PUNCT
ajlm-939	19	56	contains	contain	VERB
ajlm-939	19	57	a	a	DET
ajlm-939	19	58	minimum	minimum	NOUN
ajlm-939	19	59	of	of	ADP
ajlm-939	19	60	100	100	NUM
ajlm-939	19	61	open	open	ADJ
ajlm-939	19	62	reading	reading	NOUN
ajlm-939	19	63	frames	frame	NOUN
ajlm-939	19	64	(	(	PUNCT
ajlm-939	19	65	orf	orf	PROPN
ajlm-939	19	66	)	)	PUNCT
ajlm-939	19	67	,	,	PUNCT
ajlm-939	19	68	of	of	ADP
ajlm-939	19	69	which	which	PRON
ajlm-939	19	70	4	4	NUM
ajlm-939	19	71	to	to	PART
ajlm-939	19	72	75	75	NUM
ajlm-939	19	73	are	be	AUX
ajlm-939	19	74	known	know	VERB
ajlm-939	19	75	to	to	PART
ajlm-939	19	76	be	be	AUX
ajlm-939	19	77	unique	unique	ADJ
ajlm-939	19	78	to	to	ADP
ajlm-939	19	79	herpesvirus.4	herpesvirus.4	PROPN
ajlm-939	19	80	the	the	DET
ajlm-939	19	81	kshv	kshv	NOUN
ajlm-939	19	82	genome	genome	NOUN
ajlm-939	19	83	encodes	encode	NOUN
ajlm-939	19	84	more	more	ADJ
ajlm-939	19	85	than	than	ADP
ajlm-939	19	86	84	84	NUM
ajlm-939	19	87	proteins	protein	NOUN
ajlm-939	19	88	that	that	PRON
ajlm-939	19	89	play	play	VERB
ajlm-939	19	90	a	a	DET
ajlm-939	19	91	role	role	NOUN
ajlm-939	19	92	in	in	ADP
ajlm-939	19	93	viral	viral	ADJ
ajlm-939	19	94	replication	replication	NOUN
ajlm-939	19	95	and	and	CCONJ
ajlm-939	19	96	host	host	NOUN
ajlm-939	19	97	-	-	PUNCT
ajlm-939	19	98	virus	virus	NOUN
ajlm-939	19	99	interaction.5	interaction.5	NOUN
ajlm-939	19	100	the	the	DET
ajlm-939	19	101	replication	replication	NOUN
ajlm-939	19	102	cycle	cycle	NOUN
ajlm-939	19	103	of	of	ADP
ajlm-939	19	104	kshv	kshv	PROPN
ajlm-939	19	105	entails	entail	VERB
ajlm-939	19	106	latent	latent	NOUN
ajlm-939	19	107	and	and	CCONJ
ajlm-939	19	108	lytic	lytic	ADJ
ajlm-939	19	109	phases	phase	NOUN
ajlm-939	19	110	.	.	PUNCT
ajlm-939	20	1	during	during	ADP
ajlm-939	20	2	the	the	DET
ajlm-939	20	3	lytic	lytic	ADJ
ajlm-939	20	4	cycle	cycle	NOUN
ajlm-939	20	5	,	,	PUNCT
ajlm-939	20	6	the	the	DET
ajlm-939	20	7	orf75	orf75	ADJ
ajlm-939	20	8	genes	gene	NOUN
ajlm-939	20	9	are	be	AUX
ajlm-939	20	10	expressed	express	VERB
ajlm-939	20	11	resulting	result	VERB
ajlm-939	20	12	in	in	ADP
ajlm-939	20	13	the	the	DET
ajlm-939	20	14	manifestation	manifestation	NOUN
ajlm-939	20	15	of	of	ADP
ajlm-939	20	16	ks.6,7	ks.6,7	PROPN
ajlm-939	20	17	the	the	DET
ajlm-939	20	18	orf75	orf75	ADJ
ajlm-939	20	19	gene	gene	NOUN
ajlm-939	20	20	product	product	NOUN
ajlm-939	20	21	has	have	AUX
ajlm-939	20	22	been	be	AUX
ajlm-939	20	23	proven	prove	VERB
ajlm-939	20	24	to	to	PART
ajlm-939	20	25	aid	aid	VERB
ajlm-939	20	26	in	in	ADP
ajlm-939	20	27	lytic	lytic	ADJ
ajlm-939	20	28	replication	replication	NOUN
ajlm-939	20	29	and	and	CCONJ
ajlm-939	20	30	enhancement	enhancement	NOUN
ajlm-939	20	31	of	of	ADP
ajlm-939	20	32	virus	virus	NOUN
ajlm-939	20	33	pathogenesis	pathogenesis	NOUN
ajlm-939	20	34	in	in	ADP
ajlm-939	20	35	host	host	NOUN
ajlm-939	20	36	cells.8	cells.8	PROPN
ajlm-939	20	37	kaposi	kaposi	PROPN
ajlm-939	20	38	’s	’s	PART
ajlm-939	20	39	sarcoma	sarcoma	NOUN
ajlm-939	20	40	is	be	AUX
ajlm-939	20	41	listed	list	VERB
ajlm-939	20	42	among	among	ADP
ajlm-939	20	43	the	the	DET
ajlm-939	20	44	defining	define	VERB
ajlm-939	20	45	malignancies	malignancy	NOUN
ajlm-939	20	46	of	of	ADP
ajlm-939	20	47	hiv	hiv	PROPN
ajlm-939	20	48	/	/	SYM
ajlm-939	20	49	aids.9,10,11	aids.9,10,11	NOUN
ajlm-939	20	50	the	the	DET
ajlm-939	20	51	dis	dis	PROPN
ajlm-939	20	52	-	-	PUNCT
ajlm-939	20	53	tinct	tinct	ADJ
ajlm-939	20	54	feature	feature	NOUN
ajlm-939	20	55	of	of	ADP
ajlm-939	20	56	hiv	hiv	PROPN
ajlm-939	20	57	-	-	PUNCT
ajlm-939	20	58	associated	associate	VERB
ajlm-939	20	59	ks	ks	NOUN
ajlm-939	20	60	is	be	AUX
ajlm-939	20	61	that	that	SCONJ
ajlm-939	20	62	it	it	PRON
ajlm-939	20	63	might	might	AUX
ajlm-939	20	64	affect	affect	VERB
ajlm-939	20	65	the	the	DET
ajlm-939	20	66	lymph	lymph	NOUN
ajlm-939	20	67	nodes	node	NOUN
ajlm-939	20	68	,	,	PUNCT
ajlm-939	20	69	gastrointestinal	gastrointestinal	ADJ
ajlm-939	20	70	tract	tract	NOUN
ajlm-939	20	71	,	,	PUNCT
ajlm-939	20	72	lungs	lung	NOUN
ajlm-939	20	73	or	or	CCONJ
ajlm-939	20	74	liv	liv	NOUN
ajlm-939	20	75	-	-	PUNCT
ajlm-939	20	76	er.12,13	er.12,13	PROPN
ajlm-939	20	77	despite	despite	SCONJ
ajlm-939	20	78	the	the	DET
ajlm-939	20	79	fact	fact	NOUN
ajlm-939	20	80	that	that	SCONJ
ajlm-939	20	81	saliva	saliva	NOUN
ajlm-939	20	82	is	be	AUX
ajlm-939	20	83	the	the	DET
ajlm-939	20	84	main	main	ADJ
ajlm-939	20	85	route	route	NOUN
ajlm-939	20	86	by	by	ADP
ajlm-939	20	87	which	which	PRON
ajlm-939	20	88	kshv	kshv	PROPN
ajlm-939	20	89	is	be	AUX
ajlm-939	20	90	transmitted,14	transmitted,14	ADV
ajlm-939	20	91	hhv-8	hhv-8	NUM
ajlm-939	20	92	has	have	AUX
ajlm-939	20	93	been	be	AUX
ajlm-939	20	94	isolated	isolate	VERB
ajlm-939	20	95	from	from	ADP
ajlm-939	20	96	other	other	ADJ
ajlm-939	20	97	body	body	NOUN
ajlm-939	20	98	fluids.14,15,16	fluids.14,15,16	VERB
ajlm-939	20	99	the	the	DET
ajlm-939	20	100	main	main	ADJ
ajlm-939	20	101	route	route	NOUN
ajlm-939	20	102	of	of	ADP
ajlm-939	20	103	hhv-8	hhv-8	NOUN
ajlm-939	20	104	transmission	transmission	NOUN
ajlm-939	20	105	to	to	ADP
ajlm-939	20	106	the	the	DET
ajlm-939	20	107	opposite	opposite	ADJ
ajlm-939	20	108	sex	sex	NOUN
ajlm-939	20	109	is	be	AUX
ajlm-939	20	110	through	through	ADP
ajlm-939	20	111	sexual	sexual	ADJ
ajlm-939	20	112	relations.17	relations.17	NOUN
ajlm-939	20	113	the	the	DET
ajlm-939	20	114	pathogenesis	pathogenesis	NOUN
ajlm-939	20	115	of	of	ADP
ajlm-939	20	116	ks	ks	PROPN
ajlm-939	20	117	presents	present	NOUN
ajlm-939	20	118	as	as	ADP
ajlm-939	20	119	an	an	DET
ajlm-939	20	120	abnormal	abnormal	ADJ
ajlm-939	20	121	neoangiogenesis	neoangiogenesis	NOUN
ajlm-939	20	122	,	,	PUNCT
ajlm-939	20	123	proliferation	proliferation	NOUN
ajlm-939	20	124	of	of	ADP
ajlm-939	20	125	cancer	cancer	NOUN
ajlm-939	20	126	cells	cell	NOUN
ajlm-939	20	127	and	and	CCONJ
ajlm-939	20	128	inflammation	inflammation	NOUN
ajlm-939	20	129	of	of	ADP
ajlm-939	20	130	endothelial	endothelial	NOUN
ajlm-939	20	131	cells.18	cells.18	VERB
ajlm-939	20	132	a	a	DET
ajlm-939	20	133	classic	classic	ADJ
ajlm-939	20	134	ks	ks	NOUN
ajlm-939	20	135	lesion	lesion	NOUN
ajlm-939	20	136	manifests	manifest	VERB
ajlm-939	20	137	various	various	ADJ
ajlm-939	20	138	features	feature	NOUN
ajlm-939	20	139	ranging	range	VERB
ajlm-939	20	140	from	from	ADP
ajlm-939	20	141	maculopapular	maculopapular	ADJ
ajlm-939	20	142	to	to	ADP
ajlm-939	20	143	nodular	nodular	ADJ
ajlm-939	20	144	or	or	CCONJ
ajlm-939	20	145	plaque	plaque	NOUN
ajlm-939	20	146	-	-	PUNCT
ajlm-939	20	147	like	like	NOUN
ajlm-939	20	148	and	and	CCONJ
ajlm-939	20	149	,	,	PUNCT
ajlm-939	20	150	in	in	ADP
ajlm-939	20	151	most	most	ADJ
ajlm-939	20	152	cases	case	NOUN
ajlm-939	20	153	,	,	PUNCT
ajlm-939	20	154	is	be	AUX
ajlm-939	20	155	pain	pain	NOUN
ajlm-939	20	156	-	-	PUNCT
ajlm-939	20	157	less.12,19,20,21	less.12,19,20,21	ADJ
ajlm-939	20	158	in	in	ADP
ajlm-939	20	159	sub	sub	ADJ
ajlm-939	20	160	-	-	ADJ
ajlm-939	20	161	saharan	saharan	ADJ
ajlm-939	20	162	africa	africa	PROPN
ajlm-939	20	163	,	,	PUNCT
ajlm-939	20	164	kshv	kshv	PROPN
ajlm-939	20	165	is	be	AUX
ajlm-939	20	166	endemic	endemic	ADJ
ajlm-939	20	167	and	and	CCONJ
ajlm-939	20	168	approximately	approximately	ADV
ajlm-939	20	169	84	84	NUM
ajlm-939	20	170	%	%	NOUN
ajlm-939	20	171	of	of	ADP
ajlm-939	20	172	worldwide	worldwide	ADJ
ajlm-939	20	173	cases	case	NOUN
ajlm-939	20	174	of	of	ADP
ajlm-939	20	175	ks	k	NOUN
ajlm-939	20	176	occur	occur	VERB
ajlm-939	20	177	in	in	ADP
ajlm-939	20	178	this	this	DET
ajlm-939	20	179	region.22	region.22	NOUN
ajlm-939	20	180	since	since	SCONJ
ajlm-939	20	181	ks	ks	PROPN
ajlm-939	20	182	is	be	AUX
ajlm-939	20	183	common	common	ADJ
ajlm-939	20	184	among	among	ADP
ajlm-939	20	185	hiv	hiv	PROPN
ajlm-939	20	186	/	/	SYM
ajlm-939	20	187	aids	aids	PROPN
ajlm-939	20	188	pa	pa	PROPN
ajlm-939	20	189	-	-	PUNCT
ajlm-939	20	190	tients,13	tients,13	VERB
ajlm-939	20	191	early	early	ADJ
ajlm-939	20	192	detection	detection	NOUN
ajlm-939	20	193	of	of	ADP
ajlm-939	20	194	kshv	kshv	PROPN
ajlm-939	20	195	is	be	AUX
ajlm-939	20	196	essential	essential	ADJ
ajlm-939	20	197	in	in	ADP
ajlm-939	20	198	disease	disease	NOUN
ajlm-939	20	199	monitoring.22	monitoring.22	VERB
ajlm-939	20	200	the	the	DET
ajlm-939	20	201	sensitivity	sensitivity	NOUN
ajlm-939	20	202	of	of	ADP
ajlm-939	20	203	diagnostic	diagnostic	ADJ
ajlm-939	20	204	tests	test	NOUN
ajlm-939	20	205	for	for	ADP
ajlm-939	20	206	detection	detection	NOUN
ajlm-939	20	207	of	of	ADP
ajlm-939	20	208	kshv	kshv	PROPN
ajlm-939	20	209	depends	depend	VERB
ajlm-939	20	210	on	on	ADP
ajlm-939	20	211	the	the	DET
ajlm-939	20	212	sample	sample	NOUN
ajlm-939	20	213	selected	select	VERB
ajlm-939	20	214	for	for	ADP
ajlm-939	20	215	analysis.23	analysis.23	PROPN
ajlm-939	20	216	for	for	ADP
ajlm-939	20	217	example	example	NOUN
ajlm-939	20	218	,	,	PUNCT
ajlm-939	20	219	biopsies	biopsy	NOUN
ajlm-939	20	220	obtained	obtain	VERB
ajlm-939	20	221	from	from	ADP
ajlm-939	20	222	patients	patient	NOUN
ajlm-939	20	223	with	with	ADP
ajlm-939	20	224	hiv	hiv	PROPN
ajlm-939	20	225	/	/	SYM
ajlm-939	20	226	aids	aids	PROPN
ajlm-939	20	227	-	-	PUNCT
ajlm-939	20	228	ks	ks	PROPN
ajlm-939	20	229	were	be	AUX
ajlm-939	20	230	found	find	VERB
ajlm-939	20	231	to	to	PART
ajlm-939	20	232	yield	yield	VERB
ajlm-939	20	233	better	well	ADJ
ajlm-939	20	234	results	result	NOUN
ajlm-939	20	235	compared	compare	VERB
ajlm-939	20	236	to	to	ADP
ajlm-939	20	237	using	use	VERB
ajlm-939	20	238	peripheral	peripheral	ADJ
ajlm-939	20	239	blood	blood	NOUN
ajlm-939	20	240	mononuclear	mononuclear	ADJ
ajlm-939	20	241	cells	cell	NOUN
ajlm-939	20	242	from	from	ADP
ajlm-939	20	243	the	the	DET
ajlm-939	20	244	same	same	ADJ
ajlm-939	20	245	patient.23	patient.23	NOUN
ajlm-939	20	246	identification	identification	NOUN
ajlm-939	20	247	of	of	ADP
ajlm-939	20	248	ks	ks	PROPN
ajlm-939	20	249	in	in	ADP
ajlm-939	20	250	tissue	tissue	NOUN
ajlm-939	20	251	biopsies	biopsy	NOUN
ajlm-939	20	252	by	by	ADP
ajlm-939	20	253	use	use	NOUN
ajlm-939	20	254	of	of	ADP
ajlm-939	20	255	histological	histological	ADJ
ajlm-939	20	256	staining	stain	VERB
ajlm-939	20	257	techniques	technique	NOUN
ajlm-939	20	258	should	should	AUX
ajlm-939	20	259	not	not	PART
ajlm-939	20	260	be	be	AUX
ajlm-939	20	261	underestimated.24	underestimated.24	NOUN
ajlm-939	20	262	in	in	ADP
ajlm-939	20	263	tissue	tissue	NOUN
ajlm-939	20	264	biopsies	biopsy	NOUN
ajlm-939	20	265	,	,	PUNCT
ajlm-939	20	266	microscopic	microscopic	ADJ
ajlm-939	20	267	examination	examination	NOUN
ajlm-939	20	268	involves	involve	VERB
ajlm-939	20	269	identification	identification	NOUN
ajlm-939	20	270	of	of	ADP
ajlm-939	20	271	proliferated	proliferated	ADJ
ajlm-939	20	272	spindle	spindle	NOUN
ajlm-939	20	273	cells	cell	NOUN
ajlm-939	20	274	and	and	CCONJ
ajlm-939	20	275	oedema.25	oedema.25	NOUN
ajlm-939	20	276	clinical	clinical	ADJ
ajlm-939	20	277	diagnoses	diagnosis	NOUN
ajlm-939	20	278	of	of	ADP
ajlm-939	20	279	ks	ks	PROPN
ajlm-939	20	280	have	have	AUX
ajlm-939	20	281	been	be	AUX
ajlm-939	20	282	shown	show	VERB
ajlm-939	20	283	to	to	PART
ajlm-939	20	284	have	have	VERB
ajlm-939	20	285	limited	limit	VERB
ajlm-939	20	286	predictive	predictive	ADJ
ajlm-939	20	287	value.26	value.26	NOUN
ajlm-939	20	288	the	the	DET
ajlm-939	20	289	use	use	NOUN
ajlm-939	20	290	of	of	ADP
ajlm-939	20	291	molecular	molecular	ADJ
ajlm-939	20	292	techniques	technique	NOUN
ajlm-939	20	293	such	such	ADJ
ajlm-939	20	294	as	as	ADP
ajlm-939	20	295	polymerase	polymerase	NOUN
ajlm-939	20	296	chain	chain	NOUN
ajlm-939	20	297	reaction	reaction	NOUN
ajlm-939	20	298	(	(	PUNCT
ajlm-939	20	299	pcr	pcr	NOUN
ajlm-939	20	300	)	)	PUNCT
ajlm-939	20	301	permits	permit	VERB
ajlm-939	20	302	the	the	DET
ajlm-939	20	303	detection	detection	NOUN
ajlm-939	20	304	of	of	ADP
ajlm-939	20	305	the	the	DET
ajlm-939	20	306	hhv-8	hhv-8	NUM
ajlm-939	20	307	gene	gene	NOUN
ajlm-939	20	308	even	even	ADV
ajlm-939	20	309	for	for	ADP
ajlm-939	20	310	patients	patient	NOUN
ajlm-939	20	311	who	who	PRON
ajlm-939	20	312	present	present	VERB
ajlm-939	20	313	with	with	ADP
ajlm-939	20	314	early	early	ADJ
ajlm-939	20	315	vascular	vascular	ADJ
ajlm-939	20	316	lesions	lesion	NOUN
ajlm-939	20	317	that	that	PRON
ajlm-939	20	318	histological	histological	ADJ
ajlm-939	20	319	techniques	technique	NOUN
ajlm-939	20	320	might	might	AUX
ajlm-939	20	321	miss.27	miss.27	VERB
ajlm-939	20	322	the	the	DET
ajlm-939	20	323	use	use	NOUN
ajlm-939	20	324	of	of	ADP
ajlm-939	20	325	pcr	pcr	NOUN
ajlm-939	20	326	in	in	ADP
ajlm-939	20	327	the	the	DET
ajlm-939	20	328	diagnosis	diagnosis	NOUN
ajlm-939	20	329	of	of	ADP
ajlm-939	20	330	ks	ks	NOUN
ajlm-939	20	331	can	can	AUX
ajlm-939	20	332	detect	detect	VERB
ajlm-939	20	333	approximately	approximately	ADV
ajlm-939	20	334	95	95	NUM
ajlm-939	20	335	%	%	NOUN
ajlm-939	20	336	of	of	ADP
ajlm-939	20	337	cases.28	cases.28	NOUN
ajlm-939	20	338	the	the	DET
ajlm-939	20	339	hhv-8	hhv-8	NUM
ajlm-939	20	340	dna	dna	PROPN
ajlm-939	20	341	has	have	AUX
ajlm-939	20	342	been	be	AUX
ajlm-939	20	343	successfully	successfully	ADV
ajlm-939	20	344	amplified	amplify	VERB
ajlm-939	20	345	using	use	VERB
ajlm-939	20	346	nested	nest	VERB
ajlm-939	20	347	pcr	pcr	ADJ
ajlm-939	20	348	previously.29,30	previously.29,30	NOUN
ajlm-939	20	349	this	this	DET
ajlm-939	20	350	study	study	NOUN
ajlm-939	20	351	was	be	AUX
ajlm-939	20	352	aimed	aim	VERB
ajlm-939	20	353	at	at	ADP
ajlm-939	20	354	determining	determine	VERB
ajlm-939	20	355	the	the	DET
ajlm-939	20	356	presence	presence	NOUN
ajlm-939	20	357	of	of	ADP
ajlm-939	20	358	the	the	DET
ajlm-939	20	359	orf75	orf75	ADJ
ajlm-939	20	360	gene	gene	NOUN
ajlm-939	20	361	linked	link	VERB
ajlm-939	20	362	to	to	ADP
ajlm-939	20	363	kshv	kshv	PROPN
ajlm-939	20	364	among	among	ADP
ajlm-939	20	365	hiv-1	hiv-1	X
ajlm-939	20	366	/	/	SYM
ajlm-939	20	367	aids	aid	NOUN
ajlm-939	20	368	patients	patient	NOUN
ajlm-939	20	369	.	.	PUNCT
ajlm-939	21	1	in	in	ADP
ajlm-939	21	2	addition	addition	NOUN
ajlm-939	21	3	,	,	PUNCT
ajlm-939	21	4	the	the	DET
ajlm-939	21	5	objective	objective	NOUN
ajlm-939	21	6	of	of	ADP
ajlm-939	21	7	this	this	DET
ajlm-939	21	8	current	current	ADJ
ajlm-939	21	9	study	study	NOUN
ajlm-939	21	10	was	be	AUX
ajlm-939	21	11	to	to	PART
ajlm-939	21	12	describe	describe	VERB
ajlm-939	21	13	the	the	DET
ajlm-939	21	14	morphological	morphological	ADJ
ajlm-939	21	15	presentations	presentation	NOUN
ajlm-939	21	16	of	of	ADP
ajlm-939	21	17	ks	ks	PROPN
ajlm-939	21	18	among	among	ADP
ajlm-939	21	19	the	the	DET
ajlm-939	21	20	studied	study	VERB
ajlm-939	21	21	cases	case	NOUN
ajlm-939	21	22	.	.	PUNCT
ajlm-939	22	1	methods	method	NOUN
ajlm-939	22	2	the	the	DET
ajlm-939	22	3	present	present	ADJ
ajlm-939	22	4	study	study	NOUN
ajlm-939	22	5	only	only	ADV
ajlm-939	22	6	included	include	VERB
ajlm-939	22	7	patients	patient	NOUN
ajlm-939	22	8	aged	age	VERB
ajlm-939	22	9	18	18	NUM
ajlm-939	22	10	years	year	NOUN
ajlm-939	22	11	and	and	CCONJ
ajlm-939	22	12	older	old	ADJ
ajlm-939	22	13	.	.	PUNCT
ajlm-939	23	1	data	datum	NOUN
ajlm-939	23	2	on	on	ADP
ajlm-939	23	3	clinical	clinical	ADJ
ajlm-939	23	4	information	information	NOUN
ajlm-939	23	5	that	that	PRON
ajlm-939	23	6	was	be	AUX
ajlm-939	23	7	useful	useful	ADJ
ajlm-939	23	8	for	for	SCONJ
ajlm-939	23	9	this	this	DET
ajlm-939	23	10	study	study	NOUN
ajlm-939	23	11	were	be	AUX
ajlm-939	23	12	extracted	extract	VERB
ajlm-939	23	13	from	from	ADP
ajlm-939	23	14	the	the	DET
ajlm-939	23	15	registry	registry	NOUN
ajlm-939	23	16	records	record	NOUN
ajlm-939	23	17	with	with	ADP
ajlm-939	23	18	the	the	DET
ajlm-939	23	19	help	help	NOUN
ajlm-939	23	20	of	of	ADP
ajlm-939	23	21	the	the	DET
ajlm-939	23	22	data	datum	NOUN
ajlm-939	23	23	clerk	clerk	NOUN
ajlm-939	23	24	.	.	PUNCT
ajlm-939	24	1	the	the	DET
ajlm-939	24	2	following	follow	VERB
ajlm-939	24	3	data	datum	NOUN
ajlm-939	24	4	were	be	AUX
ajlm-939	24	5	obtained	obtain	VERB
ajlm-939	24	6	from	from	ADP
ajlm-939	24	7	the	the	DET
ajlm-939	24	8	registry	registry	NOUN
ajlm-939	24	9	records	record	NOUN
ajlm-939	24	10	:	:	PUNCT
ajlm-939	24	11	sex	sex	NOUN
ajlm-939	24	12	,	,	PUNCT
ajlm-939	24	13	age	age	NOUN
ajlm-939	24	14	,	,	PUNCT
ajlm-939	24	15	hiv-1	hiv-1	ADJ
ajlm-939	24	16	status	status	NOUN
ajlm-939	24	17	,	,	PUNCT
ajlm-939	24	18	if	if	SCONJ
ajlm-939	24	19	patient	patient	ADJ
ajlm-939	24	20	was	be	AUX
ajlm-939	24	21	on	on	ADP
ajlm-939	24	22	antiretroviral	antiretroviral	ADJ
ajlm-939	24	23	or	or	CCONJ
ajlm-939	24	24	highly	highly	ADV
ajlm-939	24	25	active	active	ADJ
ajlm-939	24	26	antiretroviral	antiretroviral	ADJ
ajlm-939	24	27	therapy	therapy	NOUN
ajlm-939	24	28	treatment	treatment	NOUN
ajlm-939	24	29	,	,	PUNCT
ajlm-939	24	30	anatomic	anatomic	ADJ
ajlm-939	24	31	location	location	NOUN
ajlm-939	24	32	of	of	ADP
ajlm-939	24	33	ks	ks	NOUN
ajlm-939	24	34	lesions	lesion	NOUN
ajlm-939	24	35	,	,	PUNCT
ajlm-939	24	36	number	number	NOUN
ajlm-939	24	37	of	of	ADP
ajlm-939	24	38	ks	ks	NOUN
ajlm-939	24	39	lesions	lesion	NOUN
ajlm-939	24	40	,	,	PUNCT
ajlm-939	24	41	distribution	distribution	NOUN
ajlm-939	24	42	of	of	ADP
ajlm-939	24	43	ks	ks	NOUN
ajlm-939	24	44	lesions	lesion	NOUN
ajlm-939	24	45	,	,	PUNCT
ajlm-939	24	46	cluster	cluster	NOUN
ajlm-939	24	47	of	of	ADP
ajlm-939	24	48	differentiation	differentiation	NOUN
ajlm-939	24	49	4	4	NUM
ajlm-939	24	50	cell	cell	NOUN
ajlm-939	24	51	count	count	NOUN
ajlm-939	24	52	and	and	CCONJ
ajlm-939	24	53	histology	histology	NOUN
ajlm-939	24	54	diagnosis	diagnosis	NOUN
ajlm-939	24	55	.	.	PUNCT
ajlm-939	25	1	ethical	ethical	ADJ
ajlm-939	25	2	considerations	consideration	NOUN
ajlm-939	25	3	study	study	VERB
ajlm-939	25	4	approval	approval	NOUN
ajlm-939	25	5	number	number	NOUN
ajlm-939	25	6	p682/11/2014	p682/11/2014	PROPN
ajlm-939	25	7	was	be	AUX
ajlm-939	25	8	assigned	assign	VERB
ajlm-939	25	9	by	by	ADP
ajlm-939	25	10	kenyatta	kenyatta	PROPN
ajlm-939	25	11	national	national	PROPN
ajlm-939	25	12	hospital	hospital	PROPN
ajlm-939	25	13	/	/	SYM
ajlm-939	25	14	university	university	PROPN
ajlm-939	25	15	of	of	ADP
ajlm-939	25	16	nairobi	nairobi	PROPN
ajlm-939	25	17	ethics	ethic	NOUN
ajlm-939	25	18	and	and	CCONJ
ajlm-939	25	19	research	research	NOUN
ajlm-939	25	20	committee	committee	NOUN
ajlm-939	25	21	.	.	PUNCT
ajlm-939	26	1	study	study	NOUN
ajlm-939	26	2	design	design	VERB
ajlm-939	26	3	a	a	DET
ajlm-939	26	4	cross	cross	ADJ
ajlm-939	26	5	-	-	ADJ
ajlm-939	26	6	sectional	sectional	ADJ
ajlm-939	26	7	,	,	PUNCT
ajlm-939	26	8	descriptive	descriptive	ADJ
ajlm-939	26	9	,	,	PUNCT
ajlm-939	26	10	hospital	hospital	NOUN
ajlm-939	26	11	-	-	PUNCT
ajlm-939	26	12	based	base	VERB
ajlm-939	26	13	study	study	NOUN
ajlm-939	26	14	was	be	AUX
ajlm-939	26	15	used	use	VERB
ajlm-939	26	16	.	.	PUNCT
ajlm-939	27	1	formalin	formalin	NOUN
ajlm-939	27	2	-	-	PUNCT
ajlm-939	27	3	fixed	fix	VERB
ajlm-939	27	4	,	,	PUNCT
ajlm-939	27	5	paraffin	paraffin	NOUN
ajlm-939	27	6	-	-	PUNCT
ajlm-939	27	7	embedded	embed	VERB
ajlm-939	27	8	tissue	tissue	NOUN
ajlm-939	27	9	blocks	block	NOUN
ajlm-939	27	10	were	be	AUX
ajlm-939	27	11	retrieved	retrieve	VERB
ajlm-939	27	12	from	from	ADP
ajlm-939	27	13	archives	archive	NOUN
ajlm-939	27	14	following	follow	VERB
ajlm-939	27	15	histological	histological	ADJ
ajlm-939	27	16	reports	report	NOUN
ajlm-939	27	17	of	of	ADP
ajlm-939	27	18	the	the	DET
ajlm-939	27	19	patients	patient	NOUN
ajlm-939	27	20	who	who	PRON
ajlm-939	27	21	were	be	AUX
ajlm-939	27	22	diagnosed	diagnose	VERB
ajlm-939	27	23	with	with	ADP
ajlm-939	27	24	ks	ks	NOUN
ajlm-939	27	25	or	or	CCONJ
ajlm-939	27	26	ks	ks	NOUN
ajlm-939	27	27	-	-	PUNCT
ajlm-939	27	28	like	like	ADJ
ajlm-939	27	29	disease	disease	NOUN
ajlm-939	27	30	between	between	ADP
ajlm-939	27	31	2013	2013	NUM
ajlm-939	27	32	and	and	CCONJ
ajlm-939	27	33	2016	2016	NUM
ajlm-939	27	34	.	.	PUNCT
ajlm-939	28	1	a	a	DET
ajlm-939	28	2	consecutive	consecutive	ADJ
ajlm-939	28	3	sampling	sampling	NOUN
ajlm-939	28	4	technique	technique	NOUN
ajlm-939	28	5	was	be	AUX
ajlm-939	28	6	used	use	VERB
ajlm-939	28	7	to	to	PART
ajlm-939	28	8	select	select	VERB
ajlm-939	28	9	the	the	DET
ajlm-939	28	10	archived	archive	VERB
ajlm-939	28	11	tissue	tissue	NOUN
ajlm-939	28	12	blocks	block	NOUN
ajlm-939	28	13	from	from	ADP
ajlm-939	28	14	thematic	thematic	ADJ
ajlm-939	28	15	unit	unit	NOUN
ajlm-939	28	16	of	of	ADP
ajlm-939	28	17	anatomic	anatomic	ADJ
ajlm-939	28	18	pathology	pathology	NOUN
ajlm-939	28	19	,	,	PUNCT
ajlm-939	28	20	department	department	PROPN
ajlm-939	28	21	of	of	ADP
ajlm-939	28	22	human	human	PROPN
ajlm-939	28	23	pathology	pathology	PROPN
ajlm-939	28	24	,	,	PUNCT
ajlm-939	28	25	college	college	PROPN
ajlm-939	28	26	of	of	ADP
ajlm-939	28	27	health	health	PROPN
ajlm-939	28	28	sciences	sciences	PROPN
ajlm-939	28	29	,	,	PUNCT
ajlm-939	28	30	university	university	NOUN
ajlm-939	28	31	of	of	ADP
ajlm-939	28	32	nairobi	nairobi	PROPN
ajlm-939	28	33	,	,	PUNCT
ajlm-939	28	34	and	and	CCONJ
ajlm-939	28	35	department	department	NOUN
ajlm-939	28	36	of	of	ADP
ajlm-939	28	37	laboratory	laboratory	NOUN
ajlm-939	28	38	medicine	medicine	NOUN
ajlm-939	28	39	,	,	PUNCT
ajlm-939	28	40	cytology	cytology	NOUN
ajlm-939	28	41	section	section	NOUN
ajlm-939	28	42	,	,	PUNCT
ajlm-939	28	43	kenyatta	kenyatta	PROPN
ajlm-939	28	44	national	national	PROPN
ajlm-939	28	45	hospital	hospital	PROPN
ajlm-939	28	46	.	.	PUNCT
ajlm-939	29	1	for	for	ADP
ajlm-939	29	2	this	this	DET
ajlm-939	29	3	study	study	NOUN
ajlm-939	29	4	,	,	PUNCT
ajlm-939	29	5	a	a	DET
ajlm-939	29	6	total	total	NOUN
ajlm-939	29	7	of	of	ADP
ajlm-939	29	8	81	81	NUM
ajlm-939	29	9	tissue	tissue	NOUN
ajlm-939	29	10	blocks	block	NOUN
ajlm-939	29	11	were	be	AUX
ajlm-939	29	12	selected	select	VERB
ajlm-939	29	13	and	and	CCONJ
ajlm-939	29	14	analysed	analyse	VERB
ajlm-939	29	15	.	.	PUNCT
ajlm-939	30	1	a	a	DET
ajlm-939	30	2	rotary	rotary	ADJ
ajlm-939	30	3	microtome	microtome	NOUN
ajlm-939	30	4	was	be	AUX
ajlm-939	30	5	used	use	VERB
ajlm-939	30	6	to	to	PART
ajlm-939	30	7	section	section	VERB
ajlm-939	30	8	the	the	DET
ajlm-939	30	9	formalin	formalin	NOUN
ajlm-939	30	10	-	-	PUNCT
ajlm-939	30	11	fixed	fix	VERB
ajlm-939	30	12	,	,	PUNCT
ajlm-939	30	13	paraffin	paraffin	NOUN
ajlm-939	30	14	-	-	PUNCT
ajlm-939	30	15	embedded	embed	VERB
ajlm-939	30	16	blocks	block	NOUN
ajlm-939	30	17	.	.	PUNCT
ajlm-939	31	1	a	a	DET
ajlm-939	31	2	different	different	ADJ
ajlm-939	31	3	blade	blade	NOUN
ajlm-939	31	4	was	be	AUX
ajlm-939	31	5	used	use	VERB
ajlm-939	31	6	for	for	ADP
ajlm-939	31	7	every	every	DET
ajlm-939	31	8	formalin	formalin	NOUN
ajlm-939	31	9	-	-	PUNCT
ajlm-939	31	10	fixed	fix	VERB
ajlm-939	31	11	,	,	PUNCT
ajlm-939	31	12	paraffin	paraffin	NOUN
ajlm-939	31	13	-	-	PUNCT
ajlm-939	31	14	embedded	embed	VERB
ajlm-939	31	15	block	block	NOUN
ajlm-939	31	16	so	so	SCONJ
ajlm-939	31	17	as	as	SCONJ
ajlm-939	31	18	to	to	PART
ajlm-939	31	19	avoid	avoid	VERB
ajlm-939	31	20	carry	carry	VERB
ajlm-939	31	21	-	-	PUNCT
ajlm-939	31	22	over	over	NOUN
ajlm-939	31	23	of	of	ADP
ajlm-939	31	24	genetic	genetic	ADJ
ajlm-939	31	25	material	material	NOUN
ajlm-939	31	26	.	.	PUNCT
ajlm-939	32	1	once	once	ADV
ajlm-939	32	2	a	a	DET
ajlm-939	32	3	block	block	NOUN
ajlm-939	32	4	was	be	AUX
ajlm-939	32	5	cut	cut	VERB
ajlm-939	32	6	,	,	PUNCT
ajlm-939	32	7	the	the	DET
ajlm-939	32	8	microtomes	microtome	NOUN
ajlm-939	32	9	surface	surface	NOUN
ajlm-939	32	10	was	be	AUX
ajlm-939	32	11	decontaminated	decontaminate	VERB
ajlm-939	32	12	using	use	VERB
ajlm-939	32	13	dnazaptm	dnazaptm	NOUN
ajlm-939	32	14	pcr	pcr	ADJ
ajlm-939	32	15	dna	dna	PROPN
ajlm-939	32	16	degradation	degradation	NOUN
ajlm-939	32	17	solution	solution	NOUN
ajlm-939	32	18	(	(	PUNCT
ajlm-939	32	19	catalog	catalog	NOUN
ajlm-939	32	20	number	number	NOUN
ajlm-939	32	21	:	:	PUNCT
ajlm-939	32	22	am9890	am9890	NOUN
ajlm-939	32	23	;	;	PUNCT
ajlm-939	32	24	thermo	thermo	PROPN
ajlm-939	32	25	fisher	fisher	PROPN
ajlm-939	32	26	scientific	scientific	PROPN
ajlm-939	32	27	,	,	PUNCT
ajlm-939	32	28	waltham	waltham	PROPN
ajlm-939	32	29	,	,	PUNCT
ajlm-939	32	30	massachusetts	massachusetts	PROPN
ajlm-939	32	31	,	,	PUNCT
ajlm-939	32	32	united	united	PROPN
ajlm-939	32	33	states	states	PROPN
ajlm-939	32	34	)	)	PUNCT
ajlm-939	32	35	.	.	PUNCT
ajlm-939	33	1	each	each	DET
ajlm-939	33	2	tissue	tissue	NOUN
ajlm-939	33	3	section	section	NOUN
ajlm-939	33	4	was	be	AUX
ajlm-939	33	5	cut	cut	VERB
ajlm-939	33	6	to	to	ADP
ajlm-939	33	7	10	10	NUM
ajlm-939	33	8	µm	µm	ADP
ajlm-939	33	9	thick	thick	ADJ
ajlm-939	33	10	.	.	PUNCT
ajlm-939	34	1	the	the	DET
ajlm-939	34	2	tissue	tissue	NOUN
ajlm-939	34	3	sections	section	NOUN
ajlm-939	34	4	were	be	AUX
ajlm-939	34	5	processed	process	VERB
ajlm-939	34	6	for	for	ADP
ajlm-939	34	7	haematoxylin	haematoxylin	NOUN
ajlm-939	34	8	and	and	CCONJ
ajlm-939	34	9	eosin	eosin	NOUN
ajlm-939	34	10	staining	stain	VERB
ajlm-939	34	11	and	and	CCONJ
ajlm-939	34	12	a	a	DET
ajlm-939	34	13	qualified	qualified	ADJ
ajlm-939	34	14	pathologist	pathologist	NOUN
ajlm-939	34	15	reported	report	VERB
ajlm-939	34	16	on	on	ADP
ajlm-939	34	17	the	the	DET
ajlm-939	34	18	results	result	NOUN
ajlm-939	34	19	.	.	PUNCT
ajlm-939	35	1	deoxyribonucleic	deoxyribonucleic	ADJ
ajlm-939	35	2	acid	acid	NOUN
ajlm-939	35	3	extraction	extraction	NOUN
ajlm-939	35	4	and	and	CCONJ
ajlm-939	35	5	polymerase	polymerase	NOUN
ajlm-939	35	6	chain	chain	NOUN
ajlm-939	35	7	reaction	reaction	NOUN
ajlm-939	35	8	isolation	isolation	NOUN
ajlm-939	35	9	of	of	ADP
ajlm-939	35	10	dna	dna	NOUN
ajlm-939	35	11	from	from	ADP
ajlm-939	35	12	tissue	tissue	NOUN
ajlm-939	35	13	sections	section	NOUN
ajlm-939	35	14	was	be	AUX
ajlm-939	35	15	done	do	VERB
ajlm-939	35	16	using	use	VERB
ajlm-939	35	17	a	a	DET
ajlm-939	35	18	generead	generead	ADJ
ajlm-939	35	19	dna	dna	NOUN
ajlm-939	35	20	ffpe	ffpe	NOUN
ajlm-939	35	21	kit	kit	NOUN
ajlm-939	35	22	(	(	PUNCT
ajlm-939	35	23	qiagen	qiagen	PROPN
ajlm-939	35	24	,	,	PUNCT
ajlm-939	35	25	hilden	hilden	PROPN
ajlm-939	35	26	,	,	PUNCT
ajlm-939	35	27	germany	germany	PROPN
ajlm-939	35	28	)	)	PUNCT
ajlm-939	35	29	.	.	PUNCT
ajlm-939	36	1	the	the	DET
ajlm-939	36	2	extraction	extraction	NOUN
ajlm-939	36	3	kit	kit	NOUN
ajlm-939	36	4	removes	remove	VERB
ajlm-939	36	5	paraffin	paraffin	NOUN
ajlm-939	36	6	and	and	CCONJ
ajlm-939	36	7	reverses	reverse	VERB
ajlm-939	36	8	formalin	formalin	NOUN
ajlm-939	36	9	cross	cross	NOUN
ajlm-939	36	10	-	-	NOUN
ajlm-939	36	11	links	link	NOUN
ajlm-939	36	12	from	from	ADP
ajlm-939	36	13	tissue	tissue	NOUN
ajlm-939	36	14	before	before	SCONJ
ajlm-939	36	15	dna	dna	PROPN
ajlm-939	36	16	is	be	AUX
ajlm-939	36	17	bound	bind	VERB
ajlm-939	36	18	to	to	ADP
ajlm-939	36	19	the	the	DET
ajlm-939	36	20	qiaampminelute	qiaampminelute	NOUN
ajlm-939	36	21	column	column	NOUN
ajlm-939	36	22	(	(	PUNCT
ajlm-939	36	23	qiagen	qiagen	PROPN
ajlm-939	36	24	,	,	PUNCT
ajlm-939	36	25	hilden	hilden	PROPN
ajlm-939	36	26	,	,	PUNCT
ajlm-939	36	27	germany	germany	PROPN
ajlm-939	36	28	)	)	PUNCT
ajlm-939	36	29	.	.	PUNCT
ajlm-939	37	1	the	the	DET
ajlm-939	37	2	eluted	eluted	ADJ
ajlm-939	37	3	dna	dna	NOUN
ajlm-939	37	4	is	be	AUX
ajlm-939	37	5	then	then	ADV
ajlm-939	37	6	ready	ready	ADJ
ajlm-939	37	7	to	to	PART
ajlm-939	37	8	be	be	AUX
ajlm-939	37	9	used	use	VERB
ajlm-939	37	10	for	for	ADP
ajlm-939	37	11	nested	nested	ADJ
ajlm-939	37	12	pcr	pcr	PROPN
ajlm-939	37	13	to	to	PART
ajlm-939	37	14	detect	detect	VERB
ajlm-939	37	15	the	the	DET
ajlm-939	37	16	orf75	orf75	ADJ
ajlm-939	37	17	gene	gene	NOUN
ajlm-939	37	18	in	in	ADP
ajlm-939	37	19	hhv-8	hhv-8	NOUN
ajlm-939	37	20	.	.	PUNCT
ajlm-939	38	1	a	a	DET
ajlm-939	38	2	taq	taq	PROPN
ajlm-939	38	3	pcr	pcr	PROPN
ajlm-939	38	4	core	core	NOUN
ajlm-939	38	5	kit	kit	NOUN
ajlm-939	38	6	(	(	PUNCT
ajlm-939	38	7	catalog	catalog	NOUN
ajlm-939	38	8	number	number	NOUN
ajlm-939	38	9	:	:	PUNCT
ajlm-939	38	10	201223	201223	NUM
ajlm-939	38	11	;	;	PUNCT
ajlm-939	38	12	qiagen	qiagen	PROPN
ajlm-939	38	13	,	,	PUNCT
ajlm-939	38	14	hilden	hilden	PROPN
ajlm-939	38	15	,	,	PUNCT
ajlm-939	38	16	germany	germany	PROPN
ajlm-939	38	17	)	)	PUNCT
ajlm-939	38	18	was	be	AUX
ajlm-939	38	19	used	use	VERB
ajlm-939	38	20	to	to	PART
ajlm-939	38	21	detect	detect	VERB
ajlm-939	38	22	the	the	DET
ajlm-939	38	23	orf75	orf75	ADJ
ajlm-939	38	24	gene	gene	NOUN
ajlm-939	38	25	.	.	PUNCT
ajlm-939	39	1	the	the	DET
ajlm-939	39	2	set	set	NOUN
ajlm-939	39	3	of	of	ADP
ajlm-939	39	4	primers	primer	NOUN
ajlm-939	39	5	used	use	VERB
ajlm-939	39	6	were	be	AUX
ajlm-939	39	7	;	;	PUNCT
ajlm-939	39	8	orf75	orf75	ADJ
ajlm-939	39	9	product	product	NOUN
ajlm-939	39	10	size	size	NOUN
ajlm-939	39	11	895	895	NUM
ajlm-939	39	12	bp	bp	NOUN
ajlm-939	39	13	forward	forward	ADV
ajlm-939	39	14	ks	ks	PROPN
ajlm-939	39	15	1000	1000	NUM
ajlm-939	39	16	5′cggttcggtggcatacaggc3′	5′cggttcggtggcatacaggc3′	NUM
ajlm-939	39	17	;	;	PUNCT
ajlm-939	39	18	reverse	reverse	VERB
ajlm-939	39	19	ks	ks	PROPN
ajlm-939	39	20	1034	1034	NUM
ajlm-939	39	21	5′ctgactacagagggtgtccccg3′.31	5′ctgactacagagggtgtccccg3′.31	NUM
ajlm-939	39	22	orf75	orf75	ADJ
ajlm-939	39	23	product	product	NOUN
ajlm-939	39	24	size	size	NOUN
ajlm-939	39	25	804	804	NUM
ajlm-939	39	26	bp	bp	PROPN
ajlm-939	39	27	forward	forward	ADV
ajlm-939	39	28	ks	ks	PROPN
ajlm-939	39	29	2000	2000	NUM
ajlm-939	39	30	5′ggaaacagggtgctgtg3′	5′ggaaacagggtgctgtg3′	NUM
ajlm-939	39	31	;	;	PUNCT
ajlm-939	39	32	reverse	reverse	VERB
ajlm-939	39	33	ks	ks	PROPN
ajlm-939	39	34	2034	2034	NUM
ajlm-939	39	35	5′catggcctacgacgtcac3′.32	5′catggcctacgacgtcac3′.32	NUM
ajlm-939	39	36	the	the	DET
ajlm-939	39	37	cycling	cycling	NOUN
ajlm-939	39	38	conditions	condition	NOUN
ajlm-939	39	39	of	of	ADP
ajlm-939	39	40	the	the	DET
ajlm-939	39	41	pcr	pcr	NOUN
ajlm-939	39	42	for	for	ADP
ajlm-939	39	43	the	the	DET
ajlm-939	39	44	targeted	target	VERB
ajlm-939	39	45	ks	ks	NOUN
ajlm-939	39	46	regions	region	NOUN
ajlm-939	39	47	were	be	AUX
ajlm-939	39	48	similar	similar	ADJ
ajlm-939	39	49	and	and	CCONJ
ajlm-939	39	50	consisted	consist	VERB
ajlm-939	39	51	of	of	ADP
ajlm-939	39	52	30	30	NUM
ajlm-939	39	53	cycles	cycle	NOUN
ajlm-939	39	54	of	of	ADP
ajlm-939	39	55	:	:	PUNCT
ajlm-939	39	56	initial	initial	ADJ
ajlm-939	39	57	denaturation	denaturation	NOUN
ajlm-939	39	58	at	at	ADP
ajlm-939	39	59	94	94	NUM
ajlm-939	39	60	°	°	ADP
ajlm-939	39	61	c	c	NOUN
ajlm-939	39	62	for	for	ADP
ajlm-939	39	63	3	3	NUM
ajlm-939	39	64	minutes	minute	NOUN
ajlm-939	39	65	,	,	PUNCT
ajlm-939	39	66	denaturation	denaturation	NOUN
ajlm-939	39	67	at	at	ADP
ajlm-939	39	68	94	94	NUM
ajlm-939	39	69	°	°	ADP
ajlm-939	39	70	c	c	NOUN
ajlm-939	39	71	for	for	ADP
ajlm-939	39	72	1	1	NUM
ajlm-939	39	73	min	min	NOUN
ajlm-939	39	74	,	,	PUNCT
ajlm-939	39	75	annealing	anneal	VERB
ajlm-939	39	76	at	at	ADP
ajlm-939	39	77	63	63	NUM
ajlm-939	39	78	°	°	ADP
ajlm-939	39	79	c	c	NOUN
ajlm-939	39	80	for	for	ADP
ajlm-939	39	81	1	1	NUM
ajlm-939	39	82	min	min	NOUN
ajlm-939	39	83	,	,	PUNCT
ajlm-939	39	84	extension	extension	NOUN
ajlm-939	39	85	at	at	ADP
ajlm-939	39	86	72	72	NUM
ajlm-939	39	87	°	°	ADP
ajlm-939	39	88	c	c	NOUN
ajlm-939	39	89	for	for	ADP
ajlm-939	39	90	1	1	NUM
ajlm-939	39	91	min	min	NOUN
ajlm-939	39	92	and	and	CCONJ
ajlm-939	39	93	final	final	ADJ
ajlm-939	39	94	extension	extension	NOUN
ajlm-939	39	95	at	at	ADP
ajlm-939	39	96	72	72	NUM
ajlm-939	39	97	°	°	ADP
ajlm-939	39	98	c	c	NOUN
ajlm-939	39	99	for	for	ADP
ajlm-939	39	100	10	10	NUM
ajlm-939	39	101	min	min	NOUN
ajlm-939	39	102	.	.	PROPN
ajlm-939	40	1	amplified	amplify	VERB
ajlm-939	40	2	pcr	pcr	ADJ
ajlm-939	40	3	products	product	NOUN
ajlm-939	40	4	were	be	AUX
ajlm-939	40	5	analysed	analyse	VERB
ajlm-939	40	6	by	by	ADP
ajlm-939	40	7	electrophoresis	electrophoresis	NOUN
ajlm-939	40	8	on	on	ADP
ajlm-939	40	9	a	a	DET
ajlm-939	40	10	1	1	NUM
ajlm-939	40	11	%	%	NOUN
ajlm-939	40	12	agarose	agarose	NOUN
ajlm-939	40	13	gel	gel	NOUN
ajlm-939	40	14	containing	contain	VERB
ajlm-939	40	15	ethidium	ethidium	NOUN
ajlm-939	40	16	bromide	bromide	NOUN
ajlm-939	40	17	(	(	PUNCT
ajlm-939	40	18	1	1	NUM
ajlm-939	40	19	µl	µl	NOUN
ajlm-939	40	20	/	/	SYM
ajlm-939	40	21	ml	ml	NOUN
ajlm-939	40	22	of	of	ADP
ajlm-939	40	23	agarose	agarose	NOUN
ajlm-939	40	24	solution	solution	NOUN
ajlm-939	40	25	)	)	PUNCT
ajlm-939	40	26	and	and	CCONJ
ajlm-939	40	27	were	be	AUX
ajlm-939	40	28	visualised	visualise	VERB
ajlm-939	40	29	under	under	ADP
ajlm-939	40	30	ultraviolet	ultraviolet	ADJ
ajlm-939	40	31	light	light	NOUN
ajlm-939	40	32	alongside	alongside	ADP
ajlm-939	40	33	a	a	DET
ajlm-939	40	34	1	1	NUM
ajlm-939	40	35	kilobase	kilobase	NOUN
ajlm-939	40	36	(	(	PUNCT
ajlm-939	40	37	kb	kb	PROPN
ajlm-939	40	38	)	)	PUNCT
ajlm-939	40	39	deoxyribonucleic	deoxyribonucleic	ADJ
ajlm-939	40	40	acid	acid	NOUN
ajlm-939	40	41	(	(	PUNCT
ajlm-939	40	42	dna	dna	NOUN
ajlm-939	40	43	)	)	PUNCT
ajlm-939	40	44	ladder	ladder	NOUN
ajlm-939	40	45	.	.	PUNCT
ajlm-939	41	1	for	for	ADP
ajlm-939	41	2	a	a	DET
ajlm-939	41	3	positive	positive	ADJ
ajlm-939	41	4	control	control	NOUN
ajlm-939	41	5	,	,	PUNCT
ajlm-939	41	6	a	a	DET
ajlm-939	41	7	known	know	VERB
ajlm-939	41	8	case	case	NOUN
ajlm-939	41	9	of	of	ADP
ajlm-939	41	10	ks	ks	PROPN
ajlm-939	41	11	was	be	AUX
ajlm-939	41	12	used	use	VERB
ajlm-939	41	13	.	.	PUNCT
ajlm-939	42	1	the	the	DET
ajlm-939	42	2	ribonuclease	ribonuclease	NOUN
ajlm-939	42	3	-	-	PUNCT
ajlm-939	42	4	free	free	ADJ
ajlm-939	42	5	water	water	NOUN
ajlm-939	42	6	was	be	AUX
ajlm-939	42	7	used	use	VERB
ajlm-939	42	8	as	as	ADP
ajlm-939	42	9	a	a	DET
ajlm-939	42	10	negative	negative	ADJ
ajlm-939	42	11	control	control	NOUN
ajlm-939	42	12	.	.	PUNCT
ajlm-939	43	1	statistical	statistical	ADJ
ajlm-939	43	2	analysis	analysis	NOUN
ajlm-939	43	3	the	the	DET
ajlm-939	43	4	data	datum	NOUN
ajlm-939	43	5	were	be	AUX
ajlm-939	43	6	analysed	analyse	VERB
ajlm-939	43	7	using	use	VERB
ajlm-939	43	8	statistical	statistical	ADJ
ajlm-939	43	9	package	package	NOUN
ajlm-939	43	10	for	for	ADP
ajlm-939	43	11	social	social	ADJ
ajlm-939	43	12	sciences	science	NOUN
ajlm-939	43	13	version	version	NOUN
ajlm-939	43	14	21	21	NUM
ajlm-939	43	15	(	(	PUNCT
ajlm-939	43	16	spss	spss	PROPN
ajlm-939	43	17	inc	inc	PROPN
ajlm-939	43	18	binghamton	binghamton	PROPN
ajlm-939	43	19	,	,	PUNCT
ajlm-939	43	20	new	new	PROPN
ajlm-939	43	21	york	york	PROPN
ajlm-939	43	22	,	,	PUNCT
ajlm-939	43	23	united	united	PROPN
ajlm-939	43	24	states	states	PROPN
ajlm-939	43	25	)	)	PUNCT
ajlm-939	43	26	;	;	PUNCT
ajlm-939	43	27	the	the	DET
ajlm-939	43	28	relationship	relationship	NOUN
ajlm-939	43	29	between	between	ADP
ajlm-939	43	30	the	the	DET
ajlm-939	43	31	orf75	orf75	ADJ
ajlm-939	43	32	gene	gene	NOUN
ajlm-939	43	33	and	and	CCONJ
ajlm-939	43	34	clinical	clinical	ADJ
ajlm-939	43	35	characteristics	characteristic	NOUN
ajlm-939	43	36	were	be	AUX
ajlm-939	43	37	tested	test	VERB
ajlm-939	43	38	by	by	ADP
ajlm-939	43	39	using	use	VERB
ajlm-939	43	40	chi	chi	ADJ
ajlm-939	43	41	-	-	PUNCT
ajlm-939	43	42	square	square	NOUN
ajlm-939	43	43	and	and	CCONJ
ajlm-939	43	44	t	t	NOUN
ajlm-939	43	45	-	-	PUNCT
ajlm-939	43	46	tests	test	NOUN
ajlm-939	43	47	.	.	PUNCT
ajlm-939	44	1	a	a	DET
ajlm-939	44	2	p	p	NOUN
ajlm-939	44	3	-	-	PUNCT
ajlm-939	44	4	value	value	NOUN
ajlm-939	44	5	of	of	ADP
ajlm-939	44	6	less	less	ADJ
ajlm-939	44	7	than	than	ADP
ajlm-939	44	8	0.05	0.05	NUM
ajlm-939	44	9	was	be	AUX
ajlm-939	44	10	considered	consider	VERB
ajlm-939	44	11	to	to	PART
ajlm-939	44	12	be	be	AUX
ajlm-939	44	13	statistically	statistically	ADV
ajlm-939	44	14	significant	significant	ADJ
ajlm-939	44	15	.	.	PUNCT
ajlm-939	45	1	odds	odd	NOUN
ajlm-939	45	2	ratios	ratio	NOUN
ajlm-939	45	3	in	in	ADP
ajlm-939	45	4	a	a	DET
ajlm-939	45	5	cross	cross	ADJ
ajlm-939	45	6	-	-	ADJ
ajlm-939	45	7	sectional	sectional	ADJ
ajlm-939	45	8	study	study	NOUN
ajlm-939	45	9	are	be	AUX
ajlm-939	45	10	known	know	VERB
ajlm-939	45	11	as	as	ADP
ajlm-939	45	12	prevalence	prevalence	NOUN
ajlm-939	45	13	odds	odd	NOUN
ajlm-939	45	14	ratios	ratio	NOUN
ajlm-939	45	15	and	and	CCONJ
ajlm-939	45	16	were	be	AUX
ajlm-939	45	17	used	use	VERB
ajlm-939	45	18	as	as	ADP
ajlm-939	45	19	a	a	DET
ajlm-939	45	20	measure	measure	NOUN
ajlm-939	45	21	of	of	ADP
ajlm-939	45	22	association.33	association.33	NOUN
ajlm-939	45	23	results	result	NOUN
ajlm-939	45	24	of	of	ADP
ajlm-939	45	25	the	the	DET
ajlm-939	45	26	81	81	NUM
ajlm-939	45	27	tissue	tissue	NOUN
ajlm-939	45	28	samples	sample	NOUN
ajlm-939	45	29	included	include	VERB
ajlm-939	45	30	in	in	ADP
ajlm-939	45	31	the	the	DET
ajlm-939	45	32	study	study	NOUN
ajlm-939	45	33	,	,	PUNCT
ajlm-939	45	34	43.2	43.2	NUM
ajlm-939	45	35	%	%	NOUN
ajlm-939	45	36	(	(	PUNCT
ajlm-939	45	37	35/81	35/81	NUM
ajlm-939	45	38	)	)	PUNCT
ajlm-939	45	39	were	be	AUX
ajlm-939	45	40	from	from	ADP
ajlm-939	45	41	women	woman	NOUN
ajlm-939	45	42	and	and	CCONJ
ajlm-939	45	43	56.8	56.8	NUM
ajlm-939	45	44	%	%	NOUN
ajlm-939	45	45	(	(	PUNCT
ajlm-939	45	46	46/81	46/81	NOUN
ajlm-939	45	47	)	)	PUNCT
ajlm-939	45	48	were	be	AUX
ajlm-939	45	49	from	from	ADP
ajlm-939	45	50	men	man	NOUN
ajlm-939	45	51	(	(	PUNCT
ajlm-939	45	52	table	table	NOUN
ajlm-939	45	53	1	1	NUM
ajlm-939	45	54	)	)	PUNCT
ajlm-939	45	55	.	.	PUNCT
ajlm-939	46	1	all	all	PRON
ajlm-939	46	2	of	of	ADP
ajlm-939	46	3	the	the	DET
ajlm-939	46	4	81	81	NUM
ajlm-939	46	5	cases	case	NOUN
ajlm-939	46	6	studied	study	VERB
ajlm-939	46	7	had	have	AUX
ajlm-939	46	8	been	be	AUX
ajlm-939	46	9	diagnosed	diagnose	VERB
ajlm-939	46	10	with	with	ADP
ajlm-939	46	11	hiv-1	hiv-1	ADV
ajlm-939	46	12	implying	imply	VERB
ajlm-939	46	13	that	that	SCONJ
ajlm-939	46	14	they	they	PRON
ajlm-939	46	15	were	be	AUX
ajlm-939	46	16	living	live	VERB
ajlm-939	46	17	with	with	ADP
ajlm-939	46	18	the	the	DET
ajlm-939	46	19	virus	virus	NOUN
ajlm-939	46	20	.	.	PUNCT
ajlm-939	47	1	in	in	ADP
ajlm-939	47	2	addition	addition	NOUN
ajlm-939	47	3	,	,	PUNCT
ajlm-939	47	4	it	it	PRON
ajlm-939	47	5	was	be	AUX
ajlm-939	47	6	observed	observe	VERB
ajlm-939	47	7	that	that	SCONJ
ajlm-939	47	8	none	none	NOUN
ajlm-939	47	9	of	of	ADP
ajlm-939	47	10	the	the	DET
ajlm-939	47	11	cases	case	NOUN
ajlm-939	47	12	had	have	VERB
ajlm-939	47	13	a	a	DET
ajlm-939	47	14	cluster	cluster	NOUN
ajlm-939	47	15	of	of	ADP
ajlm-939	47	16	differentiation	differentiation	NOUN
ajlm-939	47	17	4	4	NUM
ajlm-939	47	18	cell	cell	NOUN
ajlm-939	47	19	count	count	NOUN
ajlm-939	47	20	above	above	ADP
ajlm-939	47	21	350	350	NUM
ajlm-939	47	22	cells	cell	NOUN
ajlm-939	47	23	/	/	SYM
ajlm-939	47	24	mm3	mm3	NOUN
ajlm-939	47	25	.	.	PUNCT
ajlm-939	48	1	among	among	ADP
ajlm-939	48	2	the	the	DET
ajlm-939	48	3	81	81	NUM
ajlm-939	48	4	cases	case	NOUN
ajlm-939	48	5	,	,	PUNCT
ajlm-939	48	6	the	the	DET
ajlm-939	48	7	orf75	orf75	ADJ
ajlm-939	48	8	gene	gene	NOUN
ajlm-939	48	9	was	be	AUX
ajlm-939	48	10	detected	detect	VERB
ajlm-939	48	11	in	in	ADP
ajlm-939	48	12	49	49	NUM
ajlm-939	48	13	cases	case	NOUN
ajlm-939	48	14	(	(	PUNCT
ajlm-939	48	15	60.5	60.5	NUM
ajlm-939	48	16	%	%	NOUN
ajlm-939	48	17	)	)	PUNCT
ajlm-939	48	18	;	;	PUNCT
ajlm-939	48	19	27.2	27.2	NUM
ajlm-939	48	20	%	%	NOUN
ajlm-939	48	21	(	(	PUNCT
ajlm-939	48	22	22/81	22/81	NUM
ajlm-939	48	23	)	)	PUNCT
ajlm-939	48	24	were	be	AUX
ajlm-939	48	25	women	woman	NOUN
ajlm-939	48	26	and	and	CCONJ
ajlm-939	48	27	33.3	33.3	NUM
ajlm-939	48	28	%	%	NOUN
ajlm-939	48	29	(	(	PUNCT
ajlm-939	48	30	27/81	27/81	NUM
ajlm-939	48	31	)	)	PUNCT
ajlm-939	48	32	were	be	AUX
ajlm-939	48	33	men	man	NOUN
ajlm-939	48	34	.	.	PUNCT
ajlm-939	49	1	among	among	ADP
ajlm-939	49	2	cases	case	NOUN
ajlm-939	49	3	positive	positive	ADJ
ajlm-939	49	4	for	for	ADP
ajlm-939	49	5	the	the	DET
ajlm-939	49	6	orf75	orf75	ADJ
ajlm-939	49	7	gene	gene	NOUN
ajlm-939	49	8	,	,	PUNCT
ajlm-939	49	9	4.1	4.1	NUM
ajlm-939	49	10	%	%	NOUN
ajlm-939	49	11	(	(	PUNCT
ajlm-939	49	12	2/49	2/49	NUM
ajlm-939	49	13	)	)	PUNCT
ajlm-939	49	14	were	be	AUX
ajlm-939	49	15	never	never	ADV
ajlm-939	49	16	on	on	ADP
ajlm-939	49	17	any	any	DET
ajlm-939	49	18	form	form	NOUN
ajlm-939	49	19	of	of	ADP
ajlm-939	49	20	antiretroviral	antiretroviral	ADJ
ajlm-939	49	21	therapy	therapy	NOUN
ajlm-939	49	22	and	and	CCONJ
ajlm-939	49	23	95.9	95.9	NUM
ajlm-939	49	24	%	%	NOUN
ajlm-939	49	25	(	(	PUNCT
ajlm-939	49	26	47/49	47/49	NUM
ajlm-939	49	27	)	)	PUNCT
ajlm-939	49	28	were	be	AUX
ajlm-939	49	29	on	on	ADP
ajlm-939	49	30	antiretroviral	antiretroviral	ADJ
ajlm-939	49	31	therapy	therapy	NOUN
ajlm-939	49	32	.	.	PUNCT
ajlm-939	50	1	no	no	DET
ajlm-939	50	2	statistically	statistically	ADV
ajlm-939	50	3	significant	significant	ADJ
ajlm-939	50	4	association	association	NOUN
ajlm-939	50	5	was	be	AUX
ajlm-939	50	6	found	find	VERB
ajlm-939	50	7	between	between	ADP
ajlm-939	50	8	the	the	DET
ajlm-939	50	9	presence	presence	NOUN
ajlm-939	50	10	of	of	ADP
ajlm-939	50	11	the	the	DET
ajlm-939	50	12	orf75	orf75	ADJ
ajlm-939	50	13	gene	gene	NOUN
ajlm-939	50	14	and	and	CCONJ
ajlm-939	50	15	sex	sex	NOUN
ajlm-939	50	16	,	,	PUNCT
ajlm-939	50	17	antiretroviral	antiretroviral	ADJ
ajlm-939	50	18	treatment	treatment	NOUN
ajlm-939	50	19	status	status	NOUN
ajlm-939	50	20	,	,	PUNCT
ajlm-939	50	21	number	number	NOUN
ajlm-939	50	22	of	of	ADP
ajlm-939	50	23	ks	ks	NOUN
ajlm-939	50	24	lesions	lesion	NOUN
ajlm-939	50	25	or	or	CCONJ
ajlm-939	50	26	distribution	distribution	NOUN
ajlm-939	50	27	of	of	ADP
ajlm-939	50	28	the	the	DET
ajlm-939	50	29	ks	ks	NOUN
ajlm-939	50	30	lesions	lesion	NOUN
ajlm-939	50	31	(	(	PUNCT
ajlm-939	50	32	all	all	DET
ajlm-939	50	33	p	p	NOUN
ajlm-939	50	34	-	-	PUNCT
ajlm-939	50	35	values	value	NOUN
ajlm-939	50	36	>	>	X
ajlm-939	50	37	0.05	0.05	NUM
ajlm-939	50	38	)	)	PUNCT
ajlm-939	50	39	.	.	PUNCT
ajlm-939	51	1	table	table	NOUN
ajlm-939	51	2	1	1	NUM
ajlm-939	51	3	:	:	PUNCT
ajlm-939	51	4	 	 	SPACE
ajlm-939	51	5	crude	crude	ADJ
ajlm-939	51	6	prevalence	prevalence	NOUN
ajlm-939	51	7	odds	odd	VERB
ajlm-939	51	8	ratio	ratio	NOUN
ajlm-939	51	9	and	and	CCONJ
ajlm-939	51	10	95	95	NUM
ajlm-939	51	11	%	%	NOUN
ajlm-939	51	12	confidence	confidence	NOUN
ajlm-939	51	13	intervals	interval	NOUN
ajlm-939	51	14	for	for	ADP
ajlm-939	51	15	patient	patient	ADJ
ajlm-939	51	16	characteristics	characteristic	NOUN
ajlm-939	51	17	and	and	CCONJ
ajlm-939	51	18	presence	presence	NOUN
ajlm-939	51	19	of	of	ADP
ajlm-939	51	20	the	the	DET
ajlm-939	51	21	kshv	kshv	PROPN
ajlm-939	51	22	orf75	orf75	PROPN
ajlm-939	51	23	gene	gene	NOUN
ajlm-939	51	24	,	,	PUNCT
ajlm-939	51	25	nairobi	nairobi	PROPN
ajlm-939	51	26	,	,	PUNCT
ajlm-939	51	27	kenya	kenya	PROPN
ajlm-939	51	28	,	,	PUNCT
ajlm-939	51	29	2013–2016	2013–2016	NUM
ajlm-939	51	30	.	.	PUNCT
ajlm-939	52	1	age	age	NOUN
ajlm-939	52	2	the	the	DET
ajlm-939	52	3	mean	mean	ADJ
ajlm-939	52	4	age	age	NOUN
ajlm-939	52	5	of	of	ADP
ajlm-939	52	6	patients	patient	NOUN
ajlm-939	52	7	with	with	ADP
ajlm-939	52	8	tissue	tissue	NOUN
ajlm-939	52	9	blocks	block	NOUN
ajlm-939	52	10	positive	positive	ADJ
ajlm-939	52	11	for	for	ADP
ajlm-939	52	12	the	the	DET
ajlm-939	52	13	orf75	orf75	ADJ
ajlm-939	52	14	gene	gene	NOUN
ajlm-939	52	15	was	be	AUX
ajlm-939	52	16	41	41	NUM
ajlm-939	52	17	years	year	NOUN
ajlm-939	52	18	(	(	PUNCT
ajlm-939	52	19	standard	standard	ADJ
ajlm-939	52	20	deviation	deviation	NOUN
ajlm-939	52	21	=	=	SYM
ajlm-939	52	22	9.2	9.2	NUM
ajlm-939	52	23	;	;	PUNCT
ajlm-939	52	24	maximum	maximum	ADJ
ajlm-939	52	25	age	age	NOUN
ajlm-939	52	26	,	,	PUNCT
ajlm-939	52	27	66	66	NUM
ajlm-939	52	28	years	year	NOUN
ajlm-939	52	29	;	;	PUNCT
ajlm-939	52	30	minimum	minimum	ADJ
ajlm-939	52	31	age	age	NOUN
ajlm-939	52	32	,	,	PUNCT
ajlm-939	52	33	19	19	NUM
ajlm-939	52	34	years	year	NOUN
ajlm-939	52	35	)	)	PUNCT
ajlm-939	52	36	.	.	PUNCT
ajlm-939	53	1	detection	detection	NOUN
ajlm-939	53	2	of	of	ADP
ajlm-939	53	3	the	the	DET
ajlm-939	53	4	orf75	orf75	ADJ
ajlm-939	53	5	gene	gene	NOUN
ajlm-939	53	6	was	be	AUX
ajlm-939	53	7	most	most	ADV
ajlm-939	53	8	common	common	ADJ
ajlm-939	53	9	in	in	ADP
ajlm-939	53	10	the	the	DET
ajlm-939	53	11	30–39	30–39	NUM
ajlm-939	53	12	years	year	NOUN
ajlm-939	53	13	age	age	NOUN
ajlm-939	53	14	group	group	NOUN
ajlm-939	53	15	(	(	PUNCT
ajlm-939	53	16	n	n	NOUN
ajlm-939	53	17	=	=	SYM
ajlm-939	53	18	21	21	NUM
ajlm-939	53	19	;	;	PUNCT
ajlm-939	53	20	42.9	42.9	NUM
ajlm-939	53	21	%	%	NOUN
ajlm-939	53	22	)	)	PUNCT
ajlm-939	53	23	.	.	PUNCT
ajlm-939	54	1	age	age	NOUN
ajlm-939	54	2	had	have	VERB
ajlm-939	54	3	a	a	DET
ajlm-939	54	4	statistically	statistically	ADV
ajlm-939	54	5	significant	significant	ADJ
ajlm-939	54	6	association	association	NOUN
ajlm-939	54	7	with	with	ADP
ajlm-939	54	8	orf75	orf75	ADJ
ajlm-939	54	9	gene	gene	NOUN
ajlm-939	54	10	positivity	positivity	NOUN
ajlm-939	54	11	(	(	PUNCT
ajlm-939	54	12	prevalence	prevalence	NOUN
ajlm-939	54	13	odds	odd	VERB
ajlm-939	54	14	ratio	ratio	NOUN
ajlm-939	54	15	:	:	PUNCT
ajlm-939	54	16	1.05	1.05	NUM
ajlm-939	54	17	;	;	PUNCT
ajlm-939	54	18	95	95	NUM
ajlm-939	54	19	%	%	NOUN
ajlm-939	54	20	confidence	confidence	NOUN
ajlm-939	54	21	interval	interval	NOUN
ajlm-939	54	22	:	:	PUNCT
ajlm-939	54	23	1.00–1.11	1.00–1.11	NUM
ajlm-939	54	24	,	,	PUNCT
ajlm-939	54	25	p	p	NOUN
ajlm-939	54	26	=	=	NOUN
ajlm-939	54	27	0.047	0.047	NUM
ajlm-939	54	28	)	)	PUNCT
ajlm-939	54	29	.	.	PUNCT
ajlm-939	55	1	kaposi	kaposi	PROPN
ajlm-939	55	2	sarcoma	sarcoma	PROPN
ajlm-939	55	3	morphology	morphology	NOUN
ajlm-939	55	4	and	and	CCONJ
ajlm-939	55	5	distribution	distribution	NOUN
ajlm-939	55	6	of	of	ADP
ajlm-939	55	7	lesions	lesion	NOUN
ajlm-939	55	8	in	in	ADP
ajlm-939	55	9	the	the	DET
ajlm-939	55	10	histology	histology	NOUN
ajlm-939	55	11	report	report	NOUN
ajlm-939	55	12	,	,	PUNCT
ajlm-939	55	13	68	68	NUM
ajlm-939	55	14	cases	case	NOUN
ajlm-939	55	15	had	have	VERB
ajlm-939	55	16	hallmark	hallmark	ADJ
ajlm-939	55	17	features	feature	NOUN
ajlm-939	55	18	of	of	ADP
ajlm-939	55	19	ks	ks	NOUN
ajlm-939	55	20	,	,	PUNCT
ajlm-939	55	21	whereas	whereas	SCONJ
ajlm-939	55	22	13	13	NUM
ajlm-939	55	23	cases	case	NOUN
ajlm-939	55	24	had	have	VERB
ajlm-939	55	25	features	feature	NOUN
ajlm-939	55	26	suggestive	suggestive	ADJ
ajlm-939	55	27	of	of	ADP
ajlm-939	55	28	ks	ks	PROPN
ajlm-939	55	29	(	(	PUNCT
ajlm-939	55	30	ks	ks	NOUN
ajlm-939	55	31	-	-	PUNCT
ajlm-939	55	32	like	like	ADJ
ajlm-939	55	33	)	)	PUNCT
ajlm-939	55	34	.	.	PUNCT
ajlm-939	56	1	the	the	DET
ajlm-939	56	2	types	type	NOUN
ajlm-939	56	3	of	of	ADP
ajlm-939	56	4	ks	ks	PROPN
ajlm-939	56	5	morphology	morphology	PROPN
ajlm-939	56	6	identified	identify	VERB
ajlm-939	56	7	included	include	VERB
ajlm-939	56	8	patchy	patchy	ADJ
ajlm-939	56	9	,	,	PUNCT
ajlm-939	56	10	nodular	nodular	ADJ
ajlm-939	56	11	,	,	PUNCT
ajlm-939	56	12	plaque	plaque	NOUN
ajlm-939	56	13	and	and	CCONJ
ajlm-939	56	14	ks	ks	NOUN
ajlm-939	56	15	-	-	PUNCT
ajlm-939	56	16	like	like	ADJ
ajlm-939	56	17	(	(	PUNCT
ajlm-939	56	18	figure	figure	NOUN
ajlm-939	56	19	1	1	NUM
ajlm-939	56	20	)	)	PUNCT
ajlm-939	56	21	.	.	PUNCT
ajlm-939	57	1	the	the	DET
ajlm-939	57	2	morphological	morphological	ADJ
ajlm-939	57	3	distribution	distribution	NOUN
ajlm-939	57	4	of	of	ADP
ajlm-939	57	5	ks	ks	PROPN
ajlm-939	57	6	was	be	AUX
ajlm-939	57	7	as	as	SCONJ
ajlm-939	57	8	follows	follow	VERB
ajlm-939	57	9	:	:	PUNCT
ajlm-939	57	10	61.7	61.7	NUM
ajlm-939	57	11	%	%	NOUN
ajlm-939	57	12	(	(	PUNCT
ajlm-939	57	13	50/81	50/81	NUM
ajlm-939	57	14	)	)	PUNCT
ajlm-939	57	15	was	be	AUX
ajlm-939	57	16	nodular	nodular	ADJ
ajlm-939	57	17	,	,	PUNCT
ajlm-939	57	18	16	16	NUM
ajlm-939	57	19	%	%	NOUN
ajlm-939	57	20	(	(	PUNCT
ajlm-939	57	21	13/81	13/81	NUM
ajlm-939	57	22	)	)	PUNCT
ajlm-939	57	23	was	be	AUX
ajlm-939	57	24	patchy	patchy	ADJ
ajlm-939	57	25	,	,	PUNCT
ajlm-939	57	26	and	and	CCONJ
ajlm-939	58	1	22	22	NUM
ajlm-939	58	2	%	%	NOUN
ajlm-939	58	3	(	(	PUNCT
ajlm-939	58	4	18/81	18/81	NUM
ajlm-939	58	5	)	)	PUNCT
ajlm-939	58	6	were	be	AUX
ajlm-939	58	7	plaques	plaque	NOUN
ajlm-939	58	8	.	.	PUNCT
ajlm-939	59	1	among	among	ADP
ajlm-939	59	2	the	the	DET
ajlm-939	59	3	cases	case	NOUN
ajlm-939	59	4	that	that	PRON
ajlm-939	59	5	were	be	AUX
ajlm-939	59	6	positive	positive	ADJ
ajlm-939	59	7	for	for	ADP
ajlm-939	59	8	the	the	DET
ajlm-939	59	9	orf75	orf75	ADJ
ajlm-939	59	10	gene	gene	NOUN
ajlm-939	59	11	,	,	PUNCT
ajlm-939	59	12	75.51	75.51	NUM
ajlm-939	59	13	%	%	NOUN
ajlm-939	59	14	(	(	PUNCT
ajlm-939	59	15	37/49	37/49	NUM
ajlm-939	59	16	)	)	PUNCT
ajlm-939	59	17	was	be	AUX
ajlm-939	59	18	nodular	nodular	ADJ
ajlm-939	59	19	,	,	PUNCT
ajlm-939	59	20	4.08	4.08	NUM
ajlm-939	59	21	%	%	NOUN
ajlm-939	59	22	(	(	PUNCT
ajlm-939	59	23	2/49	2/49	NUM
ajlm-939	59	24	)	)	PUNCT
ajlm-939	59	25	patchy	patchy	ADJ
ajlm-939	59	26	,	,	PUNCT
ajlm-939	59	27	and	and	CCONJ
ajlm-939	59	28	20.41	20.41	NUM
ajlm-939	59	29	%	%	NOUN
ajlm-939	59	30	(	(	PUNCT
ajlm-939	59	31	10/49	10/49	NUM
ajlm-939	59	32	)	)	PUNCT
ajlm-939	59	33	were	be	AUX
ajlm-939	59	34	plaques	plaque	NOUN
ajlm-939	59	35	.	.	PUNCT
ajlm-939	60	1	figure	figure	VERB
ajlm-939	60	2	1	1	NUM
ajlm-939	60	3	:	:	PUNCT
ajlm-939	60	4	morphological	morphological	ADJ
ajlm-939	60	5	descriptions	description	NOUN
ajlm-939	60	6	of	of	ADP
ajlm-939	60	7	kaposi	kaposi	PROPN
ajlm-939	60	8	’s	’s	PART
ajlm-939	60	9	sarcoma	sarcoma	NOUN
ajlm-939	60	10	and	and	CCONJ
ajlm-939	60	11	ka	ka	PROPN
ajlm-939	60	12	-	-	PUNCT
ajlm-939	60	13	posi	posi	PROPN
ajlm-939	60	14	’s	’s	PART
ajlm-939	60	15	sarcoma	sarcoma	NOUN
ajlm-939	60	16	-	-	PUNCT
ajlm-939	60	17	like	like	ADJ
ajlm-939	60	18	cases	case	NOUN
ajlm-939	60	19	,	,	PUNCT
ajlm-939	60	20	obtained	obtain	VERB
ajlm-939	60	21	from	from	ADP
ajlm-939	60	22	university	university	PROPN
ajlm-939	60	23	of	of	ADP
ajlm-939	60	24	nairobi	nairobi	PROPN
ajlm-939	60	25	and	and	CCONJ
ajlm-939	60	26	kenyatta	kenyatta	PROPN
ajlm-939	60	27	national	national	PROPN
ajlm-939	60	28	hospital	hospital	PROPN
ajlm-939	60	29	,	,	PUNCT
ajlm-939	60	30	nairobi	nairobi	PROPN
ajlm-939	60	31	,	,	PUNCT
ajlm-939	60	32	kenya	kenya	PROPN
ajlm-939	60	33	,	,	PUNCT
ajlm-939	60	34	2013–2016	2013–2016	NUM
ajlm-939	60	35	.	.	PUNCT
ajlm-939	61	1	microscopic	microscopic	ADJ
ajlm-939	61	2	identification	identification	NOUN
ajlm-939	61	3	by	by	ADP
ajlm-939	61	4	haematoxylin	haematoxylin	NOUN
ajlm-939	61	5	and	and	CCONJ
ajlm-939	61	6	eosin	eosin	NOUN
ajlm-939	61	7	staining	stain	VERB
ajlm-939	61	8	,	,	PUNCT
ajlm-939	61	9	x20	x20	NOUN
ajlm-939	61	10	.	.	PUNCT
ajlm-939	62	1	(	(	PUNCT
ajlm-939	62	2	a	a	X
ajlm-939	62	3	)	)	PUNCT
ajlm-939	62	4	patchy	patchy	ADJ
ajlm-939	62	5	,	,	PUNCT
ajlm-939	62	6	(	(	PUNCT
ajlm-939	62	7	b	b	X
ajlm-939	62	8	)	)	PUNCT
ajlm-939	62	9	nodular	nodular	ADJ
ajlm-939	62	10	,	,	PUNCT
ajlm-939	62	11	(	(	PUNCT
ajlm-939	62	12	c	c	NOUN
ajlm-939	62	13	)	)	PUNCT
ajlm-939	62	14	plaque	plaque	NOUN
ajlm-939	62	15	and	and	CCONJ
ajlm-939	62	16	(	(	PUNCT
ajlm-939	62	17	d	d	NOUN
ajlm-939	62	18	)	)	PUNCT
ajlm-939	62	19	ks	ks	NOUN
ajlm-939	62	20	-	-	PUNCT
ajlm-939	62	21	like	like	PROPN
ajlm-939	62	22	.	.	PUNCT
ajlm-939	63	1	the	the	DET
ajlm-939	63	2	total	total	ADJ
ajlm-939	63	3	number	number	NOUN
ajlm-939	63	4	of	of	ADP
ajlm-939	63	5	ks	ks	NOUN
ajlm-939	63	6	cases	case	NOUN
ajlm-939	63	7	diagnosed	diagnose	VERB
ajlm-939	63	8	by	by	ADP
ajlm-939	63	9	histology	histology	NOUN
ajlm-939	63	10	was	be	AUX
ajlm-939	63	11	68	68	NUM
ajlm-939	63	12	(	(	PUNCT
ajlm-939	63	13	84	84	NUM
ajlm-939	63	14	%	%	NOUN
ajlm-939	63	15	)	)	PUNCT
ajlm-939	63	16	and	and	CCONJ
ajlm-939	63	17	13	13	NUM
ajlm-939	63	18	cases	case	NOUN
ajlm-939	63	19	(	(	PUNCT
ajlm-939	63	20	16	16	NUM
ajlm-939	63	21	%	%	NOUN
ajlm-939	63	22	)	)	PUNCT
ajlm-939	63	23	had	have	VERB
ajlm-939	63	24	ks	ks	NOUN
ajlm-939	63	25	-	-	PUNCT
ajlm-939	63	26	like	like	ADJ
ajlm-939	63	27	features	feature	NOUN
ajlm-939	63	28	(	(	PUNCT
ajlm-939	63	29	table	table	NOUN
ajlm-939	63	30	1	1	NUM
ajlm-939	63	31	)	)	PUNCT
ajlm-939	63	32	.	.	PUNCT
ajlm-939	64	1	among	among	ADP
ajlm-939	64	2	the	the	DET
ajlm-939	64	3	49	49	NUM
ajlm-939	64	4	cases	case	NOUN
ajlm-939	64	5	with	with	ADP
ajlm-939	64	6	the	the	DET
ajlm-939	64	7	orf75	orf75	ADJ
ajlm-939	64	8	gene	gene	NOUN
ajlm-939	64	9	,	,	PUNCT
ajlm-939	64	10	47	47	NUM
ajlm-939	64	11	(	(	PUNCT
ajlm-939	64	12	95.9	95.9	NUM
ajlm-939	64	13	%	%	NOUN
ajlm-939	64	14	)	)	PUNCT
ajlm-939	64	15	showed	show	VERB
ajlm-939	64	16	hallmark	hallmark	ADJ
ajlm-939	64	17	features	feature	NOUN
ajlm-939	64	18	of	of	ADP
ajlm-939	64	19	ks	ks	PROPN
ajlm-939	64	20	and	and	CCONJ
ajlm-939	64	21	2	2	NUM
ajlm-939	64	22	(	(	PUNCT
ajlm-939	64	23	4.1	4.1	NUM
ajlm-939	64	24	%	%	NOUN
ajlm-939	64	25	)	)	PUNCT
ajlm-939	64	26	had	have	VERB
ajlm-939	64	27	ks	ks	NOUN
ajlm-939	64	28	-	-	PUNCT
ajlm-939	64	29	like	like	ADJ
ajlm-939	64	30	features	feature	NOUN
ajlm-939	64	31	with	with	ADP
ajlm-939	64	32	microscopic	microscopic	ADJ
ajlm-939	64	33	examination	examination	NOUN
ajlm-939	64	34	.	.	PUNCT
ajlm-939	65	1	there	there	PRON
ajlm-939	65	2	was	be	VERB
ajlm-939	65	3	an	an	DET
ajlm-939	65	4	association	association	NOUN
ajlm-939	65	5	between	between	ADP
ajlm-939	65	6	microscopic	microscopic	ADJ
ajlm-939	65	7	identification	identification	NOUN
ajlm-939	65	8	of	of	ADP
ajlm-939	65	9	ks	ks	NOUN
ajlm-939	65	10	by	by	ADP
ajlm-939	65	11	histology	histology	NOUN
ajlm-939	65	12	and	and	CCONJ
ajlm-939	65	13	the	the	DET
ajlm-939	65	14	presence	presence	NOUN
ajlm-939	65	15	of	of	ADP
ajlm-939	65	16	the	the	DET
ajlm-939	65	17	orf75	orf75	ADJ
ajlm-939	65	18	gene	gene	NOUN
ajlm-939	65	19	(	(	PUNCT
ajlm-939	65	20	prevalence	prevalence	NOUN
ajlm-939	65	21	odds	odd	VERB
ajlm-939	65	22	ratio	ratio	NOUN
ajlm-939	65	23	=	=	NOUN
ajlm-939	65	24	12.3	12.3	NUM
ajlm-939	65	25	;	;	PUNCT
ajlm-939	65	26	95	95	NUM
ajlm-939	65	27	%	%	NOUN
ajlm-939	65	28	confidence	confidence	NOUN
ajlm-939	65	29	interval	interval	NOUN
ajlm-939	65	30	=	=	NOUN
ajlm-939	65	31	12.51	12.51	NUM
ajlm-939	65	32	–	–	PUNCT
ajlm-939	65	33	60.49	60.49	NUM
ajlm-939	65	34	;	;	PUNCT
ajlm-939	65	35	p	p	PROPN
ajlm-939	65	36	=	=	NOUN
ajlm-939	65	37	0.002	0.002	NUM
ajlm-939	65	38	)	)	PUNCT
ajlm-939	65	39	(	(	PUNCT
ajlm-939	65	40	table	table	NOUN
ajlm-939	65	41	1	1	NUM
ajlm-939	65	42	)	)	PUNCT
ajlm-939	65	43	.	.	PUNCT
ajlm-939	66	1	the	the	DET
ajlm-939	66	2	amplified	amplify	VERB
ajlm-939	66	3	orf75	orf75	ADJ
ajlm-939	66	4	genes	gene	NOUN
ajlm-939	66	5	of	of	ADP
ajlm-939	66	6	hhv-8	hhv-8	NUM
ajlm-939	66	7	were	be	AUX
ajlm-939	66	8	identified	identify	VERB
ajlm-939	66	9	by	by	ADP
ajlm-939	66	10	1	1	NUM
ajlm-939	66	11	%	%	NOUN
ajlm-939	66	12	agarose	agarose	NOUN
ajlm-939	66	13	gel	gel	NOUN
ajlm-939	66	14	electrophoresis	electrophoresis	NOUN
ajlm-939	66	15	(	(	PUNCT
ajlm-939	66	16	figure	figure	NOUN
ajlm-939	66	17	2	2	NUM
ajlm-939	66	18	)	)	PUNCT
ajlm-939	66	19	.	.	PUNCT
ajlm-939	67	1	figure	figure	VERB
ajlm-939	67	2	2	2	NUM
ajlm-939	67	3	:	:	PUNCT
ajlm-939	67	4	polymerase	polymerase	NOUN
ajlm-939	67	5	chain	chain	NOUN
ajlm-939	67	6	reaction	reaction	NOUN
ajlm-939	67	7	agarose	agarose	VERB
ajlm-939	67	8	gel	gel	NOUN
ajlm-939	67	9	electrophoresis	electrophoresis	NOUN
ajlm-939	67	10	results	result	NOUN
ajlm-939	67	11	of	of	ADP
ajlm-939	67	12	ka	ka	PROPN
ajlm-939	67	13	-	-	PUNCT
ajlm-939	67	14	posi	posi	PROPN
ajlm-939	67	15	’s	’s	PART
ajlm-939	67	16	sarcoma	sarcoma	NOUN
ajlm-939	67	17	herpes	herpe	NOUN
ajlm-939	67	18	virus	virus	NOUN
ajlm-939	67	19	orf75	orf75	ADJ
ajlm-939	67	20	gene	gene	NOUN
ajlm-939	67	21	.	.	PUNCT
ajlm-939	68	1	cases	case	NOUN
ajlm-939	68	2	obtained	obtain	VERB
ajlm-939	68	3	from	from	ADP
ajlm-939	68	4	university	university	PROPN
ajlm-939	68	5	of	of	ADP
ajlm-939	68	6	nairobi	nairobi	PROPN
ajlm-939	68	7	and	and	CCONJ
ajlm-939	68	8	kenyatta	kenyatta	PROPN
ajlm-939	68	9	national	national	PROPN
ajlm-939	68	10	hospital	hospital	PROPN
ajlm-939	68	11	,	,	PUNCT
ajlm-939	68	12	nairobi	nairobi	PROPN
ajlm-939	68	13	,	,	PUNCT
ajlm-939	68	14	kenya	kenya	PROPN
ajlm-939	68	15	,	,	PUNCT
ajlm-939	68	16	2013–2016	2013–2016	NUM
ajlm-939	68	17	.	.	PUNCT
ajlm-939	69	1	discussion	discussion	NOUN
ajlm-939	69	2	retrieved	retrieve	VERB
ajlm-939	69	3	clinical	clinical	ADJ
ajlm-939	69	4	data	datum	NOUN
ajlm-939	69	5	revealed	reveal	VERB
ajlm-939	69	6	that	that	SCONJ
ajlm-939	69	7	all	all	PRON
ajlm-939	69	8	of	of	ADP
ajlm-939	69	9	the	the	DET
ajlm-939	69	10	tissue	tissue	NOUN
ajlm-939	69	11	blocks	block	NOUN
ajlm-939	69	12	retrieved	retrieve	VERB
ajlm-939	69	13	in	in	ADP
ajlm-939	69	14	the	the	DET
ajlm-939	69	15	present	present	ADJ
ajlm-939	69	16	study	study	NOUN
ajlm-939	69	17	were	be	AUX
ajlm-939	69	18	collected	collect	VERB
ajlm-939	69	19	from	from	ADP
ajlm-939	69	20	patients	patient	NOUN
ajlm-939	69	21	who	who	PRON
ajlm-939	69	22	had	have	AUX
ajlm-939	69	23	been	be	AUX
ajlm-939	69	24	diagnosed	diagnose	VERB
ajlm-939	69	25	with	with	ADP
ajlm-939	69	26	hiv-1	hiv-1	NOUN
ajlm-939	69	27	.	.	PUNCT
ajlm-939	70	1	these	these	DET
ajlm-939	70	2	patients	patient	NOUN
ajlm-939	70	3	might	might	AUX
ajlm-939	70	4	have	have	AUX
ajlm-939	70	5	developed	develop	VERB
ajlm-939	70	6	ks	ks	PROPN
ajlm-939	70	7	lesions	lesion	NOUN
ajlm-939	70	8	due	due	ADP
ajlm-939	70	9	to	to	ADP
ajlm-939	70	10	immunosup	immunosup	NOUN
ajlm-939	70	11	-	-	PUNCT
ajlm-939	70	12	pression	pression	NOUN
ajlm-939	70	13	or	or	CCONJ
ajlm-939	70	14	because	because	SCONJ
ajlm-939	70	15	they	they	PRON
ajlm-939	70	16	were	be	AUX
ajlm-939	70	17	immunocomprised	immunocomprise	VERB
ajlm-939	70	18	due	due	ADP
ajlm-939	70	19	to	to	ADP
ajlm-939	70	20	increased	increase	VERB
ajlm-939	70	21	viral	viral	ADJ
ajlm-939	70	22	load	load	NOUN
ajlm-939	70	23	that	that	PRON
ajlm-939	70	24	impaired	impair	VERB
ajlm-939	70	25	their	their	PRON
ajlm-939	70	26	immune	immune	ADJ
ajlm-939	70	27	system	system	NOUN
ajlm-939	70	28	.	.	PUNCT
ajlm-939	71	1	other	other	ADJ
ajlm-939	71	2	studies	study	NOUN
ajlm-939	71	3	have	have	AUX
ajlm-939	71	4	also	also	ADV
ajlm-939	71	5	associated	associate	VERB
ajlm-939	71	6	ks	ks	PROPN
ajlm-939	71	7	as	as	ADP
ajlm-939	71	8	an	an	DET
ajlm-939	71	9	hiv	hiv	PROPN
ajlm-939	71	10	/	/	SYM
ajlm-939	71	11	aids	aids	PROPN
ajlm-939	71	12	-	-	PUNCT
ajlm-939	71	13	defining	define	VERB
ajlm-939	71	14	illness.9,13,24,34,35,36	illness.9,13,24,34,35,36	VERB
ajlm-939	71	15	the	the	DET
ajlm-939	71	16	findings	finding	NOUN
ajlm-939	71	17	of	of	ADP
ajlm-939	71	18	this	this	DET
ajlm-939	71	19	study	study	NOUN
ajlm-939	71	20	revealed	reveal	VERB
ajlm-939	71	21	that	that	SCONJ
ajlm-939	71	22	men	man	NOUN
ajlm-939	71	23	were	be	AUX
ajlm-939	71	24	more	more	ADV
ajlm-939	71	25	prone	prone	ADJ
ajlm-939	71	26	to	to	ADP
ajlm-939	71	27	development	development	NOUN
ajlm-939	71	28	of	of	ADP
ajlm-939	71	29	ks	ks	NOUN
ajlm-939	71	30	:	:	PUNCT
ajlm-939	71	31	56.8	56.8	NUM
ajlm-939	71	32	%	%	NOUN
ajlm-939	71	33	(	(	PUNCT
ajlm-939	71	34	46/81	46/81	NOUN
ajlm-939	71	35	)	)	PUNCT
ajlm-939	71	36	compared	compare	VERB
ajlm-939	71	37	with	with	ADP
ajlm-939	71	38	women	woman	NOUN
ajlm-939	71	39	43.2	43.2	NUM
ajlm-939	71	40	%	%	NOUN
ajlm-939	71	41	(	(	PUNCT
ajlm-939	71	42	35/81	35/81	NUM
ajlm-939	71	43	)	)	PUNCT
ajlm-939	71	44	.	.	PUNCT
ajlm-939	72	1	this	this	DET
ajlm-939	72	2	observation	observation	NOUN
ajlm-939	72	3	is	be	AUX
ajlm-939	72	4	concordant	concordant	ADJ
ajlm-939	72	5	with	with	ADP
ajlm-939	72	6	others	other	NOUN
ajlm-939	72	7	who	who	PRON
ajlm-939	72	8	also	also	ADV
ajlm-939	72	9	noted	note	VERB
ajlm-939	72	10	more	more	ADV
ajlm-939	72	11	frequent	frequent	ADJ
ajlm-939	72	12	development	development	NOUN
ajlm-939	72	13	of	of	ADP
ajlm-939	72	14	ks	ks	PROPN
ajlm-939	72	15	among	among	ADP
ajlm-939	72	16	men.37,38,39,40	men.37,38,39,40	NOUN
ajlm-939	72	17	there	there	PRON
ajlm-939	72	18	is	be	VERB
ajlm-939	72	19	a	a	DET
ajlm-939	72	20	lack	lack	NOUN
ajlm-939	72	21	of	of	ADP
ajlm-939	72	22	consensus	consensus	NOUN
ajlm-939	72	23	as	as	ADP
ajlm-939	72	24	to	to	ADP
ajlm-939	72	25	why	why	SCONJ
ajlm-939	72	26	all	all	DET
ajlm-939	72	27	forms	form	NOUN
ajlm-939	72	28	of	of	ADP
ajlm-939	72	29	ks	k	NOUN
ajlm-939	72	30	are	be	AUX
ajlm-939	72	31	more	more	ADV
ajlm-939	72	32	common	common	ADJ
ajlm-939	72	33	among	among	ADP
ajlm-939	72	34	men	man	NOUN
ajlm-939	72	35	than	than	ADP
ajlm-939	72	36	women.41,42	women.41,42	ADJ
ajlm-939	72	37	we	we	PRON
ajlm-939	72	38	hypothesise	hypothesise	VERB
ajlm-939	72	39	that	that	SCONJ
ajlm-939	72	40	gender	gender	NOUN
ajlm-939	72	41	-	-	PUNCT
ajlm-939	72	42	related	relate	VERB
ajlm-939	72	43	factors	factor	NOUN
ajlm-939	72	44	such	such	ADJ
ajlm-939	72	45	as	as	ADP
ajlm-939	72	46	hormones	hormone	NOUN
ajlm-939	72	47	might	might	AUX
ajlm-939	72	48	influence	influence	VERB
ajlm-939	72	49	the	the	DET
ajlm-939	72	50	development	development	NOUN
ajlm-939	72	51	of	of	ADP
ajlm-939	72	52	ks	ks	NOUN
ajlm-939	72	53	lesions	lesion	NOUN
ajlm-939	72	54	.	.	PUNCT
ajlm-939	73	1	the	the	DET
ajlm-939	73	2	results	result	NOUN
ajlm-939	73	3	of	of	ADP
ajlm-939	73	4	this	this	DET
ajlm-939	73	5	study	study	NOUN
ajlm-939	73	6	showing	show	VERB
ajlm-939	73	7	ks	ks	X
ajlm-939	73	8	pre	pre	PROPN
ajlm-939	73	9	-	-	PROPN
ajlm-939	73	10	ponderance	ponderance	PROPN
ajlm-939	73	11	among	among	ADP
ajlm-939	73	12	men	man	NOUN
ajlm-939	73	13	was	be	AUX
ajlm-939	73	14	consistent	consistent	ADJ
ajlm-939	73	15	with	with	ADP
ajlm-939	73	16	the	the	DET
ajlm-939	73	17	country	country	NOUN
ajlm-939	73	18	’s	’s	PART
ajlm-939	73	19	published	publish	VERB
ajlm-939	73	20	data	datum	NOUN
ajlm-939	73	21	on	on	ADP
ajlm-939	73	22	the	the	DET
ajlm-939	73	23	distribution	distribution	NOUN
ajlm-939	73	24	of	of	ADP
ajlm-939	73	25	malignancy	malignancy	NOUN
ajlm-939	73	26	cases	case	NOUN
ajlm-939	73	27	as	as	SCONJ
ajlm-939	73	28	captured	capture	VERB
ajlm-939	73	29	in	in	ADP
ajlm-939	73	30	the	the	DET
ajlm-939	73	31	national	national	ADJ
ajlm-939	73	32	cancer	cancer	PROPN
ajlm-939	73	33	control	control	PROPN
ajlm-939	73	34	strategy	strategy	NOUN
ajlm-939	73	35	,	,	PUNCT
ajlm-939	73	36	2017.43	2017.43	NUM
ajlm-939	73	37	kaposi	kaposi	PROPN
ajlm-939	73	38	’s	’s	PART
ajlm-939	73	39	sarcoma	sarcoma	PROPN
ajlm-939	73	40	immune	immune	ADJ
ajlm-939	73	41	reconstitution	reconstitution	NOUN
ajlm-939	73	42	occurs	occur	VERB
ajlm-939	73	43	when	when	SCONJ
ajlm-939	73	44	a	a	DET
ajlm-939	73	45	portion	portion	NOUN
ajlm-939	73	46	of	of	ADP
ajlm-939	73	47	aids	aids	PROPN
ajlm-939	73	48	-	-	PUNCT
ajlm-939	73	49	ks	ks	NOUN
ajlm-939	73	50	cases	case	NOUN
ajlm-939	73	51	responds	respond	VERB
ajlm-939	73	52	to	to	ADP
ajlm-939	73	53	the	the	DET
ajlm-939	73	54	introduction	introduction	NOUN
ajlm-939	73	55	of	of	ADP
ajlm-939	73	56	combined	combine	VERB
ajlm-939	73	57	antiretroviral	antiretroviral	ADJ
ajlm-939	73	58	therapy	therapy	NOUN
ajlm-939	73	59	with	with	ADP
ajlm-939	73	60	disease	disease	NOUN
ajlm-939	73	61	advancement.44,45,46	advancement.44,45,46	NOUN
ajlm-939	73	62	in	in	ADP
ajlm-939	73	63	this	this	DET
ajlm-939	73	64	study	study	NOUN
ajlm-939	73	65	,	,	PUNCT
ajlm-939	74	1	ks	ks	PROPN
ajlm-939	74	2	lesions	lesion	NOUN
ajlm-939	74	3	manifested	manifest	VERB
ajlm-939	74	4	among	among	ADP
ajlm-939	74	5	patients	patient	NOUN
ajlm-939	74	6	despite	despite	SCONJ
ajlm-939	74	7	the	the	DET
ajlm-939	74	8	fact	fact	NOUN
ajlm-939	74	9	that	that	SCONJ
ajlm-939	74	10	77	77	NUM
ajlm-939	74	11	(	(	PUNCT
ajlm-939	74	12	95.1	95.1	NUM
ajlm-939	74	13	%	%	NOUN
ajlm-939	74	14	)	)	PUNCT
ajlm-939	74	15	were	be	AUX
ajlm-939	74	16	on	on	ADP
ajlm-939	74	17	antiretroviral	antiretroviral	ADJ
ajlm-939	74	18	treat	treat	NOUN
ajlm-939	74	19	-	-	PUNCT
ajlm-939	74	20	ment	ment	NOUN
ajlm-939	74	21	.	.	PUNCT
ajlm-939	75	1	contrary	contrary	ADJ
ajlm-939	75	2	to	to	ADP
ajlm-939	75	3	other	other	ADJ
ajlm-939	75	4	findings	finding	NOUN
ajlm-939	75	5	that	that	SCONJ
ajlm-939	75	6	antiretroviral	antiretroviral	ADJ
ajlm-939	75	7	therapy	therapy	NOUN
ajlm-939	75	8	alone	alone	ADV
ajlm-939	75	9	can	can	AUX
ajlm-939	75	10	result	result	VERB
ajlm-939	75	11	in	in	ADP
ajlm-939	75	12	the	the	DET
ajlm-939	75	13	resolution	resolution	NOUN
ajlm-939	75	14	of	of	ADP
ajlm-939	75	15	ks,47,48	ks,47,48	PROPN
ajlm-939	75	16	in	in	ADP
ajlm-939	75	17	our	our	PRON
ajlm-939	75	18	study	study	NOUN
ajlm-939	75	19	,	,	PUNCT
ajlm-939	75	20	being	be	AUX
ajlm-939	75	21	on	on	ADP
ajlm-939	75	22	antiretroviral	antiretroviral	ADJ
ajlm-939	75	23	treatment	treatment	NOUN
ajlm-939	75	24	did	do	AUX
ajlm-939	75	25	not	not	PART
ajlm-939	75	26	have	have	VERB
ajlm-939	75	27	a	a	DET
ajlm-939	75	28	statistically	statistically	ADV
ajlm-939	75	29	significant	significant	ADJ
ajlm-939	75	30	association	association	NOUN
ajlm-939	75	31	with	with	ADP
ajlm-939	75	32	the	the	DET
ajlm-939	75	33	presence	presence	NOUN
ajlm-939	75	34	of	of	ADP
ajlm-939	75	35	ks	ks	PROPN
ajlm-939	75	36	(	(	PUNCT
ajlm-939	75	37	p	p	X
ajlm-939	75	38	=	=	NOUN
ajlm-939	75	39	0.66	0.66	NUM
ajlm-939	75	40	)	)	PUNCT
ajlm-939	75	41	.	.	PUNCT
ajlm-939	76	1	this	this	DET
ajlm-939	76	2	finding	finding	NOUN
ajlm-939	76	3	is	be	AUX
ajlm-939	76	4	in	in	ADP
ajlm-939	76	5	agreement	agreement	NOUN
ajlm-939	76	6	with	with	ADP
ajlm-939	76	7	another	another	DET
ajlm-939	76	8	study	study	NOUN
ajlm-939	76	9	that	that	PRON
ajlm-939	76	10	stated	state	VERB
ajlm-939	76	11	that	that	SCONJ
ajlm-939	76	12	there	there	PRON
ajlm-939	76	13	has	have	AUX
ajlm-939	76	14	been	be	AUX
ajlm-939	76	15	continued	continue	VERB
ajlm-939	76	16	diagnosis	diagnosis	NOUN
ajlm-939	76	17	of	of	ADP
ajlm-939	76	18	ks	ks	PROPN
ajlm-939	76	19	in	in	ADP
ajlm-939	76	20	hiv	hiv	PROPN
ajlm-939	76	21	-	-	PUNCT
ajlm-939	76	22	positive	positive	ADJ
ajlm-939	76	23	patients	patient	NOUN
ajlm-939	76	24	,	,	PUNCT
ajlm-939	76	25	despite	despite	SCONJ
ajlm-939	76	26	the	the	DET
ajlm-939	76	27	availability	availability	NOUN
ajlm-939	76	28	of	of	ADP
ajlm-939	76	29	highly	highly	ADV
ajlm-939	76	30	active	active	ADJ
ajlm-939	76	31	antiretroviral	antiretroviral	ADJ
ajlm-939	76	32	therapy.49	therapy.49	ADP
ajlm-939	76	33	other	other	ADJ
ajlm-939	76	34	studies	study	NOUN
ajlm-939	76	35	have	have	AUX
ajlm-939	76	36	stated	state	VERB
ajlm-939	76	37	that	that	SCONJ
ajlm-939	76	38	patients	patient	NOUN
ajlm-939	76	39	infected	infect	VERB
ajlm-939	76	40	with	with	ADP
ajlm-939	76	41	aids	aids	PROPN
ajlm-939	76	42	-	-	PUNCT
ajlm-939	76	43	associated	associate	VERB
ajlm-939	76	44	ks	ks	NOUN
ajlm-939	76	45	respond	respond	VERB
ajlm-939	76	46	to	to	ADP
ajlm-939	76	47	combined	combined	ADJ
ajlm-939	76	48	antiretroviral	antiretroviral	ADJ
ajlm-939	76	49	therapy	therapy	NOUN
ajlm-939	76	50	by	by	ADP
ajlm-939	76	51	50	50	NUM
ajlm-939	76	52	%	%	NOUN
ajlm-939	76	53	depending	depend	VERB
ajlm-939	76	54	on	on	ADP
ajlm-939	76	55	geographical	geographical	ADJ
ajlm-939	76	56	location	location	NOUN
ajlm-939	76	57	and	and	CCONJ
ajlm-939	76	58	severity	severity	NOUN
ajlm-939	76	59	of	of	ADP
ajlm-939	76	60	the	the	DET
ajlm-939	76	61	presentation	presentation	NOUN
ajlm-939	76	62	,	,	PUNCT
ajlm-939	76	63	thereby	thereby	ADV
ajlm-939	76	64	resulting	result	VERB
ajlm-939	76	65	in	in	ADP
ajlm-939	76	66	immune	immune	ADJ
ajlm-939	76	67	reconstitution	reconstitution	NOUN
ajlm-939	76	68	and	and	CCONJ
ajlm-939	76	69	hiv	hiv	PROPN
ajlm-939	76	70	suppression.50,51,52	suppression.50,51,52	PUNCT
ajlm-939	76	71	in	in	ADP
ajlm-939	76	72	the	the	DET
ajlm-939	76	73	current	current	ADJ
ajlm-939	76	74	study	study	NOUN
ajlm-939	76	75	,	,	PUNCT
ajlm-939	76	76	these	these	DET
ajlm-939	76	77	manifestations	manifestation	NOUN
ajlm-939	76	78	of	of	ADP
ajlm-939	76	79	ks	ks	NOUN
ajlm-939	76	80	could	could	AUX
ajlm-939	76	81	be	be	AUX
ajlm-939	76	82	attributed	attribute	VERB
ajlm-939	76	83	to	to	ADP
ajlm-939	76	84	the	the	DET
ajlm-939	76	85	weakening	weakening	NOUN
ajlm-939	76	86	of	of	ADP
ajlm-939	76	87	the	the	DET
ajlm-939	76	88	immune	immune	ADJ
ajlm-939	76	89	system	system	NOUN
ajlm-939	76	90	by	by	ADP
ajlm-939	76	91	hiv-1	hiv-1	NOUN
ajlm-939	76	92	.	.	PUNCT
ajlm-939	77	1	this	this	DET
ajlm-939	77	2	study	study	NOUN
ajlm-939	77	3	found	find	VERB
ajlm-939	77	4	patchy	patchy	ADJ
ajlm-939	77	5	,	,	PUNCT
ajlm-939	77	6	plaque	plaque	NOUN
ajlm-939	77	7	and	and	CCONJ
ajlm-939	77	8	nodular	nodular	ADJ
ajlm-939	77	9	morphological	morphological	ADJ
ajlm-939	77	10	presentations	presentation	NOUN
ajlm-939	77	11	of	of	ADP
ajlm-939	77	12	ks	ks	PROPN
ajlm-939	77	13	.	.	PUNCT
ajlm-939	78	1	the	the	DET
ajlm-939	78	2	morphological	morphological	ADJ
ajlm-939	78	3	appearance	appearance	NOUN
ajlm-939	78	4	of	of	ADP
ajlm-939	78	5	ks	ks	PROPN
ajlm-939	78	6	shows	show	VERB
ajlm-939	78	7	progression	progression	NOUN
ajlm-939	78	8	from	from	ADP
ajlm-939	78	9	plaques	plaque	NOUN
ajlm-939	78	10	to	to	ADP
ajlm-939	78	11	nodular	nodular	ADJ
ajlm-939	78	12	form	form	NOUN
ajlm-939	78	13	and	and	CCONJ
ajlm-939	78	14	fungiform.1	fungiform.1	PROPN
ajlm-939	78	15	kaposi	kaposi	PROPN
ajlm-939	78	16	sarcoma	sarcoma	PROPN
ajlm-939	78	17	lesions	lesion	NOUN
ajlm-939	78	18	are	be	AUX
ajlm-939	78	19	known	know	VERB
ajlm-939	78	20	to	to	PART
ajlm-939	78	21	progress	progress	VERB
ajlm-939	78	22	from	from	ADP
ajlm-939	78	23	asymptomatic	asymptomatic	ADJ
ajlm-939	78	24	to	to	PART
ajlm-939	78	25	macule	macule	VERB
ajlm-939	78	26	,	,	PUNCT
ajlm-939	78	27	papule	papule	NOUN
ajlm-939	78	28	,	,	PUNCT
ajlm-939	78	29	plaque	plaque	NOUN
ajlm-939	78	30	and	and	CCONJ
ajlm-939	78	31	nodule	nodule	NOUN
ajlm-939	78	32	forms.53	forms.53	PROPN
ajlm-939	78	33	the	the	DET
ajlm-939	78	34	findings	finding	NOUN
ajlm-939	78	35	of	of	ADP
ajlm-939	78	36	this	this	DET
ajlm-939	78	37	study	study	NOUN
ajlm-939	78	38	revealed	reveal	VERB
ajlm-939	78	39	that	that	SCONJ
ajlm-939	78	40	the	the	DET
ajlm-939	78	41	ks	ks	NOUN
ajlm-939	78	42	lesions	lesion	NOUN
ajlm-939	78	43	were	be	AUX
ajlm-939	78	44	disseminated	disseminate	VERB
ajlm-939	78	45	in	in	ADP
ajlm-939	78	46	different	different	ADJ
ajlm-939	78	47	body	body	NOUN
ajlm-939	78	48	regions	region	NOUN
ajlm-939	78	49	,	,	PUNCT
ajlm-939	78	50	including	include	VERB
ajlm-939	78	51	the	the	DET
ajlm-939	78	52	lower	low	ADJ
ajlm-939	78	53	limbs	limb	NOUN
ajlm-939	78	54	,	,	PUNCT
ajlm-939	78	55	upper	upper	ADJ
ajlm-939	78	56	limbs	limb	NOUN
ajlm-939	78	57	,	,	PUNCT
ajlm-939	78	58	genitalia	genitalia	NOUN
ajlm-939	78	59	,	,	PUNCT
ajlm-939	78	60	eyelids	eyelid	NOUN
ajlm-939	78	61	,	,	PUNCT
ajlm-939	78	62	palate	palate	VERB
ajlm-939	78	63	,	,	PUNCT
ajlm-939	78	64	oral	oral	ADJ
ajlm-939	78	65	cavity	cavity	NOUN
ajlm-939	78	66	and	and	CCONJ
ajlm-939	78	67	trunk	trunk	NOUN
ajlm-939	78	68	(	(	PUNCT
ajlm-939	78	69	chest	chest	NOUN
ajlm-939	78	70	and	and	CCONJ
ajlm-939	78	71	back	back	ADV
ajlm-939	78	72	)	)	PUNCT
ajlm-939	78	73	.	.	PUNCT
ajlm-939	79	1	in	in	ADP
ajlm-939	79	2	another	another	DET
ajlm-939	79	3	study	study	NOUN
ajlm-939	79	4	,	,	PUNCT
ajlm-939	79	5	fatality	fatality	NOUN
ajlm-939	79	6	was	be	AUX
ajlm-939	79	7	witnessed	witness	VERB
ajlm-939	79	8	in	in	ADP
ajlm-939	79	9	hiv	hiv	PROPN
ajlm-939	79	10	-	-	PUNCT
ajlm-939	79	11	positive	positive	ADJ
ajlm-939	79	12	patients	patient	NOUN
ajlm-939	79	13	who	who	PRON
ajlm-939	79	14	had	have	VERB
ajlm-939	79	15	ks	ks	PROPN
ajlm-939	79	16	lesions	lesion	NOUN
ajlm-939	79	17	manifested	manifest	VERB
ajlm-939	79	18	in	in	ADP
ajlm-939	79	19	the	the	DET
ajlm-939	79	20	gastrointestinal	gastrointestinal	ADJ
ajlm-939	79	21	tract	tract	NOUN
ajlm-939	79	22	,	,	PUNCT
ajlm-939	79	23	lungs	lung	NOUN
ajlm-939	79	24	and	and	CCONJ
ajlm-939	79	25	lymph	lymph	NOUN
ajlm-939	79	26	nodes.54	nodes.54	PROPN
ajlm-939	79	27	the	the	DET
ajlm-939	79	28	decision	decision	NOUN
ajlm-939	79	29	in	in	ADP
ajlm-939	79	30	this	this	DET
ajlm-939	79	31	study	study	NOUN
ajlm-939	79	32	to	to	PART
ajlm-939	79	33	use	use	VERB
ajlm-939	79	34	tissue	tissue	NOUN
ajlm-939	79	35	biopsy	biopsy	NOUN
ajlm-939	79	36	for	for	ADP
ajlm-939	79	37	detection	detection	NOUN
ajlm-939	79	38	of	of	ADP
ajlm-939	79	39	the	the	DET
ajlm-939	79	40	orf75	orf75	ADJ
ajlm-939	79	41	gene	gene	NOUN
ajlm-939	79	42	of	of	ADP
ajlm-939	79	43	hhv-8	hhv-8	NOUN
ajlm-939	79	44	is	be	AUX
ajlm-939	79	45	in	in	ADP
ajlm-939	79	46	agreement	agreement	NOUN
ajlm-939	79	47	with	with	ADP
ajlm-939	79	48	another	another	DET
ajlm-939	79	49	study	study	NOUN
ajlm-939	79	50	that	that	PRON
ajlm-939	79	51	supported	support	VERB
ajlm-939	79	52	the	the	DET
ajlm-939	79	53	use	use	NOUN
ajlm-939	79	54	of	of	ADP
ajlm-939	79	55	tumor	tumor	NOUN
ajlm-939	79	56	biopsies	biopsy	NOUN
ajlm-939	79	57	as	as	ADP
ajlm-939	79	58	suitable	suitable	ADJ
ajlm-939	79	59	for	for	ADP
ajlm-939	79	60	viral	viral	ADJ
ajlm-939	79	61	dna	dna	NOUN
ajlm-939	79	62	identification	identification	NOUN
ajlm-939	79	63	due	due	ADP
ajlm-939	79	64	to	to	ADP
ajlm-939	79	65	high	high	ADJ
ajlm-939	79	66	viral	viral	ADJ
ajlm-939	79	67	load	load	NOUN
ajlm-939	79	68	as	as	SCONJ
ajlm-939	79	69	opposed	oppose	VERB
ajlm-939	79	70	to	to	ADP
ajlm-939	79	71	the	the	DET
ajlm-939	79	72	use	use	NOUN
ajlm-939	79	73	of	of	ADP
ajlm-939	79	74	blood.30	blood.30	NOUN
ajlm-939	79	75	further	far	ADV
ajlm-939	79	76	to	to	ADP
ajlm-939	79	77	that	that	PRON
ajlm-939	79	78	,	,	PUNCT
ajlm-939	79	79	nested	nest	VERB
ajlm-939	79	80	pcr	pcr	PROPN
ajlm-939	79	81	has	have	AUX
ajlm-939	79	82	been	be	AUX
ajlm-939	79	83	used	use	VERB
ajlm-939	79	84	successfully	successfully	ADV
ajlm-939	79	85	to	to	PART
ajlm-939	79	86	assess	assess	VERB
ajlm-939	79	87	the	the	DET
ajlm-939	79	88	prevalence	prevalence	NOUN
ajlm-939	79	89	of	of	ADP
ajlm-939	79	90	hhv-8	hhv-8	NOUN
ajlm-939	79	91	among	among	ADP
ajlm-939	79	92	hiv	hiv	PROPN
ajlm-939	79	93	-	-	PUNCT
ajlm-939	79	94	positive	positive	ADJ
ajlm-939	79	95	patients	patient	NOUN
ajlm-939	79	96	in	in	ADP
ajlm-939	79	97	brazil.27	brazil.27	PROPN
ajlm-939	79	98	a	a	DET
ajlm-939	79	99	tissue	tissue	NOUN
ajlm-939	79	100	biopsy	biopsy	NOUN
ajlm-939	79	101	excised	excise	VERB
ajlm-939	79	102	from	from	ADP
ajlm-939	79	103	a	a	DET
ajlm-939	79	104	ks	ks	NOUN
ajlm-939	79	105	lesion	lesion	NOUN
ajlm-939	79	106	has	have	AUX
ajlm-939	79	107	been	be	AUX
ajlm-939	79	108	shown	show	VERB
ajlm-939	79	109	to	to	PART
ajlm-939	79	110	have	have	VERB
ajlm-939	79	111	high	high	ADJ
ajlm-939	79	112	viral	viral	ADJ
ajlm-939	79	113	load	load	NOUN
ajlm-939	79	114	;	;	PUNCT
ajlm-939	79	115	hence	hence	ADV
ajlm-939	79	116	,	,	PUNCT
ajlm-939	79	117	biopsies	biopsy	NOUN
ajlm-939	79	118	are	be	AUX
ajlm-939	79	119	the	the	DET
ajlm-939	79	120	ideal	ideal	ADJ
ajlm-939	79	121	sample	sample	NOUN
ajlm-939	79	122	for	for	ADP
ajlm-939	79	123	the	the	DET
ajlm-939	79	124	detection	detection	NOUN
ajlm-939	79	125	of	of	ADP
ajlm-939	79	126	kshv	kshv	PROPN
ajlm-939	79	127	dna.55	dna.55	VERB
ajlm-939	79	128	the	the	DET
ajlm-939	79	129	detection	detection	NOUN
ajlm-939	79	130	of	of	ADP
ajlm-939	79	131	the	the	DET
ajlm-939	79	132	orf75	orf75	ADJ
ajlm-939	79	133	gene	gene	NOUN
ajlm-939	79	134	implies	imply	VERB
ajlm-939	79	135	that	that	SCONJ
ajlm-939	79	136	this	this	DET
ajlm-939	79	137	gene	gene	NOUN
ajlm-939	79	138	was	be	AUX
ajlm-939	79	139	present	present	ADJ
ajlm-939	79	140	in	in	ADP
ajlm-939	79	141	49	49	NUM
ajlm-939	79	142	(	(	PUNCT
ajlm-939	79	143	60.5	60.5	NUM
ajlm-939	79	144	%	%	NOUN
ajlm-939	79	145	)	)	PUNCT
ajlm-939	79	146	of	of	ADP
ajlm-939	79	147	the	the	DET
ajlm-939	79	148	studied	study	VERB
ajlm-939	79	149	cases	case	NOUN
ajlm-939	79	150	.	.	PUNCT
ajlm-939	80	1	strength	strength	NOUN
ajlm-939	80	2	and	and	CCONJ
ajlm-939	80	3	limitations	limitation	NOUN
ajlm-939	80	4	our	our	PRON
ajlm-939	80	5	study	study	NOUN
ajlm-939	80	6	used	use	VERB
ajlm-939	80	7	the	the	DET
ajlm-939	80	8	haematoxylin	haematoxylin	NOUN
ajlm-939	80	9	and	and	CCONJ
ajlm-939	80	10	eosin	eosin	NOUN
ajlm-939	80	11	staining	stain	VERB
ajlm-939	80	12	technique	technique	NOUN
ajlm-939	80	13	and	and	CCONJ
ajlm-939	80	14	the	the	DET
ajlm-939	80	15	nested	nested	ADJ
ajlm-939	80	16	pcr	pcr	ADJ
ajlm-939	80	17	method	method	NOUN
ajlm-939	80	18	for	for	ADP
ajlm-939	80	19	detection	detection	NOUN
ajlm-939	80	20	of	of	ADP
ajlm-939	80	21	the	the	DET
ajlm-939	80	22	orf75	orf75	ADJ
ajlm-939	80	23	genes	gene	NOUN
ajlm-939	80	24	of	of	ADP
ajlm-939	80	25	the	the	DET
ajlm-939	80	26	kshv	kshv	PROPN
ajlm-939	80	27	.	.	PUNCT
ajlm-939	81	1	however	however	ADV
ajlm-939	81	2	,	,	PUNCT
ajlm-939	81	3	hhv-8	hhv-8	VERB
ajlm-939	81	4	immunohistochemical	immunohistochemical	ADJ
ajlm-939	81	5	biopsy	biopsy	NOUN
ajlm-939	81	6	has	have	AUX
ajlm-939	81	7	been	be	AUX
ajlm-939	81	8	demonstrated	demonstrate	VERB
ajlm-939	81	9	to	to	PART
ajlm-939	81	10	be	be	AUX
ajlm-939	81	11	the	the	DET
ajlm-939	81	12	‘	'	PUNCT
ajlm-939	81	13	gold	gold	ADJ
ajlm-939	81	14	standard	standard	NOUN
ajlm-939	81	15	’	'	PUNCT
ajlm-939	81	16	for	for	ADP
ajlm-939	81	17	ks	ks	PROPN
ajlm-939	81	18	diagnosis.56	diagnosis.56	NOUN
ajlm-939	81	19	cases	case	NOUN
ajlm-939	81	20	in	in	ADP
ajlm-939	81	21	the	the	DET
ajlm-939	81	22	present	present	ADJ
ajlm-939	81	23	study	study	NOUN
ajlm-939	81	24	had	have	VERB
ajlm-939	81	25	a	a	DET
ajlm-939	81	26	dark	dark	ADJ
ajlm-939	81	27	skin	skin	NOUN
ajlm-939	81	28	pigmentation	pigmentation	NOUN
ajlm-939	81	29	.	.	PUNCT
ajlm-939	82	1	in	in	ADP
ajlm-939	82	2	another	another	DET
ajlm-939	82	3	study	study	NOUN
ajlm-939	82	4	of	of	ADP
ajlm-939	82	5	dark	dark	ADJ
ajlm-939	82	6	-	-	PUNCT
ajlm-939	82	7	skinned	skinned	ADJ
ajlm-939	82	8	patients	patient	NOUN
ajlm-939	82	9	,	,	PUNCT
ajlm-939	82	10	ks	ks	PROPN
ajlm-939	82	11	had	have	AUX
ajlm-939	82	12	been	be	AUX
ajlm-939	82	13	confirmed	confirm	VERB
ajlm-939	82	14	to	to	PART
ajlm-939	82	15	mimic	mimic	VERB
ajlm-939	82	16	a	a	DET
ajlm-939	82	17	number	number	NOUN
ajlm-939	82	18	of	of	ADP
ajlm-939	82	19	non	non	ADJ
ajlm-939	82	20	-	-	ADJ
ajlm-939	82	21	ks	ks	ADJ
ajlm-939	82	22	-	-	PUNCT
ajlm-939	82	23	like	like	ADJ
ajlm-939	82	24	dermatological	dermatological	ADJ
ajlm-939	82	25	conditions.56	conditions.56	NOUN
ajlm-939	82	26	in	in	ADP
ajlm-939	82	27	another	another	DET
ajlm-939	82	28	study	study	NOUN
ajlm-939	82	29	,	,	PUNCT
ajlm-939	82	30	it	it	PRON
ajlm-939	82	31	was	be	AUX
ajlm-939	82	32	observed	observe	VERB
ajlm-939	82	33	that	that	SCONJ
ajlm-939	82	34	it	it	PRON
ajlm-939	82	35	is	be	AUX
ajlm-939	82	36	difficult	difficult	ADJ
ajlm-939	82	37	to	to	PART
ajlm-939	82	38	identify	identify	VERB
ajlm-939	82	39	ks	ks	PROPN
ajlm-939	82	40	in	in	ADP
ajlm-939	82	41	dark	dark	ADJ
ajlm-939	82	42	-	-	PUNCT
ajlm-939	82	43	skinned	skin	VERB
ajlm-939	82	44	individuals	individual	NOUN
ajlm-939	82	45	,	,	PUNCT
ajlm-939	82	46	who	who	PRON
ajlm-939	82	47	presented	present	VERB
ajlm-939	82	48	with	with	ADP
ajlm-939	82	49	violaceous	violaceous	ADJ
ajlm-939	82	50	skin	skin	NOUN
ajlm-939	82	51	lesions.56	lesions.56	NOUN
ajlm-939	82	52	the	the	DET
ajlm-939	82	53	use	use	NOUN
ajlm-939	82	54	of	of	ADP
ajlm-939	82	55	the	the	DET
ajlm-939	82	56	pcr	pcr	ADJ
ajlm-939	82	57	technique	technique	NOUN
ajlm-939	82	58	in	in	ADP
ajlm-939	82	59	the	the	DET
ajlm-939	82	60	detection	detection	NOUN
ajlm-939	82	61	of	of	ADP
ajlm-939	82	62	kshv	kshv	PROPN
ajlm-939	82	63	has	have	AUX
ajlm-939	82	64	been	be	AUX
ajlm-939	82	65	shown	show	VERB
ajlm-939	82	66	to	to	PART
ajlm-939	82	67	give	give	VERB
ajlm-939	82	68	the	the	DET
ajlm-939	82	69	utmost	utmost	ADJ
ajlm-939	82	70	specificity	specificity	NOUN
ajlm-939	82	71	compared	compare	VERB
ajlm-939	82	72	to	to	ADP
ajlm-939	82	73	the	the	DET
ajlm-939	82	74	use	use	NOUN
ajlm-939	82	75	of	of	ADP
ajlm-939	82	76	tests	test	NOUN
ajlm-939	82	77	that	that	PRON
ajlm-939	82	78	determine	determine	VERB
ajlm-939	82	79	exposure	exposure	NOUN
ajlm-939	82	80	to	to	ADP
ajlm-939	82	81	infection.28	infection.28	NOUN
ajlm-939	82	82	in	in	ADP
ajlm-939	82	83	addition	addition	NOUN
ajlm-939	82	84	,	,	PUNCT
ajlm-939	82	85	the	the	DET
ajlm-939	82	86	pcr	pcr	NOUN
ajlm-939	82	87	technique	technique	NOUN
ajlm-939	82	88	can	can	AUX
ajlm-939	82	89	detect	detect	VERB
ajlm-939	82	90	approximately	approximately	ADV
ajlm-939	82	91	95	95	NUM
ajlm-939	82	92	%	%	NOUN
ajlm-939	82	93	of	of	ADP
ajlm-939	82	94	all	all	PRON
ajlm-939	82	95	ks	ks	NOUN
ajlm-939	82	96	cases.28	cases.28	NOUN
ajlm-939	82	97	however	however	ADV
ajlm-939	82	98	,	,	PUNCT
ajlm-939	82	99	the	the	DET
ajlm-939	82	100	cost	cost	NOUN
ajlm-939	82	101	associated	associate	VERB
ajlm-939	82	102	with	with	ADP
ajlm-939	82	103	the	the	DET
ajlm-939	82	104	use	use	NOUN
ajlm-939	82	105	of	of	ADP
ajlm-939	82	106	pcr	pcr	NOUN
ajlm-939	82	107	is	be	AUX
ajlm-939	82	108	quite	quite	ADV
ajlm-939	82	109	high	high	ADJ
ajlm-939	82	110	,	,	PUNCT
ajlm-939	82	111	which	which	PRON
ajlm-939	82	112	would	would	AUX
ajlm-939	82	113	limit	limit	VERB
ajlm-939	82	114	the	the	DET
ajlm-939	82	115	clinical	clinical	ADJ
ajlm-939	82	116	application	application	NOUN
ajlm-939	82	117	of	of	ADP
ajlm-939	82	118	hhv-8	hhv-8	NUM
ajlm-939	82	119	dna	dna	PROPN
ajlm-939	82	120	detection	detection	NOUN
ajlm-939	82	121	in	in	ADP
ajlm-939	82	122	resource	resource	NOUN
ajlm-939	82	123	-	-	PUNCT
ajlm-939	82	124	limited	limit	VERB
ajlm-939	82	125	facili	facili	NOUN
ajlm-939	82	126	-	-	PUNCT
ajlm-939	82	127	ties.28	ties.28	NOUN
ajlm-939	82	128	implications	implication	NOUN
ajlm-939	82	129	and	and	CCONJ
ajlm-939	82	130	recommendations	recommendation	NOUN
ajlm-939	82	131	the	the	DET
ajlm-939	82	132	present	present	ADJ
ajlm-939	82	133	study	study	NOUN
ajlm-939	82	134	considered	consider	VERB
ajlm-939	82	135	microscopic	microscopic	ADJ
ajlm-939	82	136	detection	detection	NOUN
ajlm-939	82	137	of	of	ADP
ajlm-939	82	138	ks	ks	PROPN
ajlm-939	82	139	by	by	ADP
ajlm-939	82	140	haematoxylin	haematoxylin	NOUN
ajlm-939	82	141	and	and	CCONJ
ajlm-939	82	142	eosin	eosin	NOUN
ajlm-939	82	143	as	as	ADP
ajlm-939	82	144	a	a	DET
ajlm-939	82	145	significant	significant	ADJ
ajlm-939	82	146	indicator	indicator	NOUN
ajlm-939	82	147	of	of	ADP
ajlm-939	82	148	kshv	kshv	PROPN
ajlm-939	82	149	orf75	orf75	PROPN
ajlm-939	82	150	gene	gene	NOUN
ajlm-939	82	151	positivity	positivity	NOUN
ajlm-939	82	152	.	.	PUNCT
ajlm-939	83	1	it	it	PRON
ajlm-939	83	2	therefore	therefore	ADV
ajlm-939	83	3	recommends	recommend	VERB
ajlm-939	83	4	the	the	DET
ajlm-939	83	5	use	use	NOUN
ajlm-939	83	6	of	of	ADP
ajlm-939	83	7	both	both	CCONJ
ajlm-939	83	8	clinical	clinical	ADJ
ajlm-939	83	9	diagnosis	diagnosis	NOUN
ajlm-939	83	10	and	and	CCONJ
ajlm-939	83	11	routine	routine	ADJ
ajlm-939	83	12	microscopy	microscopy	NOUN
ajlm-939	83	13	in	in	ADP
ajlm-939	83	14	the	the	DET
ajlm-939	83	15	diagnosis	diagnosis	NOUN
ajlm-939	83	16	of	of	ADP
ajlm-939	83	17	ks	ks	PROPN
ajlm-939	83	18	in	in	ADP
ajlm-939	83	19	resource	resource	NOUN
ajlm-939	83	20	-	-	PUNCT
ajlm-939	83	21	limited	limit	VERB
ajlm-939	83	22	facilities	facility	NOUN
ajlm-939	83	23	.	.	PUNCT
ajlm-939	84	1	however	however	ADV
ajlm-939	84	2	,	,	PUNCT
ajlm-939	84	3	among	among	ADP
ajlm-939	84	4	individuals	individual	NOUN
ajlm-939	84	5	with	with	ADP
ajlm-939	84	6	dark	dark	ADJ
ajlm-939	84	7	skin	skin	NOUN
ajlm-939	84	8	pigmentation	pigmentation	NOUN
ajlm-939	84	9	,	,	PUNCT
ajlm-939	84	10	there	there	PRON
ajlm-939	84	11	is	be	VERB
ajlm-939	84	12	the	the	DET
ajlm-939	84	13	need	need	NOUN
ajlm-939	84	14	to	to	PART
ajlm-939	84	15	employ	employ	VERB
ajlm-939	84	16	the	the	DET
ajlm-939	84	17	use	use	NOUN
ajlm-939	84	18	of	of	ADP
ajlm-939	84	19	a	a	DET
ajlm-939	84	20	robust	robust	ADJ
ajlm-939	84	21	diagnostic	diagnostic	ADJ
ajlm-939	84	22	technique	technique	NOUN
ajlm-939	84	23	to	to	PART
ajlm-939	84	24	ascertain	ascertain	VERB
ajlm-939	84	25	the	the	DET
ajlm-939	84	26	true	true	ADJ
ajlm-939	84	27	causative	causative	ADJ
ajlm-939	84	28	agent	agent	NOUN
ajlm-939	84	29	.	.	PUNCT
ajlm-939	85	1	conclusion	conclusion	NOUN
ajlm-939	85	2	the	the	DET
ajlm-939	85	3	presence	presence	NOUN
ajlm-939	85	4	of	of	ADP
ajlm-939	85	5	the	the	DET
ajlm-939	85	6	orf75	orf75	ADJ
ajlm-939	85	7	gene	gene	NOUN
ajlm-939	85	8	of	of	ADP
ajlm-939	85	9	kshv	kshv	NOUN
ajlm-939	85	10	among	among	ADP
ajlm-939	85	11	immunosuppressed	immunosuppressed	ADJ
ajlm-939	85	12	patients	patient	NOUN
ajlm-939	85	13	due	due	ADJ
ajlm-939	85	14	to	to	ADP
ajlm-939	85	15	hiv-1	hiv-1	X
ajlm-939	85	16	was	be	AUX
ajlm-939	85	17	successfully	successfully	ADV
ajlm-939	85	18	detected	detect	VERB
ajlm-939	85	19	.	.	PUNCT
ajlm-939	86	1	following	follow	VERB
ajlm-939	86	2	the	the	DET
ajlm-939	86	3	initial	initial	ADJ
ajlm-939	86	4	diagnosis	diagnosis	NOUN
ajlm-939	86	5	of	of	ADP
ajlm-939	86	6	ks	ks	NOUN
ajlm-939	86	7	by	by	ADP
ajlm-939	86	8	histology	histology	NOUN
ajlm-939	86	9	,	,	PUNCT
ajlm-939	86	10	the	the	DET
ajlm-939	86	11	orf75	orf75	ADJ
ajlm-939	86	12	gene	gene	NOUN
ajlm-939	86	13	was	be	AUX
ajlm-939	86	14	further	far	ADV
ajlm-939	86	15	detected	detect	VERB
ajlm-939	86	16	from	from	ADP
ajlm-939	86	17	both	both	DET
ajlm-939	86	18	cases	case	NOUN
ajlm-939	86	19	that	that	PRON
ajlm-939	86	20	had	have	VERB
ajlm-939	86	21	the	the	DET
ajlm-939	86	22	hallmark	hallmark	NOUN
ajlm-939	86	23	features	feature	NOUN
ajlm-939	86	24	ks	ks	PROPN
ajlm-939	86	25	and	and	CCONJ
ajlm-939	86	26	those	those	PRON
ajlm-939	86	27	that	that	PRON
ajlm-939	86	28	had	have	VERB
ajlm-939	86	29	ks	ks	NOUN
ajlm-939	86	30	-	-	PUNCT
ajlm-939	86	31	like	like	ADJ
ajlm-939	86	32	features	feature	NOUN
ajlm-939	86	33	.	.	PUNCT
ajlm-939	87	1	microscopic	microscopic	ADJ
ajlm-939	87	2	detection	detection	NOUN
ajlm-939	87	3	of	of	ADP
ajlm-939	87	4	ks	ks	PROPN
ajlm-939	87	5	by	by	ADP
ajlm-939	87	6	haematoxylin	haematoxylin	NOUN
ajlm-939	87	7	and	and	CCONJ
ajlm-939	87	8	eosin	eosin	NOUN
ajlm-939	87	9	should	should	AUX
ajlm-939	87	10	be	be	AUX
ajlm-939	87	11	considered	consider	VERB
ajlm-939	87	12	a	a	DET
ajlm-939	87	13	significant	significant	ADJ
ajlm-939	87	14	indicator	indicator	NOUN
ajlm-939	87	15	of	of	ADP
ajlm-939	87	16	kshv	kshv	PROPN
ajlm-939	87	17	orf75	orf75	PROPN
ajlm-939	87	18	gene	gene	NOUN
ajlm-939	87	19	positivity	positivity	NOUN
ajlm-939	87	20	.	.	PUNCT
ajlm-939	88	1	acknowledgements	acknowledgement	VERB
ajlm-939	88	2	the	the	DET
ajlm-939	88	3	authors	author	NOUN
ajlm-939	88	4	of	of	ADP
ajlm-939	88	5	this	this	DET
ajlm-939	88	6	manuscript	manuscript	NOUN
ajlm-939	88	7	would	would	AUX
ajlm-939	88	8	like	like	VERB
ajlm-939	88	9	to	to	PART
ajlm-939	88	10	extend	extend	VERB
ajlm-939	88	11	their	their	PRON
ajlm-939	88	12	gratitude	gratitude	NOUN
ajlm-939	88	13	to	to	ADP
ajlm-939	88	14	kenyatta	kenyatta	PROPN
ajlm-939	88	15	national	national	PROPN
ajlm-939	88	16	hospital	hospital	PROPN
ajlm-939	88	17	and	and	CCONJ
ajlm-939	88	18	university	university	PROPN
ajlm-939	88	19	of	of	ADP
ajlm-939	88	20	nairobi	nairobi	PROPN
ajlm-939	88	21	for	for	ADP
ajlm-939	88	22	allowing	allow	VERB
ajlm-939	88	23	them	they	PRON
ajlm-939	88	24	to	to	PART
ajlm-939	88	25	use	use	VERB
ajlm-939	88	26	their	their	PRON
ajlm-939	88	27	archived	archive	VERB
ajlm-939	88	28	tissue	tissue	NOUN
ajlm-939	88	29	blocks	block	NOUN
ajlm-939	88	30	.	.	PUNCT
ajlm-939	89	1	competing	compete	VERB
ajlm-939	89	2	interests	interest	NOUN
ajlm-939	89	3	the	the	DET
ajlm-939	89	4	authors	author	NOUN
ajlm-939	89	5	declare	declare	VERB
ajlm-939	89	6	no	no	DET
ajlm-939	89	7	conflict	conflict	NOUN
ajlm-939	89	8	of	of	ADP
ajlm-939	89	9	interest	interest	NOUN
ajlm-939	89	10	.	.	PUNCT
ajlm-939	90	1	authors	author	NOUN
ajlm-939	90	2	’	’	PART
ajlm-939	90	3	contributions	contribution	NOUN
ajlm-939	90	4	r.n.d	r.n.d	NOUN
ajlm-939	90	5	.	.	PROPN
ajlm-939	90	6	,	,	PUNCT
ajlm-939	90	7	s.m.a	s.m.a	PROPN
ajlm-939	90	8	.	.	PROPN
ajlm-939	90	9	,	,	PUNCT
ajlm-939	90	10	m.m	m.m	PROPN
ajlm-939	90	11	.	.	PROPN
ajlm-939	90	12	and	and	CCONJ
ajlm-939	90	13	w.o.m	w.o.m	PROPN
ajlm-939	90	14	.	.	PUNCT
ajlm-939	91	1	critically	critically	ADV
ajlm-939	91	2	revised	revise	VERB
ajlm-939	91	3	the	the	DET
ajlm-939	91	4	manuscript	manuscript	NOUN
ajlm-939	91	5	for	for	ADP
ajlm-939	91	6	important	important	ADJ
ajlm-939	91	7	intellectual	intellectual	ADJ
ajlm-939	91	8	content	content	NOUN
ajlm-939	91	9	.	.	PUNCT
ajlm-939	92	1	r.n.d	r.n.d	PROPN
ajlm-939	92	2	.	.	PROPN
ajlm-939	92	3	,	,	PUNCT
ajlm-939	92	4	s.m.a	s.m.a	PROPN
ajlm-939	92	5	.	.	PUNCT
ajlm-939	93	1	and	and	CCONJ
ajlm-939	93	2	w.o.m	w.o.m	PROPN
ajlm-939	93	3	.	.	PROPN
ajlm-939	93	4	drafted	draft	VERB
ajlm-939	93	5	the	the	DET
ajlm-939	93	6	manuscript	manuscript	NOUN
ajlm-939	93	7	.	.	PUNCT
ajlm-939	94	1	r.n.d	r.n.d	PROPN
ajlm-939	94	2	.	.	PROPN
ajlm-939	94	3	and	and	CCONJ
ajlm-939	94	4	w.o.m	w.o.m	PROPN
ajlm-939	94	5	.	.	PROPN
ajlm-939	94	6	conceptualised	conceptualise	VERB
ajlm-939	94	7	and	and	CCONJ
ajlm-939	94	8	designed	design	VERB
ajlm-939	94	9	the	the	DET
ajlm-939	94	10	study	study	NOUN
ajlm-939	94	11	and	and	CCONJ
ajlm-939	94	12	ana	ana	PROPN
ajlm-939	94	13	-	-	PUNCT
ajlm-939	94	14	lysed	lyse	VERB
ajlm-939	94	15	and	and	CCONJ
ajlm-939	94	16	interpreted	interpret	VERB
ajlm-939	94	17	the	the	DET
ajlm-939	94	18	data	datum	NOUN
ajlm-939	94	19	.	.	PUNCT
ajlm-939	95	1	r.n.d	r.n.d	PROPN
ajlm-939	95	2	.	.	PROPN
ajlm-939	96	1	and	and	CCONJ
ajlm-939	96	2	s.m.a	s.m.a	PROPN
ajlm-939	96	3	.	.	PROPN
ajlm-939	96	4	acquired	acquire	VERB
ajlm-939	96	5	the	the	DET
ajlm-939	96	6	data	datum	NOUN
ajlm-939	96	7	.	.	PUNCT
ajlm-939	97	1	sources	source	NOUN
ajlm-939	97	2	of	of	ADP
ajlm-939	97	3	support	support	NOUN
ajlm-939	97	4	this	this	DET
ajlm-939	97	5	study	study	NOUN
ajlm-939	97	6	was	be	AUX
ajlm-939	97	7	funded	fund	VERB
ajlm-939	97	8	by	by	ADP
ajlm-939	97	9	the	the	DET
ajlm-939	97	10	principal	principal	ADJ
ajlm-939	97	11	investigator	investigator	NOUN
ajlm-939	97	12	(	(	PUNCT
ajlm-939	97	13	r.n.d	r.n.d	PROPN
ajlm-939	97	14	.	.	PUNCT
ajlm-939	97	15	)	)	PUNCT
ajlm-939	97	16	as	as	ADP
ajlm-939	97	17	a	a	DET
ajlm-939	97	18	fulfilment	fulfilment	NOUN
ajlm-939	97	19	for	for	ADP
ajlm-939	97	20	the	the	DET
ajlm-939	97	21	award	award	NOUN
ajlm-939	97	22	of	of	ADP
ajlm-939	97	23	a	a	DET
ajlm-939	97	24	postgraduate	postgraduate	NOUN
ajlm-939	97	25	de	de	NOUN
ajlm-939	97	26	-	-	NOUN
ajlm-939	97	27	gree	gree	NOUN
ajlm-939	97	28	.	.	PUNCT
ajlm-939	98	1	data	datum	NOUN
ajlm-939	98	2	availability	availability	NOUN
ajlm-939	98	3	statement	statement	NOUN
ajlm-939	98	4	data	datum	NOUN
ajlm-939	98	5	sharing	sharing	NOUN
ajlm-939	98	6	is	be	AUX
ajlm-939	98	7	not	not	PART
ajlm-939	98	8	applicable	applicable	ADJ
ajlm-939	98	9	to	to	ADP
ajlm-939	98	10	this	this	DET
ajlm-939	98	11	article	article	NOUN
ajlm-939	98	12	as	as	SCONJ
ajlm-939	98	13	no	no	DET
ajlm-939	98	14	new	new	ADJ
ajlm-939	98	15	data	datum	NOUN
ajlm-939	98	16	were	be	AUX
ajlm-939	98	17	created	create	VERB
ajlm-939	98	18	or	or	CCONJ
ajlm-939	98	19	analysed	analyse	VERB
ajlm-939	98	20	in	in	ADP
ajlm-939	98	21	this	this	DET
ajlm-939	98	22	study	study	NOUN
ajlm-939	98	23	.	.	PUNCT
ajlm-939	99	1	disclaimer	disclaimer	VERB
ajlm-939	99	2	the	the	DET
ajlm-939	99	3	views	view	NOUN
ajlm-939	99	4	and	and	CCONJ
ajlm-939	99	5	opinions	opinion	NOUN
ajlm-939	99	6	expressed	express	VERB
ajlm-939	99	7	in	in	ADP
ajlm-939	99	8	this	this	DET
ajlm-939	99	9	article	article	NOUN
ajlm-939	99	10	are	be	AUX
ajlm-939	99	11	those	those	PRON
ajlm-939	99	12	of	of	ADP
ajlm-939	99	13	the	the	DET
ajlm-939	99	14	authors	author	NOUN
ajlm-939	99	15	and	and	CCONJ
ajlm-939	99	16	do	do	AUX
ajlm-939	99	17	not	not	PART
ajlm-939	99	18	necessarily	necessarily	ADV
ajlm-939	99	19	reflect	reflect	VERB
ajlm-939	99	20	the	the	DET
ajlm-939	99	21	offi	offi	ADJ
ajlm-939	99	22	-	-	ADJ
ajlm-939	99	23	cial	cial	ADJ
ajlm-939	99	24	policy	policy	NOUN
ajlm-939	99	25	or	or	CCONJ
ajlm-939	99	26	position	position	NOUN
ajlm-939	99	27	of	of	ADP
ajlm-939	99	28	any	any	DET
ajlm-939	99	29	affiliated	affiliated	ADJ
ajlm-939	99	30	agency	agency	NOUN
ajlm-939	99	31	of	of	ADP
ajlm-939	99	32	the	the	DET
ajlm-939	99	33	authors	author	NOUN
ajlm-939	99	34	.	.	PUNCT
ajlm-939	100	1	references	reference	NOUN
ajlm-939	100	2	warpe	warpe	PROPN
ajlm-939	100	3	bm	bm	PROPN
ajlm-939	100	4	,	,	PUNCT
ajlm-939	100	5	kaposi	kaposi	PROPN
ajlm-939	100	6	sarcoma	sarcoma	PROPN
ajlm-939	100	7	as	as	ADP
ajlm-939	100	8	initial	initial	ADJ
ajlm-939	100	9	presentation	presentation	NOUN
ajlm-939	100	10	of	of	ADP
ajlm-939	100	11	hiv	hiv	PROPN
ajlm-939	100	12	infection	infection	NOUN
ajlm-939	100	13	.	.	PUNCT
ajlm-939	101	1	n	n	PRON
ajlm-939	101	2	am	be	AUX
ajlm-939	101	3	j	j	PROPN
ajlm-939	101	4	med	med	PROPN
ajlm-939	101	5	sci	sci	PROPN
ajlm-939	101	6	.	.	PUNCT
ajlm-939	102	1	2014;6(12):650	2014;6(12):650	PROPN
ajlm-939	102	2	.	.	PUNCT
ajlm-939	103	1	https://doi.org/10.4103/1947-2714.147984	https://doi.org/10.4103/1947-2714.147984	PROPN
ajlm-939	103	2	betsem	betsem	PROPN
ajlm-939	103	3	e	e	PROPN
ajlm-939	103	4	,	,	PUNCT
ajlm-939	103	5	cassar	cassar	PROPN
ajlm-939	103	6	o	o	PROPN
ajlm-939	103	7	,	,	PUNCT
ajlm-939	103	8	afonso	afonso	PROPN
ajlm-939	103	9	pv	pv	PROPN
ajlm-939	103	10	,	,	PUNCT
ajlm-939	103	11	et	et	PROPN
ajlm-939	103	12	al	al	PROPN
ajlm-939	103	13	.	.	PUNCT
ajlm-939	103	14	epidemiology	epidemiology	NOUN
ajlm-939	103	15	and	and	CCONJ
ajlm-939	103	16	genetic	genetic	ADJ
ajlm-939	103	17	variability	variability	NOUN
ajlm-939	103	18	of	of	ADP
ajlm-939	103	19	hhv-8	hhv-8	NOUN
ajlm-939	103	20	/	/	SYM
ajlm-939	103	21	kshv	kshv	NOUN
ajlm-939	103	22	in	in	ADP
ajlm-939	103	23	pygmy	pygmy	NOUN
ajlm-939	103	24	and	and	CCONJ
ajlm-939	103	25	bantu	bantu	PROPN
ajlm-939	103	26	populations	population	NOUN
ajlm-939	103	27	in	in	ADP
ajlm-939	103	28	cameroon	cameroon	NOUN
ajlm-939	103	29	.	.	PUNCT
ajlm-939	104	1	plos	plos	PROPN
ajlm-939	104	2	negl	negl	PROPN
ajlm-939	104	3	trop	trop	X
ajlm-939	104	4	dis	dis	PROPN
ajlm-939	104	5	.	.	PUNCT
ajlm-939	105	1	2014;15;8(5):e2851	2014;15;8(5):e2851	NUM
ajlm-939	105	2	.	.	PUNCT
ajlm-939	106	1	https://doi.org/10.1371/journal.pntd.0002851	https://doi.org/10.1371/journal.pntd.0002851	NOUN
ajlm-939	106	2	coen	coen	PROPN
ajlm-939	106	3	n	n	CCONJ
ajlm-939	106	4	,	,	PUNCT
ajlm-939	106	5	duraffour	duraffour	PROPN
ajlm-939	106	6	s	s	PROPN
ajlm-939	106	7	,	,	PUNCT
ajlm-939	106	8	snoeck	snoeck	NOUN
ajlm-939	106	9	r	r	NOUN
ajlm-939	106	10	,	,	PUNCT
ajlm-939	106	11	et	et	PROPN
ajlm-939	106	12	al	al	PROPN
ajlm-939	106	13	.	.	PROPN
ajlm-939	106	14	kshv	kshv	PROPN
ajlm-939	106	15	targeted	target	VERB
ajlm-939	106	16	therapy	therapy	NOUN
ajlm-939	106	17	:	:	PUNCT
ajlm-939	106	18	an	an	DET
ajlm-939	106	19	update	update	NOUN
ajlm-939	106	20	on	on	ADP
ajlm-939	106	21	inhibitors	inhibitor	NOUN
ajlm-939	106	22	of	of	ADP
ajlm-939	106	23	viral	viral	ADJ
ajlm-939	106	24	lytic	lytic	ADJ
ajlm-939	106	25	replication	replication	NOUN
ajlm-939	106	26	.	.	PUNCT
ajlm-939	107	1	viruses	virus	NOUN
ajlm-939	107	2	.	.	PUNCT
ajlm-939	108	1	2014;6(11):4731–459	2014;6(11):4731–459	NUM
ajlm-939	108	2	.	.	PUNCT
ajlm-939	109	1	https://doi.org/10.3390/v6114731	https://doi.org/10.3390/v6114731	NOUN
ajlm-939	109	2	raab	raab	NOUN
ajlm-939	109	3	-	-	PUNCT
ajlm-939	109	4	traub	traub	NOUN
ajlm-939	109	5	n.	n.	NOUN
ajlm-939	109	6	novel	novel	NOUN
ajlm-939	109	7	mechanisms	mechanism	NOUN
ajlm-939	109	8	of	of	ADP
ajlm-939	109	9	ebv	ebv	NOUN
ajlm-939	109	10	-	-	PUNCT
ajlm-939	109	11	induced	induce	VERB
ajlm-939	109	12	oncogenesis	oncogenesis	NOUN
ajlm-939	109	13	.	.	PUNCT
ajlm-939	110	1	curr	curr	PROPN
ajlm-939	110	2	opin	opin	NOUN
ajlm-939	110	3	virol	virol	NOUN
ajlm-939	110	4	.	.	PUNCT
ajlm-939	111	1	2012;2(4):453–458	2012;2(4):453–458	X
ajlm-939	111	2	.	.	PUNCT
ajlm-939	111	3	https://doi.org/10.1016/j.coviro.2012.07.001	https://doi.org/10.1016/j.coviro.2012.07.001	NOUN
ajlm-939	111	4	dittmer	dittmer	PROPN
ajlm-939	111	5	dp	dp	PROPN
ajlm-939	111	6	,	,	PUNCT
ajlm-939	111	7	damania	damania	PROPN
ajlm-939	111	8	b.	b.	PROPN
ajlm-939	111	9	kaposi	kaposi	PROPN
ajlm-939	111	10	sarcoma	sarcoma	PROPN
ajlm-939	111	11	associated	associate	VERB
ajlm-939	111	12	herpesvirus	herpesvirus	NOUN
ajlm-939	111	13	pathogenesis	pathogenesis	NOUN
ajlm-939	111	14	(	(	PUNCT
ajlm-939	111	15	kshv	kshv	PROPN
ajlm-939	111	16	)	)	PUNCT
ajlm-939	111	17	–	–	PUNCT
ajlm-939	111	18	an	an	DET
ajlm-939	111	19	update	update	NOUN
ajlm-939	111	20	.	.	PUNCT
ajlm-939	112	1	curr	curr	PROPN
ajlm-939	112	2	opin	opin	NOUN
ajlm-939	112	3	virol	virol	NOUN
ajlm-939	112	4	.	.	PUNCT
ajlm-939	113	1	2013;1;3(3):238–244	2013;1;3(3):238–244	NUM
ajlm-939	113	2	.	.	PUNCT
ajlm-939	114	1	https://doi.org/10.1016/j.coviro.2013.05.012	https://doi.org/10.1016/j.coviro.2013.05.012	PROPN
ajlm-939	114	2	thomas	thomas	PROPN
ajlm-939	114	3	s	s	PROPN
ajlm-939	114	4	,	,	PUNCT
ajlm-939	114	5	sindhu	sindhu	PROPN
ajlm-939	114	6	cb	cb	PROPN
ajlm-939	114	7	,	,	PUNCT
ajlm-939	114	8	sreekumar	sreekumar	PROPN
ajlm-939	114	9	s	s	PART
ajlm-939	114	10	,	,	PUNCT
ajlm-939	114	11	et	et	PROPN
ajlm-939	114	12	al	al	PROPN
ajlm-939	114	13	.	.	PROPN
ajlm-939	114	14	aids	aids	PROPN
ajlm-939	114	15	associated	associated	PROPN
ajlm-939	114	16	kaposi	kaposi	PROPN
ajlm-939	114	17	’s	’s	PART
ajlm-939	114	18	sarcoma	sarcoma	NOUN
ajlm-939	114	19	.	.	PUNCT
ajlm-939	115	1	j	j	PROPN
ajlm-939	115	2	assoc	assoc	PROPN
ajlm-939	115	3	phys	phys	PROPN
ajlm-939	115	4	india	india	PROPN
ajlm-939	116	1	[	[	X
ajlm-939	116	2	serial	serial	ADJ
ajlm-939	116	3	online	online	NOUN
ajlm-939	116	4	]	]	PUNCT
ajlm-939	116	5	.	.	PUNCT
ajlm-939	117	1	2011;59:387–389	2011;59:387–389	NOUN
ajlm-939	117	2	.	.	PUNCT
ajlm-939	117	3	available	available	ADJ
ajlm-939	117	4	from	from	ADP
ajlm-939	117	5	:	:	PUNCT
ajlm-939	117	6	https://europepmc.org/abstract/med/21751599	https://europepmc.org/abstract/med/21751599	NUM
ajlm-939	117	7	ye	ye	PROPN
ajlm-939	117	8	f	f	NOUN
ajlm-939	117	9	,	,	PUNCT
ajlm-939	117	10	lei	lei	X
ajlm-939	117	11	x	x	PROPN
ajlm-939	117	12	,	,	PUNCT
ajlm-939	117	13	gao	gao	PROPN
ajlm-939	117	14	sj	sj	PROPN
ajlm-939	117	15	.	.	PROPN
ajlm-939	117	16	mechanisms	mechanism	NOUN
ajlm-939	117	17	of	of	ADP
ajlm-939	117	18	kaposi	kaposi	PROPN
ajlm-939	117	19	’s	’s	PART
ajlm-939	117	20	sarcoma	sarcoma	NOUN
ajlm-939	117	21	-	-	PUNCT
ajlm-939	117	22	associated	associate	VERB
ajlm-939	117	23	herpesvirus	herpesvirus	NOUN
ajlm-939	117	24	latency	latency	NOUN
ajlm-939	117	25	and	and	CCONJ
ajlm-939	117	26	reactiva	reactiva	NOUN
ajlm-939	117	27	-	-	PUNCT
ajlm-939	117	28	tion	tion	NOUN
ajlm-939	117	29	.	.	PUNCT
ajlm-939	118	1	adv	adv	PROPN
ajlm-939	118	2	virol	virol	PROPN
ajlm-939	118	3	.	.	PUNCT
ajlm-939	119	1	2011;2011	2011;2011	NUM
ajlm-939	119	2	.	.	PUNCT
ajlm-939	120	1	https://doi.org/10.1155/2011/193860	https://doi.org/10.1155/2011/193860	NOUN
ajlm-939	120	2	van	van	PROPN
ajlm-939	120	3	skike	skike	PROPN
ajlm-939	120	4	nd	nd	PROPN
ajlm-939	120	5	,	,	PUNCT
ajlm-939	120	6	minkah	minkah	PROPN
ajlm-939	120	7	nk	nk	PROPN
ajlm-939	120	8	,	,	PUNCT
ajlm-939	120	9	hogan	hogan	PROPN
ajlm-939	120	10	ch	ch	PROPN
ajlm-939	120	11	,	,	PUNCT
ajlm-939	120	12	et	et	PROPN
ajlm-939	120	13	al	al	PROPN
ajlm-939	120	14	.	.	PROPN
ajlm-939	120	15	viral	viral	ADJ
ajlm-939	120	16	fgarat	fgarat	NOUN
ajlm-939	120	17	orf75a	orf75a	NOUN
ajlm-939	120	18	promotes	promote	VERB
ajlm-939	120	19	early	early	ADJ
ajlm-939	120	20	events	event	NOUN
ajlm-939	120	21	in	in	ADP
ajlm-939	120	22	lytic	lytic	ADJ
ajlm-939	120	23	infection	infection	NOUN
ajlm-939	120	24	and	and	CCONJ
ajlm-939	120	25	gammaherpesvirus	gammaherpesvirus	NOUN
ajlm-939	120	26	pathogenesis	pathogenesis	NOUN
ajlm-939	120	27	in	in	ADP
ajlm-939	120	28	mice	mouse	NOUN
ajlm-939	120	29	.	.	PUNCT
ajlm-939	121	1	plos	plos	PROPN
ajlm-939	121	2	pathog	pathog	PROPN
ajlm-939	121	3	.	.	PUNCT
ajlm-939	122	1	2018;14(2):e1006843	2018;14(2):e1006843	X
ajlm-939	122	2	.	.	PUNCT
ajlm-939	122	3	https://doi.org/10.1371/journal.ppat.1006843	https://doi.org/10.1371/journal.ppat.1006843	PROPN
ajlm-939	122	4	stolka	stolka	VERB
ajlm-939	122	5	k	k	NOUN
ajlm-939	122	6	,	,	PUNCT
ajlm-939	122	7	ndom	ndom	ADJ
ajlm-939	122	8	p	p	NOUN
ajlm-939	122	9	,	,	PUNCT
ajlm-939	122	10	hemingway	hemingway	PROPN
ajlm-939	122	11	-	-	PUNCT
ajlm-939	122	12	foday	foday	PROPN
ajlm-939	122	13	j	j	PROPN
ajlm-939	122	14	,	,	PUNCT
ajlm-939	122	15	et	et	PROPN
ajlm-939	122	16	al	al	PROPN
ajlm-939	122	17	.	.	PUNCT
ajlm-939	123	1	risk	risk	NOUN
ajlm-939	123	2	factors	factor	NOUN
ajlm-939	123	3	for	for	ADP
ajlm-939	123	4	kaposi	kaposi	PROPN
ajlm-939	123	5	’s	’s	PART
ajlm-939	123	6	sarcoma	sarcoma	NOUN
ajlm-939	123	7	among	among	ADP
ajlm-939	123	8	hiv	hiv	PROPN
ajlm-939	123	9	-	-	PUNCT
ajlm-939	123	10	positive	positive	ADJ
ajlm-939	123	11	individuals	individual	NOUN
ajlm-939	123	12	in	in	ADP
ajlm-939	123	13	a	a	DET
ajlm-939	123	14	case	case	NOUN
ajlm-939	123	15	control	control	NOUN
ajlm-939	123	16	study	study	NOUN
ajlm-939	123	17	in	in	ADP
ajlm-939	123	18	cameroon	cameroon	PROPN
ajlm-939	123	19	.	.	PUNCT
ajlm-939	124	1	cancer	cancer	NOUN
ajlm-939	124	2	epidemiol	epidemiol	PROPN
ajlm-939	124	3	.	.	PUNCT
ajlm-939	125	1	2014;38(2):137–143	2014;38(2):137–143	NOUN
ajlm-939	125	2	.	.	PUNCT
ajlm-939	126	1	https://doi.org/10.1016/j.canep.2014.02.006	https://doi.org/10.1016/j.canep.2014.02.006	NUM
ajlm-939	126	2	rohner	rohner	NOUN
ajlm-939	126	3	e	e	NOUN
ajlm-939	126	4	,	,	PUNCT
ajlm-939	126	5	wyss	wyss	NOUN
ajlm-939	126	6	n	n	CCONJ
ajlm-939	126	7	,	,	PUNCT
ajlm-939	126	8	heg	heg	PROPN
ajlm-939	126	9	z	z	PROPN
ajlm-939	126	10	,	,	PUNCT
ajlm-939	126	11	et	et	PROPN
ajlm-939	126	12	al	al	PROPN
ajlm-939	126	13	hiv	hiv	PROPN
ajlm-939	126	14	and	and	CCONJ
ajlm-939	126	15	human	human	ADJ
ajlm-939	126	16	herpesvirus	herpesvirus	NOUN
ajlm-939	126	17	8	8	NUM
ajlm-939	126	18	co	co	NOUN
ajlm-939	126	19	-	-	NOUN
ajlm-939	126	20	infection	infection	NOUN
ajlm-939	126	21	across	across	ADP
ajlm-939	126	22	the	the	DET
ajlm-939	126	23	globe	globe	NOUN
ajlm-939	126	24	:	:	PUNCT
ajlm-939	126	25	systematic	systematic	ADJ
ajlm-939	126	26	review	review	NOUN
ajlm-939	126	27	and	and	CCONJ
ajlm-939	126	28	meta	meta	ADJ
ajlm-939	126	29	-	-	PUNCT
ajlm-939	126	30	analysis	analysis	NOUN
ajlm-939	126	31	.	.	PUNCT
ajlm-939	127	1	int	int	NOUN
ajlm-939	127	2	j	j	PROPN
ajlm-939	127	3	cancer	cancer	NOUN
ajlm-939	127	4	.	.	PUNCT
ajlm-939	128	1	2016;138(1):45–54	2016;138(1):45–54	X
ajlm-939	128	2	.	.	PUNCT
ajlm-939	129	1	https://doi.org/10.1002/ijc.29687	https://doi.org/10.1002/ijc.29687	PROPN
ajlm-939	129	2	fang	fang	PROPN
ajlm-939	129	3	q	q	PROPN
ajlm-939	129	4	,	,	PUNCT
ajlm-939	129	5	liu	liu	PROPN
ajlm-939	129	6	z	z	PROPN
ajlm-939	129	7	,	,	PUNCT
ajlm-939	129	8	zhang	zhang	PROPN
ajlm-939	129	9	z	z	PROPN
ajlm-939	129	10	,	,	PUNCT
ajlm-939	129	11	zeng	zeng	PROPN
ajlm-939	129	12	y	y	PROPN
ajlm-939	129	13	,	,	PUNCT
ajlm-939	129	14	zhang	zhang	PROPN
ajlm-939	129	15	t.	t.	PROPN
ajlm-939	129	16	prevalence	prevalence	NOUN
ajlm-939	129	17	of	of	ADP
ajlm-939	129	18	kaposi	kaposi	PROPN
ajlm-939	129	19	’s	’s	PART
ajlm-939	129	20	sarcoma	sarcoma	NOUN
ajlm-939	129	21	-	-	PUNCT
ajlm-939	129	22	associated	associate	VERB
ajlm-939	129	23	herpesvirus	herpesvirus	NOUN
ajlm-939	129	24	among	among	ADP
ajlm-939	129	25	intravenous	intravenous	ADJ
ajlm-939	129	26	drug	drug	NOUN
ajlm-939	129	27	users	user	NOUN
ajlm-939	129	28	:	:	PUNCT
ajlm-939	129	29	a	a	DET
ajlm-939	129	30	systematic	systematic	ADJ
ajlm-939	129	31	review	review	NOUN
ajlm-939	129	32	and	and	CCONJ
ajlm-939	129	33	meta	meta	ADJ
ajlm-939	129	34	-	-	PUNCT
ajlm-939	129	35	analysis	analysis	NOUN
ajlm-939	129	36	.	.	PUNCT
ajlm-939	130	1	virol	virol	NOUN
ajlm-939	130	2	sin	sin	PROPN
ajlm-939	130	3	.	.	PUNCT
ajlm-939	131	1	2017;32(5):415–422	2017;32(5):415–422	X
ajlm-939	131	2	.	.	PUNCT
ajlm-939	131	3	https://doi.org/10.1007/s12250-017-4051-2	https://doi.org/10.1007/s12250-017-4051-2	VERB
ajlm-939	131	4	la	la	PRON
ajlm-939	131	5	ferla	ferla	PROPN
ajlm-939	131	6	l	l	PROPN
ajlm-939	131	7	,	,	PUNCT
ajlm-939	131	8	pinzone	pinzone	ADJ
ajlm-939	131	9	mr	mr	PROPN
ajlm-939	131	10	,	,	PUNCT
ajlm-939	131	11	nunnari	nunnari	ADJ
ajlm-939	131	12	g	g	PROPN
ajlm-939	131	13	,	,	PUNCT
ajlm-939	131	14	et	et	PROPN
ajlm-939	131	15	al	al	PROPN
ajlm-939	131	16	.	.	PUNCT
ajlm-939	132	1	kaposi	kaposi	PROPN
ajlm-939	132	2	’s	’s	PART
ajlm-939	132	3	sarcoma	sarcoma	NOUN
ajlm-939	132	4	in	in	ADP
ajlm-939	132	5	hiv	hiv	PROPN
ajlm-939	132	6	-	-	PUNCT
ajlm-939	132	7	positive	positive	ADJ
ajlm-939	132	8	patients	patient	NOUN
ajlm-939	132	9	:	:	PUNCT
ajlm-939	132	10	the	the	DET
ajlm-939	132	11	state	state	NOUN
ajlm-939	132	12	of	of	ADP
ajlm-939	132	13	art	art	NOUN
ajlm-939	132	14	in	in	ADP
ajlm-939	132	15	the	the	DET
ajlm-939	132	16	haart	haart	PROPN
ajlm-939	132	17	-	-	PUNCT
ajlm-939	132	18	era	era	NOUN
ajlm-939	132	19	.	.	PUNCT
ajlm-939	133	1	eur	eur	PROPN
ajlm-939	133	2	rev	rev	PROPN
ajlm-939	133	3	med	med	PROPN
ajlm-939	133	4	pharmacol	pharmacol	PROPN
ajlm-939	133	5	sci	sci	PROPN
ajlm-939	134	1	[	[	X
ajlm-939	134	2	serial	serial	ADJ
ajlm-939	134	3	online	online	NOUN
ajlm-939	134	4	]	]	PUNCT
ajlm-939	134	5	.	.	PUNCT
ajlm-939	135	1	2013;17(17):2354–2365	2013;17(17):2354–2365	NOUN
ajlm-939	135	2	.	.	PUNCT
ajlm-939	136	1	available	available	ADJ
ajlm-939	136	2	from	from	ADP
ajlm-939	136	3	:	:	PUNCT
ajlm-939	136	4	https://www.researchgate.net//links/02e7e53537273f30c7000000.pdf	https://www.researchgate.net//links/02e7e53537273f30c7000000.pdf	PROPN
ajlm-939	136	5	hoffmann	hoffmann	PROPN
ajlm-939	136	6	c	c	PROPN
ajlm-939	136	7	,	,	PUNCT
ajlm-939	136	8	sabranski	sabranski	PROPN
ajlm-939	136	9	m	m	PROPN
ajlm-939	136	10	,	,	PUNCT
ajlm-939	136	11	esser	esser	PROPN
ajlm-939	136	12	s.	s.	PROPN
ajlm-939	136	13	hiv	hiv	PROPN
ajlm-939	136	14	-	-	PUNCT
ajlm-939	136	15	associated	associate	VERB
ajlm-939	136	16	kaposi	kaposi	PROPN
ajlm-939	136	17	’s	’s	PART
ajlm-939	136	18	sarcoma	sarcoma	NOUN
ajlm-939	136	19	.	.	PUNCT
ajlm-939	137	1	oncol	oncol	ADJ
ajlm-939	137	2	res	re	NOUN
ajlm-939	137	3	treat	treat	NOUN
ajlm-939	137	4	.	.	PUNCT
ajlm-939	138	1	2017;40(3):94–98	2017;40(3):94–98	X
ajlm-939	138	2	.	.	PUNCT
ajlm-939	139	1	https://doi.org/10.1159/issn.2296-5270	https://doi.org/10.1159/issn.2296-5270	PROPN
ajlm-939	139	2	minhas	minhas	PROPN
ajlm-939	139	3	v	v	NOUN
ajlm-939	139	4	,	,	PUNCT
ajlm-939	139	5	wood	wood	NOUN
ajlm-939	139	6	c.	c.	NOUN
ajlm-939	139	7	epidemiology	epidemiology	NOUN
ajlm-939	139	8	and	and	CCONJ
ajlm-939	139	9	transmission	transmission	NOUN
ajlm-939	139	10	of	of	ADP
ajlm-939	139	11	kaposi	kaposi	PROPN
ajlm-939	139	12	’s	’s	PART
ajlm-939	139	13	sarcoma	sarcoma	NOUN
ajlm-939	139	14	-	-	PUNCT
ajlm-939	139	15	associated	associate	VERB
ajlm-939	139	16	herpesvirus	herpesvirus	NOUN
ajlm-939	139	17	.	.	PUNCT
ajlm-939	140	1	viruses	virus	NOUN
ajlm-939	140	2	.	.	PUNCT
ajlm-939	141	1	2014;6(11):4178–4194	2014;6(11):4178–4194	X
ajlm-939	141	2	.	.	PUNCT
ajlm-939	142	1	https://doi.org/10.3390/v6114178	https://doi.org/10.3390/v6114178	NUM
ajlm-939	142	2	ganem	ganem	PROPN
ajlm-939	142	3	d.	d.	PROPN
ajlm-939	142	4	kshv	kshv	PROPN
ajlm-939	142	5	and	and	CCONJ
ajlm-939	142	6	the	the	DET
ajlm-939	142	7	pathogenesis	pathogenesis	NOUN
ajlm-939	142	8	of	of	ADP
ajlm-939	142	9	kaposi	kaposi	PROPN
ajlm-939	142	10	sarcoma	sarcoma	PROPN
ajlm-939	142	11	:	:	PUNCT
ajlm-939	142	12	listening	listen	VERB
ajlm-939	142	13	to	to	ADP
ajlm-939	142	14	human	human	ADJ
ajlm-939	142	15	biology	biology	NOUN
ajlm-939	142	16	and	and	CCONJ
ajlm-939	142	17	medicine	medicine	NOUN
ajlm-939	142	18	.	.	PUNCT
ajlm-939	143	1	j	j	PROPN
ajlm-939	143	2	clin	clin	PROPN
ajlm-939	143	3	invest	invest	VERB
ajlm-939	143	4	.	.	PUNCT
ajlm-939	144	1	2010;120(4):939–949	2010;120(4):939–949	NUM
ajlm-939	144	2	.	.	PUNCT
ajlm-939	144	3	https://doi.org/10.1172/jci40567	https://doi.org/10.1172/jci40567	PROPN
ajlm-939	144	4	sathish	sathish	PROPN
ajlm-939	144	5	n	n	CCONJ
ajlm-939	144	6	,	,	PUNCT
ajlm-939	144	7	yuan	yuan	PROPN
ajlm-939	144	8	y.	y.	NOUN
ajlm-939	144	9	evasion	evasion	NOUN
ajlm-939	144	10	and	and	CCONJ
ajlm-939	144	11	subversion	subversion	NOUN
ajlm-939	144	12	of	of	ADP
ajlm-939	144	13	interferon	interferon	ADJ
ajlm-939	144	14	-	-	PUNCT
ajlm-939	144	15	mediated	mediate	VERB
ajlm-939	144	16	antiviral	antiviral	ADJ
ajlm-939	144	17	immunity	immunity	NOUN
ajlm-939	144	18	by	by	ADP
ajlm-939	144	19	kaposi	kaposi	PROPN
ajlm-939	144	20	’s	’s	PART
ajlm-939	144	21	sarcoma	sarcoma	NOUN
ajlm-939	144	22	-	-	PUNCT
ajlm-939	144	23	associated	associate	VERB
ajlm-939	144	24	herpesvirus	herpesvirus	NOUN
ajlm-939	144	25	:	:	PUNCT
ajlm-939	144	26	an	an	DET
ajlm-939	144	27	overview	overview	NOUN
ajlm-939	144	28	.	.	PUNCT
ajlm-939	145	1	j	j	PROPN
ajlm-939	145	2	virol	virol	NOUN
ajlm-939	145	3	.	.	PUNCT
ajlm-939	146	1	2011;85(21):10934–10944	2011;85(21):10934–10944	X
ajlm-939	146	2	.	.	PUNCT
ajlm-939	147	1	https://doi.org/10.1128/jvi.00687-11	https://doi.org/10.1128/jvi.00687-11	PROPN
ajlm-939	147	2	shebl	shebl	PROPN
ajlm-939	147	3	fm	fm	PROPN
ajlm-939	147	4	,	,	PUNCT
ajlm-939	147	5	dollard	dollard	PROPN
ajlm-939	147	6	sc	sc	PROPN
ajlm-939	147	7	,	,	PUNCT
ajlm-939	147	8	pfeiffer	pfeiffer	PROPN
ajlm-939	147	9	rm	rm	PROPN
ajlm-939	147	10	,	,	PUNCT
ajlm-939	147	11	et	et	PROPN
ajlm-939	147	12	al	al	PROPN
ajlm-939	147	13	.	.	PUNCT
ajlm-939	148	1	human	human	ADJ
ajlm-939	148	2	herpesvirus	herpesvirus	NOUN
ajlm-939	148	3	8	8	NUM
ajlm-939	148	4	seropositivity	seropositivity	NOUN
ajlm-939	148	5	among	among	ADP
ajlm-939	148	6	sexually	sexually	ADV
ajlm-939	148	7	active	active	ADJ
ajlm-939	148	8	adults	adult	NOUN
ajlm-939	148	9	in	in	ADP
ajlm-939	148	10	uganda	uganda	PROPN
ajlm-939	148	11	.	.	PUNCT
ajlm-939	149	1	plos	plos	PROPN
ajlm-939	149	2	one	one	NUM
ajlm-939	149	3	.	.	PUNCT
ajlm-939	150	1	2011;6(6):e21286	2011;6(6):e21286	NUM
ajlm-939	150	2	.	.	PUNCT
ajlm-939	151	1	https://doi.org/10.1371/journal.pone.0021286	https://doi.org/10.1371/journal.pone.0021286	ADJ
ajlm-939	151	2	cancian	cancian	ADJ
ajlm-939	151	3	l	l	NOUN
ajlm-939	151	4	,	,	PUNCT
ajlm-939	151	5	hansen	hansen	PROPN
ajlm-939	151	6	a	a	PROPN
ajlm-939	151	7	,	,	PUNCT
ajlm-939	151	8	boshoff	boshoff	ADJ
ajlm-939	151	9	c.	c.	PROPN
ajlm-939	151	10	cellular	cellular	ADJ
ajlm-939	151	11	origin	origin	NOUN
ajlm-939	151	12	of	of	ADP
ajlm-939	151	13	kaposi	kaposi	PROPN
ajlm-939	151	14	’s	’s	PART
ajlm-939	151	15	sarcoma	sarcoma	NOUN
ajlm-939	151	16	and	and	CCONJ
ajlm-939	151	17	kaposi	kaposi	PROPN
ajlm-939	151	18	’s	’s	PART
ajlm-939	151	19	sar	sar	PROPN
ajlm-939	151	20	-	-	PROPN
ajlm-939	151	21	coma	coma	NOUN
ajlm-939	151	22	-	-	PUNCT
ajlm-939	151	23	associated	associate	VERB
ajlm-939	151	24	herpesvirus	herpesvirus	NOUN
ajlm-939	151	25	-	-	PUNCT
ajlm-939	151	26	induced	induce	VERB
ajlm-939	151	27	cell	cell	NOUN
ajlm-939	151	28	reprogramming	reprogramming	NOUN
ajlm-939	151	29	.	.	PUNCT
ajlm-939	152	1	trends	trend	NOUN
ajlm-939	152	2	cell	cell	NOUN
ajlm-939	152	3	biol	biol	NOUN
ajlm-939	152	4	.	.	PUNCT
ajlm-939	153	1	2013;23(9):421–432	2013;23(9):421–432	X
ajlm-939	153	2	.	.	PUNCT
ajlm-939	153	3	https://doi.org/10.1016/j.tcb.2013.04.001	https://doi.org/10.1016/j.tcb.2013.04.001	PROPN
ajlm-939	153	4	curtiss	curtiss	PROPN
ajlm-939	153	5	p	p	NOUN
ajlm-939	153	6	,	,	PUNCT
ajlm-939	153	7	strazzulla	strazzulla	NOUN
ajlm-939	153	8	lc	lc	PROPN
ajlm-939	153	9	,	,	PUNCT
ajlm-939	153	10	friedman	friedman	PROPN
ajlm-939	153	11	-	-	PUNCT
ajlm-939	153	12	kien	kien	PROPN
ajlm-939	153	13	ae	ae	PROPN
ajlm-939	153	14	.	.	PUNCT
ajlm-939	154	1	an	an	DET
ajlm-939	154	2	update	update	NOUN
ajlm-939	154	3	on	on	ADP
ajlm-939	154	4	kaposi	kaposi	PROPN
ajlm-939	154	5	’s	’s	PART
ajlm-939	154	6	sarcoma	sarcoma	NOUN
ajlm-939	154	7	:	:	PUNCT
ajlm-939	154	8	epidemiology	epidemiology	NOUN
ajlm-939	154	9	,	,	PUNCT
ajlm-939	154	10	patho	patho	NOUN
ajlm-939	154	11	-	-	PUNCT
ajlm-939	154	12	genesis	genesis	NOUN
ajlm-939	154	13	and	and	CCONJ
ajlm-939	154	14	treatment	treatment	NOUN
ajlm-939	154	15	.	.	PUNCT
ajlm-939	155	1	dermatol	dermatol	NOUN
ajlm-939	155	2	ther	ther	ADV
ajlm-939	155	3	.	.	PUNCT
ajlm-939	156	1	2016;6(4):465–470	2016;6(4):465–470	X
ajlm-939	156	2	.	.	PUNCT
ajlm-939	156	3	https://doi.org/10.1007/s13555-016-0152-3	https://doi.org/10.1007/s13555-016-0152-3	NUM
ajlm-939	157	1	el	el	PROPN
ajlm-939	157	2	-	-	PUNCT
ajlm-939	157	3	mallawany	mallawany	PROPN
ajlm-939	157	4	nk	nk	PROPN
ajlm-939	157	5	,	,	PUNCT
ajlm-939	157	6	kamiyango	kamiyango	PROPN
ajlm-939	157	7	w	w	PROPN
ajlm-939	157	8	,	,	PUNCT
ajlm-939	157	9	slone	slone	PROPN
ajlm-939	157	10	js	js	PROPN
ajlm-939	157	11	,	,	PUNCT
ajlm-939	157	12	et	et	PROPN
ajlm-939	157	13	al	al	PROPN
ajlm-939	157	14	.	.	PUNCT
ajlm-939	158	1	clinical	clinical	ADJ
ajlm-939	158	2	factors	factor	NOUN
ajlm-939	158	3	associated	associate	VERB
ajlm-939	158	4	with	with	ADP
ajlm-939	158	5	long	long	ADJ
ajlm-939	158	6	-	-	PUNCT
ajlm-939	158	7	term	term	NOUN
ajlm-939	158	8	complete	complete	ADJ
ajlm-939	158	9	remis	remis	NOUN
ajlm-939	158	10	-	-	PUNCT
ajlm-939	158	11	sion	sion	NOUN
ajlm-939	158	12	versus	versus	ADP
ajlm-939	158	13	poor	poor	ADJ
ajlm-939	158	14	response	response	NOUN
ajlm-939	158	15	to	to	ADP
ajlm-939	158	16	chemotherapy	chemotherapy	NOUN
ajlm-939	158	17	in	in	ADP
ajlm-939	158	18	hiv	hiv	PROPN
ajlm-939	158	19	-	-	PUNCT
ajlm-939	158	20	infected	infect	VERB
ajlm-939	158	21	children	child	NOUN
ajlm-939	158	22	and	and	CCONJ
ajlm-939	158	23	adolescents	adolescent	NOUN
ajlm-939	158	24	with	with	ADP
ajlm-939	158	25	kaposi	kaposi	PROPN
ajlm-939	158	26	sarcoma	sarcoma	PROPN
ajlm-939	158	27	receiving	receive	VERB
ajlm-939	158	28	bleomycin	bleomycin	NOUN
ajlm-939	158	29	and	and	CCONJ
ajlm-939	158	30	vincristine	vincristine	NOUN
ajlm-939	158	31	:	:	PUNCT
ajlm-939	158	32	a	a	DET
ajlm-939	158	33	retrospective	retrospective	ADJ
ajlm-939	158	34	observational	observational	ADJ
ajlm-939	158	35	study	study	NOUN
ajlm-939	158	36	.	.	PUNCT
ajlm-939	159	1	plos	plos	PROPN
ajlm-939	159	2	one	one	NUM
ajlm-939	159	3	.	.	PUNCT
ajlm-939	160	1	2016;11(4):e0153335	2016;11(4):e0153335	X
ajlm-939	160	2	.	.	PUNCT
ajlm-939	160	3	https://doi.org/10.1371/journal.pone.0153335	https://doi.org/10.1371/journal.pone.0153335	PROPN
ajlm-939	160	4	stefan	stefan	PROPN
ajlm-939	160	5	dc	dc	PROPN
ajlm-939	160	6	.	.	PUNCT
ajlm-939	161	1	patterns	pattern	NOUN
ajlm-939	161	2	of	of	ADP
ajlm-939	161	3	distribution	distribution	NOUN
ajlm-939	161	4	of	of	ADP
ajlm-939	161	5	childhood	childhood	NOUN
ajlm-939	161	6	cancer	cancer	NOUN
ajlm-939	161	7	in	in	ADP
ajlm-939	161	8	africa	africa	PROPN
ajlm-939	161	9	.	.	PUNCT
ajlm-939	162	1	j	j	PROPN
ajlm-939	162	2	trop	trop	X
ajlm-939	162	3	pediatr	pediatr	PROPN
ajlm-939	162	4	.	.	PUNCT
ajlm-939	163	1	2015;61(3):165–173	2015;61(3):165–173	NUM
ajlm-939	163	2	.	.	PUNCT
ajlm-939	163	3	https://doi.org/10.1093/tropej/fmv005	https://doi.org/10.1093/tropej/fmv005	VERB
ajlm-939	163	4	olp	olp	PROPN
ajlm-939	163	5	ln	ln	PROPN
ajlm-939	163	6	,	,	PUNCT
ajlm-939	163	7	shea	shea	PROPN
ajlm-939	163	8	dm	dm	PROPN
ajlm-939	163	9	,	,	PUNCT
ajlm-939	163	10	white	white	PROPN
ajlm-939	163	11	mk	mk	PROPN
ajlm-939	163	12	,	,	PUNCT
ajlm-939	163	13	gondwe	gondwe	PROPN
ajlm-939	163	14	c	c	PROPN
ajlm-939	163	15	,	,	PUNCT
ajlm-939	163	16	kankasa	kankasa	PROPN
ajlm-939	163	17	c	c	PROPN
ajlm-939	163	18	,	,	PUNCT
ajlm-939	163	19	wood	wood	PROPN
ajlm-939	163	20	c.	c.	PROPN
ajlm-939	163	21	early	early	ADJ
ajlm-939	163	22	childhood	childhood	ADJ
ajlm-939	163	23	infection	infection	NOUN
ajlm-939	163	24	of	of	ADP
ajlm-939	163	25	kaposi	kaposi	PROPN
ajlm-939	163	26	’s	’s	PART
ajlm-939	163	27	sarcoma	sarcoma	NOUN
ajlm-939	163	28	-	-	PUNCT
ajlm-939	163	29	associated	associate	VERB
ajlm-939	163	30	herpesvirus	herpesvirus	NOUN
ajlm-939	163	31	in	in	ADP
ajlm-939	163	32	zambian	zambian	ADJ
ajlm-939	163	33	households	household	NOUN
ajlm-939	163	34	:	:	PUNCT
ajlm-939	163	35	a	a	DET
ajlm-939	163	36	molecular	molecular	ADJ
ajlm-939	163	37	analysis	analysis	NOUN
ajlm-939	163	38	.	.	PUNCT
ajlm-939	164	1	int	int	NOUN
ajlm-939	164	2	j	j	PROPN
ajlm-939	164	3	cancer	cancer	NOUN
ajlm-939	164	4	.	.	PUNCT
ajlm-939	165	1	2013;1;132(5):1182–1190	2013;1;132(5):1182–1190	ADJ
ajlm-939	165	2	.	.	PUNCT
ajlm-939	166	1	https://doi.org/10.1002/ijc.27729	https://doi.org/10.1002/ijc.27729	PROPN
ajlm-939	166	2	oetvoes	oetvoes	PROPN
ajlm-939	166	3	r	r	NOUN
ajlm-939	166	4	,	,	PUNCT
ajlm-939	166	5	juhasz	juhasz	NOUN
ajlm-939	166	6	a	a	PRON
ajlm-939	166	7	,	,	PUNCT
ajlm-939	166	8	szalai	szalai	PROPN
ajlm-939	166	9	e	e	NOUN
ajlm-939	166	10	,	,	PUNCT
ajlm-939	166	11	et	et	PROPN
ajlm-939	166	12	al	al	PROPN
ajlm-939	166	13	.	.	PUNCT
ajlm-939	167	1	molecular	molecular	ADJ
ajlm-939	167	2	typing	typing	NOUN
ajlm-939	167	3	of	of	ADP
ajlm-939	167	4	human	human	ADJ
ajlm-939	167	5	herpesvirus	herpesvirus	NOUN
ajlm-939	167	6	8	8	NUM
ajlm-939	167	7	isolates	isolate	NOUN
ajlm-939	167	8	from	from	ADP
ajlm-939	167	9	patients	patient	NOUN
ajlm-939	167	10	with	with	ADP
ajlm-939	167	11	kaposi	kaposi	PROPN
ajlm-939	167	12	’s	’s	PART
ajlm-939	167	13	sarcoma	sarcoma	NOUN
ajlm-939	167	14	in	in	ADP
ajlm-939	167	15	hungary	hungary	PROPN
ajlm-939	167	16	.	.	PUNCT
ajlm-939	168	1	anticancer	anticancer	NOUN
ajlm-939	168	2	res	re	NOUN
ajlm-939	168	3	[	[	X
ajlm-939	168	4	serial	serial	ADJ
ajlm-939	168	5	online	online	NOUN
ajlm-939	168	6	]	]	PUNCT
ajlm-939	168	7	.	.	PUNCT
ajlm-939	169	1	2014;34(2):893–898	2014;34(2):893–898	X
ajlm-939	169	2	.	.	PUNCT
ajlm-939	169	3	available	available	ADJ
ajlm-939	169	4	from	from	ADP
ajlm-939	169	5	:	:	PUNCT
ajlm-939	169	6	http://ar.iiarjournals.org/content/34/2/893.short	http://ar.iiarjournals.org/content/34/2/893.short	PROPN
ajlm-939	169	7	johann	johann	PROPN
ajlm-939	169	8	ws	ws	PROPN
ajlm-939	169	9	,	,	PUNCT
ajlm-939	169	10	dirk	dirk	PROPN
ajlm-939	169	11	pd	pd	PROPN
ajlm-939	169	12	.	.	PROPN
ajlm-939	169	13	diagnosis	diagnosis	NOUN
ajlm-939	169	14	and	and	CCONJ
ajlm-939	169	15	treatment	treatment	NOUN
ajlm-939	169	16	of	of	ADP
ajlm-939	169	17	kaposi	kaposi	PROPN
ajlm-939	169	18	sarcoma	sarcoma	PROPN
ajlm-939	169	19	.	.	PUNCT
ajlm-939	170	1	am	be	AUX
ajlm-939	170	2	j	j	PROPN
ajlm-939	170	3	clin	clin	PROPN
ajlm-939	170	4	dermatol	dermatol	NOUN
ajlm-939	170	5	.	.	PUNCT
ajlm-939	171	1	2017;18(4):529–539	2017;18(4):529–539	NOUN
ajlm-939	171	2	.	.	PUNCT
ajlm-939	172	1	https://doi.org/10.1007/s40257-017-0270-4	https://doi.org/10.1007/s40257-017-0270-4	PROPN
ajlm-939	172	2	kumar	kumar	PROPN
ajlm-939	172	3	p	p	PROPN
ajlm-939	172	4	,	,	PUNCT
ajlm-939	172	5	kuwa	kuwa	PROPN
ajlm-939	172	6	ny	ny	PROPN
ajlm-939	172	7	,	,	PUNCT
ajlm-939	172	8	minhas	minhas	PROPN
ajlm-939	172	9	v	v	PROPN
ajlm-939	172	10	,	,	PUNCT
ajlm-939	172	11	et	et	PROPN
ajlm-939	172	12	al	al	PROPN
ajlm-939	172	13	.	.	PUNCT
ajlm-939	173	1	higher	high	ADJ
ajlm-939	173	2	levels	level	NOUN
ajlm-939	173	3	of	of	ADP
ajlm-939	173	4	neutralizing	neutralize	VERB
ajlm-939	173	5	antibodies	antibody	NOUN
ajlm-939	173	6	against	against	ADP
ajlm-939	173	7	kshv	kshv	PROPN
ajlm-939	173	8	in	in	ADP
ajlm-939	173	9	ks	ks	NOUN
ajlm-939	173	10	patients	patient	NOUN
ajlm-939	173	11	compared	compare	VERB
ajlm-939	173	12	to	to	ADP
ajlm-939	173	13	asymptomatic	asymptomatic	ADJ
ajlm-939	173	14	individuals	individual	NOUN
ajlm-939	173	15	from	from	ADP
ajlm-939	173	16	zambia	zambia	PROPN
ajlm-939	173	17	.	.	PUNCT
ajlm-939	174	1	plos	plos	PROPN
ajlm-939	174	2	one	one	NUM
ajlm-939	174	3	.	.	PUNCT
ajlm-939	175	1	2013;14;8(8):e71254	2013;14;8(8):e71254	PROPN
ajlm-939	175	2	.	.	PUNCT
ajlm-939	176	1	https://doi.org/10.1371/journal.pone.0071254	https://doi.org/10.1371/journal.pone.0071254	PROPN
ajlm-939	176	2	amerson	amerson	PROPN
ajlm-939	176	3	e	e	PROPN
ajlm-939	176	4	,	,	PUNCT
ajlm-939	176	5	woodruff	woodruff	PROPN
ajlm-939	176	6	cm	cm	PROPN
ajlm-939	176	7	,	,	PUNCT
ajlm-939	176	8	forrestel	forrestel	PROPN
ajlm-939	176	9	a	a	X
ajlm-939	176	10	,	,	PUNCT
ajlm-939	176	11	et	et	PROPN
ajlm-939	176	12	al	al	PROPN
ajlm-939	176	13	.	.	PROPN
ajlm-939	176	14	accuracy	accuracy	NOUN
ajlm-939	176	15	of	of	ADP
ajlm-939	176	16	clinical	clinical	ADJ
ajlm-939	176	17	suspicion	suspicion	NOUN
ajlm-939	176	18	and	and	CCONJ
ajlm-939	176	19	pathologic	pathologic	ADJ
ajlm-939	176	20	diagnosis	diagnosis	NOUN
ajlm-939	176	21	of	of	ADP
ajlm-939	176	22	kaposi	kaposi	PROPN
ajlm-939	176	23	sarcoma	sarcoma	PROPN
ajlm-939	176	24	in	in	ADP
ajlm-939	176	25	east	east	PROPN
ajlm-939	176	26	africa	africa	PROPN
ajlm-939	176	27	.	.	PUNCT
ajlm-939	177	1	j	j	PROPN
ajlm-939	177	2	acquir	acquir	PROPN
ajlm-939	177	3	immune	immune	VERB
ajlm-939	177	4	defic	defic	ADJ
ajlm-939	177	5	syndr	syndr	NOUN
ajlm-939	177	6	.	.	PUNCT
ajlm-939	178	1	2016;71(3):295–301	2016;71(3):295–301	NUM
ajlm-939	178	2	.	.	PUNCT
ajlm-939	179	1	https://doi.org/10.1097/qai.0000000000000862	https://doi.org/10.1097/qai.0000000000000862	PROPN
ajlm-939	179	2	machado	machado	PROPN
ajlm-939	179	3	pr	pr	PROPN
ajlm-939	179	4	,	,	PUNCT
ajlm-939	179	5	farias	farias	PROPN
ajlm-939	179	6	kj	kj	PROPN
ajlm-939	179	7	,	,	PUNCT
ajlm-939	179	8	pereira	pereira	PROPN
ajlm-939	179	9	mg	mg	PROPN
ajlm-939	179	10	,	,	PUNCT
ajlm-939	179	11	freitas	freitas	PROPN
ajlm-939	179	12	pp	pp	PROPN
ajlm-939	179	13	,	,	PUNCT
ajlm-939	179	14	fonseca	fonseca	PROPN
ajlm-939	179	15	ba	ba	PROPN
ajlm-939	179	16	.	.	PUNCT
ajlm-939	180	1	human	human	ADJ
ajlm-939	180	2	herpesvirus	herpesvirus	NOUN
ajlm-939	180	3	8	8	NUM
ajlm-939	180	4	(	(	PUNCT
ajlm-939	180	5	hhv-8	hhv-8	NOUN
ajlm-939	180	6	)	)	PUNCT
ajlm-939	180	7	detected	detect	VERB
ajlm-939	180	8	by	by	ADP
ajlm-939	180	9	nested	nested	ADJ
ajlm-939	180	10	polymerase	polymerase	NOUN
ajlm-939	180	11	chain	chain	NOUN
ajlm-939	180	12	reaction	reaction	NOUN
ajlm-939	180	13	(	(	PUNCT
ajlm-939	180	14	pcr	pcr	NOUN
ajlm-939	180	15	)	)	PUNCT
ajlm-939	180	16	in	in	ADP
ajlm-939	180	17	hiv	hiv	PROPN
ajlm-939	180	18	patients	patient	NOUN
ajlm-939	180	19	with	with	ADP
ajlm-939	180	20	or	or	CCONJ
ajlm-939	180	21	without	without	ADP
ajlm-939	180	22	kaposi	kaposi	PROPN
ajlm-939	180	23	’s	’s	PART
ajlm-939	180	24	sarcoma	sarcoma	NOUN
ajlm-939	180	25	.	.	PUNCT
ajlm-939	181	1	an	an	DET
ajlm-939	181	2	analytic	analytic	ADJ
ajlm-939	181	3	cross	cross	ADJ
ajlm-939	181	4	-	-	ADJ
ajlm-939	181	5	sectional	sectional	ADJ
ajlm-939	181	6	study	study	NOUN
ajlm-939	181	7	.	.	PUNCT
ajlm-939	182	1	sao	sao	PROPN
ajlm-939	182	2	paulo	paulo	PROPN
ajlm-939	182	3	med	med	PROPN
ajlm-939	182	4	j.	j.	PROPN
ajlm-939	182	5	2016;134(3):187–192	2016;134(3):187–192	PROPN
ajlm-939	182	6	.	.	PUNCT
ajlm-939	182	7	https://doi.org/10.1590/1516-3180.2014.8973010	https://doi.org/10.1590/1516-3180.2014.8973010	PROPN
ajlm-939	182	8	crabtree	crabtree	PROPN
ajlm-939	182	9	kl	kl	PROPN
ajlm-939	182	10	.	.	PUNCT
ajlm-939	183	1	the	the	DET
ajlm-939	183	2	epidemiology	epidemiology	NOUN
ajlm-939	183	3	of	of	ADP
ajlm-939	183	4	human	human	NOUN
ajlm-939	183	5	herpesvirus-8	herpesvirus-8	PROPN
ajlm-939	183	6	:	:	PUNCT
ajlm-939	183	7	transmission	transmission	NOUN
ajlm-939	183	8	of	of	ADP
ajlm-939	183	9	infection	infection	NOUN
ajlm-939	183	10	to	to	ADP
ajlm-939	183	11	children	child	NOUN
ajlm-939	183	12	in	in	ADP
ajlm-939	183	13	zambian	zambian	ADJ
ajlm-939	183	14	households	household	NOUN
ajlm-939	184	1	[	[	X
ajlm-939	184	2	homepage	homepage	NOUN
ajlm-939	184	3	on	on	ADP
ajlm-939	184	4	the	the	DET
ajlm-939	184	5	internet	internet	NOUN
ajlm-939	184	6	]	]	PUNCT
ajlm-939	184	7	.	.	PUNCT
ajlm-939	185	1	2013	2013	NUM
ajlm-939	186	1	[	[	X
ajlm-939	186	2	cited	cite	VERB
ajlm-939	186	3	2013	2013	NUM
ajlm-939	186	4	dec	dec	PROPN
ajlm-939	186	5	7];(12	7];(12	NUM
ajlm-939	186	6	)	)	PUNCT
ajlm-939	186	7	available	available	ADJ
ajlm-939	186	8	from	from	ADP
ajlm-939	186	9	:	:	PUNCT
ajlm-939	186	10	https://digitalcommons.unl.edu/bioscidiss/53/	https://digitalcommons.unl.edu/bioscidiss/53/	PROPN
ajlm-939	186	11	jalilvand	jalilvand	NOUN
ajlm-939	186	12	s	s	X
ajlm-939	186	13	,	,	PUNCT
ajlm-939	186	14	tornesello	tornesello	PROPN
ajlm-939	186	15	ml	ml	NOUN
ajlm-939	186	16	,	,	PUNCT
ajlm-939	186	17	buonaguro	buonaguro	PROPN
ajlm-939	186	18	fm	fm	PROPN
ajlm-939	186	19	,	,	PUNCT
ajlm-939	186	20	et	et	PROPN
ajlm-939	186	21	al	al	PROPN
ajlm-939	186	22	.	.	PROPN
ajlm-939	187	1	molecular	molecular	ADJ
ajlm-939	187	2	epidemiology	epidemiology	NOUN
ajlm-939	187	3	of	of	ADP
ajlm-939	187	4	human	human	ADJ
ajlm-939	187	5	herpesvirus	herpesvirus	NOUN
ajlm-939	187	6	8	8	NUM
ajlm-939	187	7	variants	variant	NOUN
ajlm-939	187	8	in	in	ADP
ajlm-939	187	9	kaposi	kaposi	PROPN
ajlm-939	187	10	’s	’s	PART
ajlm-939	187	11	sarcoma	sarcoma	NOUN
ajlm-939	187	12	from	from	ADP
ajlm-939	187	13	iranian	iranian	ADJ
ajlm-939	187	14	patients	patient	NOUN
ajlm-939	187	15	.	.	PUNCT
ajlm-939	188	1	virus	virus	NOUN
ajlm-939	188	2	res	re	NOUN
ajlm-939	188	3	.	.	PUNCT
ajlm-939	189	1	2012;163(2):644–649	2012;163(2):644–649	NUM
ajlm-939	189	2	.	.	PUNCT
ajlm-939	190	1	https://doi.org/10.1016/j.virusres.2011.09.027	https://doi.org/10.1016/j.virusres.2011.09.027	PROPN
ajlm-939	190	2	kourí	kourí	PROPN
ajlm-939	190	3	v	v	NOUN
ajlm-939	190	4	,	,	PUNCT
ajlm-939	190	5	martínez	martínez	PROPN
ajlm-939	190	6	pa	pa	PROPN
ajlm-939	190	7	,	,	PUNCT
ajlm-939	190	8	capo	capo	PROPN
ajlm-939	190	9	v	v	PROPN
ajlm-939	190	10	,	,	PUNCT
ajlm-939	190	11	et	et	PROPN
ajlm-939	190	12	al	al	PROPN
ajlm-939	190	13	.	.	PUNCT
ajlm-939	191	1	kaposi	kaposi	PROPN
ajlm-939	191	2	’s	’s	PART
ajlm-939	191	3	sarcoma	sarcoma	NOUN
ajlm-939	191	4	and	and	CCONJ
ajlm-939	191	5	human	human	ADJ
ajlm-939	191	6	herpesvirus	herpesvirus	NOUN
ajlm-939	191	7	8	8	NUM
ajlm-939	191	8	in	in	ADP
ajlm-939	191	9	cuba	cuba	PROPN
ajlm-939	191	10	:	:	PUNCT
ajlm-939	191	11	evidence	evidence	NOUN
ajlm-939	191	12	of	of	ADP
ajlm-939	191	13	subtype	subtype	NOUN
ajlm-939	191	14	b	b	NOUN
ajlm-939	191	15	expansion	expansion	NOUN
ajlm-939	191	16	.	.	PUNCT
ajlm-939	192	1	virology	virology	NOUN
ajlm-939	192	2	.	.	PUNCT
ajlm-939	193	1	2012;432(2):361–369	2012;432(2):361–369	NUM
ajlm-939	193	2	.	.	PUNCT
ajlm-939	194	1	https://doi.org/10.1016/j.virol.2012.06.014	https://doi.org/10.1016/j.virol.2012.06.014	PROPN
ajlm-939	194	2	kakoola	kakoola	PROPN
ajlm-939	194	3	dn	dn	PROPN
ajlm-939	194	4	,	,	PUNCT
ajlm-939	194	5	sheldon	sheldon	PROPN
ajlm-939	194	6	j	j	PROPN
ajlm-939	194	7	,	,	PUNCT
ajlm-939	194	8	byabazaire	byabazaire	VERB
ajlm-939	194	9	n	n	PRON
ajlm-939	194	10	,	,	PUNCT
ajlm-939	195	1	et	et	PROPN
ajlm-939	195	2	al	al	PROPN
ajlm-939	195	3	.	.	PUNCT
ajlm-939	195	4	recombination	recombination	NOUN
ajlm-939	195	5	in	in	ADP
ajlm-939	195	6	human	human	ADJ
ajlm-939	195	7	herpesvirus-8	herpesvirus-8	NUM
ajlm-939	195	8	strains	strain	NOUN
ajlm-939	195	9	from	from	ADP
ajlm-939	195	10	uganda	uganda	PROPN
ajlm-939	195	11	and	and	CCONJ
ajlm-939	195	12	evolution	evolution	NOUN
ajlm-939	195	13	of	of	ADP
ajlm-939	195	14	the	the	DET
ajlm-939	195	15	k15	k15	PROPN
ajlm-939	195	16	gene	gene	NOUN
ajlm-939	195	17	.	.	PUNCT
ajlm-939	196	1	j	j	PROPN
ajlm-939	196	2	gen	gen	PROPN
ajlm-939	196	3	virol	virol	NOUN
ajlm-939	196	4	.	.	PUNCT
ajlm-939	197	1	2001;82(10):2393–2404	2001;82(10):2393–2404	X
ajlm-939	197	2	.	.	PUNCT
ajlm-939	198	1	https://doi.org/10.1099/0022-1317-82-10-2393	https://doi.org/10.1099/0022-1317-82-10-2393	PROPN
ajlm-939	198	2	poole	poole	PROPN
ajlm-939	198	3	lj	lj	PROPN
ajlm-939	198	4	,	,	PUNCT
ajlm-939	198	5	zong	zong	PROPN
ajlm-939	198	6	jc	jc	PROPN
ajlm-939	198	7	,	,	PUNCT
ajlm-939	198	8	ciufo	ciufo	PROPN
ajlm-939	198	9	dm	dm	PROPN
ajlm-939	198	10	,	,	PUNCT
ajlm-939	198	11	et	et	PROPN
ajlm-939	198	12	al	al	PROPN
ajlm-939	198	13	.	.	PROPN
ajlm-939	198	14	comparison	comparison	NOUN
ajlm-939	198	15	of	of	ADP
ajlm-939	198	16	genetic	genetic	ADJ
ajlm-939	198	17	variability	variability	NOUN
ajlm-939	198	18	at	at	ADP
ajlm-939	198	19	multiple	multiple	ADJ
ajlm-939	198	20	loci	locus	NOUN
ajlm-939	198	21	across	across	ADP
ajlm-939	198	22	the	the	DET
ajlm-939	198	23	genomes	genome	NOUN
ajlm-939	198	24	of	of	ADP
ajlm-939	198	25	the	the	DET
ajlm-939	198	26	major	major	ADJ
ajlm-939	198	27	subtypes	subtype	NOUN
ajlm-939	198	28	of	of	ADP
ajlm-939	198	29	kaposi	kaposi	PROPN
ajlm-939	198	30	’s	’s	PART
ajlm-939	198	31	sarcoma	sarcoma	NOUN
ajlm-939	198	32	-	-	PUNCT
ajlm-939	198	33	associated	associate	VERB
ajlm-939	198	34	herpesvirus	herpesvirus	NOUN
ajlm-939	198	35	reveals	reveal	VERB
ajlm-939	198	36	evidence	evidence	NOUN
ajlm-939	198	37	for	for	ADP
ajlm-939	198	38	recombination	recombination	NOUN
ajlm-939	198	39	and	and	CCONJ
ajlm-939	198	40	for	for	ADP
ajlm-939	198	41	two	two	NUM
ajlm-939	198	42	distinct	distinct	ADJ
ajlm-939	198	43	types	type	NOUN
ajlm-939	198	44	of	of	ADP
ajlm-939	198	45	open	open	ADJ
ajlm-939	198	46	reading	reading	NOUN
ajlm-939	198	47	frame	frame	NOUN
ajlm-939	198	48	k15	k15	NOUN
ajlm-939	198	49	alleles	allele	NOUN
ajlm-939	198	50	at	at	ADP
ajlm-939	198	51	the	the	DET
ajlm-939	198	52	right	right	ADJ
ajlm-939	198	53	-	-	PUNCT
ajlm-939	198	54	hand	hand	NOUN
ajlm-939	198	55	end	end	NOUN
ajlm-939	198	56	.	.	PUNCT
ajlm-939	199	1	j	j	PROPN
ajlm-939	199	2	virol	virol	NOUN
ajlm-939	199	3	.	.	PUNCT
ajlm-939	200	1	1999;73(8):6646–6660	1999;73(8):6646–6660	NUM
ajlm-939	200	2	.	.	PUNCT
ajlm-939	201	1	https://doi.org/10.1128/jvi.73.8.6646-6660.1999	https://doi.org/10.1128/jvi.73.8.6646-6660.1999	PROPN
ajlm-939	201	2	ashutosh	ashutosh	PROPN
ajlm-939	201	3	rt	rt	PROPN
ajlm-939	201	4	,	,	PUNCT
ajlm-939	201	5	andrew	andrew	PROPN
ajlm-939	201	6	ow	ow	PROPN
ajlm-939	201	7	,	,	PUNCT
ajlm-939	201	8	greer	greer	PROPN
ajlm-939	201	9	ab	ab	PROPN
ajlm-939	201	10	,	,	PUNCT
ajlm-939	201	11	gary	gary	PROPN
ajlm-939	201	12	rc	rc	PROPN
ajlm-939	201	13	.	.	PUNCT
ajlm-939	202	1	prevalence	prevalence	NOUN
ajlm-939	202	2	odds	odd	VERB
ajlm-939	202	3	ratio	ratio	NOUN
ajlm-939	202	4	versus	versus	ADP
ajlm-939	202	5	prevalence	prevalence	NOUN
ajlm-939	202	6	ratio	ratio	NOUN
ajlm-939	202	7	:	:	PUNCT
ajlm-939	202	8	choice	choice	NOUN
ajlm-939	202	9	comes	come	VERB
ajlm-939	202	10	with	with	ADP
ajlm-939	202	11	consequences	consequence	NOUN
ajlm-939	202	12	.	.	PUNCT
ajlm-939	203	1	stat	stat	PROPN
ajlm-939	203	2	med	med	PROPN
ajlm-939	203	3	.	.	PUNCT
ajlm-939	204	1	2016;35(30):5730–5735	2016;35(30):5730–5735	X
ajlm-939	204	2	.	.	PUNCT
ajlm-939	205	1	https://doi.org/10.1002/sim.7059	https://doi.org/10.1002/sim.7059	PROPN
ajlm-939	205	2	robbins	robbins	PROPN
ajlm-939	205	3	ha	ha	PROPN
ajlm-939	205	4	,	,	PUNCT
ajlm-939	205	5	pfeiffer	pfeiffer	PROPN
ajlm-939	205	6	rm	rm	PROPN
ajlm-939	205	7	,	,	PUNCT
ajlm-939	205	8	shiels	shiels	PROPN
ajlm-939	205	9	ms	ms	PROPN
ajlm-939	205	10	,	,	PUNCT
ajlm-939	205	11	li	li	PROPN
ajlm-939	205	12	j	j	PROPN
ajlm-939	205	13	,	,	PUNCT
ajlm-939	205	14	hall	hall	PROPN
ajlm-939	205	15	hi	hi	PROPN
ajlm-939	205	16	,	,	PUNCT
ajlm-939	205	17	engels	engels	PROPN
ajlm-939	205	18	ea	ea	PROPN
ajlm-939	205	19	.	.	PUNCT
ajlm-939	206	1	excess	excess	ADJ
ajlm-939	206	2	cancers	cancer	NOUN
ajlm-939	206	3	among	among	ADP
ajlm-939	206	4	hiv	hiv	PROPN
ajlm-939	206	5	-	-	PUNCT
ajlm-939	206	6	infected	infect	VERB
ajlm-939	206	7	people	people	NOUN
ajlm-939	206	8	in	in	ADP
ajlm-939	206	9	the	the	DET
ajlm-939	206	10	united	united	PROPN
ajlm-939	206	11	states	states	PROPN
ajlm-939	206	12	.	.	PUNCT
ajlm-939	207	1	j	j	PROPN
ajlm-939	207	2	natl	natl	PROPN
ajlm-939	207	3	cancer	cancer	PROPN
ajlm-939	207	4	inst	inst	PROPN
ajlm-939	207	5	.	.	PUNCT
ajlm-939	207	6	2015;107(4	2015;107(4	NUM
ajlm-939	207	7	)	)	PUNCT
ajlm-939	207	8	,	,	PUNCT
ajlm-939	207	9	article	article	NOUN
ajlm-939	207	10	#	#	SYM
ajlm-939	207	11	dju503	dju503	PROPN
ajlm-939	207	12	.	.	PUNCT
ajlm-939	208	1	https://doi.org/10.1093/jnci/dju503	https://doi.org/10.1093/jnci/dju503	PROPN
ajlm-939	208	2	dryden	dryden	PROPN
ajlm-939	208	3	-	-	PUNCT
ajlm-939	208	4	peterson	peterson	PROPN
ajlm-939	208	5	s	s	PROPN
ajlm-939	208	6	,	,	PUNCT
ajlm-939	208	7	medhin	medhin	ADJ
ajlm-939	208	8	h	h	NOUN
ajlm-939	208	9	,	,	PUNCT
ajlm-939	208	10	kebabonye	kebabonye	PROPN
ajlm-939	208	11	-	-	PUNCT
ajlm-939	208	12	pusoentsi	pusoentsi	PROPN
ajlm-939	208	13	m	m	PROPN
ajlm-939	208	14	,	,	PUNCT
ajlm-939	208	15	et	et	PROPN
ajlm-939	208	16	al	al	PROPN
ajlm-939	208	17	.	.	PUNCT
ajlm-939	209	1	cancer	cancer	NOUN
ajlm-939	209	2	incidence	incidence	NOUN
ajlm-939	209	3	following	follow	VERB
ajlm-939	209	4	expansion	expansion	NOUN
ajlm-939	209	5	of	of	ADP
ajlm-939	209	6	hiv	hiv	PROPN
ajlm-939	209	7	treatment	treatment	NOUN
ajlm-939	209	8	in	in	ADP
ajlm-939	209	9	botswana	botswana	PROPN
ajlm-939	209	10	.	.	PUNCT
ajlm-939	210	1	plos	plos	PROPN
ajlm-939	210	2	one	one	NUM
ajlm-939	210	3	.	.	PUNCT
ajlm-939	211	1	2015;10(8):e0135602	2015;10(8):e0135602	NUM
ajlm-939	211	2	.	.	PUNCT
ajlm-939	212	1	https://doi.org/10.1371/journal.pone.0135602	https://doi.org/10.1371/journal.pone.0135602	VERB
ajlm-939	212	2	mehta	mehta	PROPN
ajlm-939	212	3	s	s	PROPN
ajlm-939	212	4	,	,	PUNCT
ajlm-939	212	5	garg	garg	NOUN
ajlm-939	212	6	a	a	PRON
ajlm-939	212	7	,	,	PUNCT
ajlm-939	212	8	gupta	gupta	PROPN
ajlm-939	212	9	lk	lk	PROPN
ajlm-939	212	10	,	,	PUNCT
ajlm-939	212	11	et	et	PROPN
ajlm-939	212	12	al	al	PROPN
ajlm-939	212	13	.	.	PUNCT
ajlm-939	213	1	kaposi	kaposi	PROPN
ajlm-939	213	2	’s	’s	PART
ajlm-939	213	3	sarcoma	sarcoma	NOUN
ajlm-939	213	4	as	as	ADP
ajlm-939	213	5	a	a	DET
ajlm-939	213	6	presenting	present	VERB
ajlm-939	213	7	manifestation	manifestation	NOUN
ajlm-939	213	8	of	of	ADP
ajlm-939	213	9	hiv	hiv	PROPN
ajlm-939	213	10	.	.	PUNCT
ajlm-939	214	1	indian	indian	PROPN
ajlm-939	214	2	j	j	PROPN
ajlm-939	214	3	sex	sex	PROPN
ajlm-939	214	4	transm	transm	PROPN
ajlm-939	214	5	dis	dis	PROPN
ajlm-939	214	6	.	.	PUNCT
ajlm-939	215	1	2011;32(2):108	2011;32(2):108	PROPN
ajlm-939	215	2	.	.	PUNCT
ajlm-939	216	1	https://doi.org/10.4103/0253-7184.85415	https://doi.org/10.4103/0253-7184.85415	PROPN
ajlm-939	216	2	ahmed	ahme	VERB
ajlm-939	216	3	a	a	PRON
ajlm-939	216	4	,	,	PUNCT
ajlm-939	216	5	muktar	muktar	PROPN
ajlm-939	216	6	hm	hm	PROPN
ajlm-939	216	7	,	,	PUNCT
ajlm-939	216	8	bugaje	bugaje	PROPN
ajlm-939	216	9	ma	ma	PROPN
ajlm-939	216	10	.	.	PROPN
ajlm-939	216	11	epidemiological	epidemiological	ADJ
ajlm-939	216	12	and	and	CCONJ
ajlm-939	216	13	clinical	clinical	ADJ
ajlm-939	216	14	features	feature	NOUN
ajlm-939	216	15	of	of	ADP
ajlm-939	216	16	aids	aids	PROPN
ajlm-939	216	17	-	-	PUNCT
ajlm-939	216	18	associated	associate	VERB
ajlm-939	216	19	kaposi	kaposi	PROPN
ajlm-939	216	20	’s	’s	PART
ajlm-939	216	21	sarcoma	sarcoma	NOUN
ajlm-939	216	22	in	in	ADP
ajlm-939	216	23	northern	northern	PROPN
ajlm-939	216	24	nigeria	nigeria	PROPN
ajlm-939	216	25	.	.	PUNCT
ajlm-939	217	1	archiv	archiv	PROPN
ajlm-939	217	2	int	int	PROPN
ajlm-939	217	3	surg	surg	PROPN
ajlm-939	217	4	.	.	PUNCT
ajlm-939	218	1	2013;3(1):29	2013;3(1):29	NUM
ajlm-939	218	2	.	.	X
ajlm-939	219	1	https://doi.org/10.4103/2278-9596.117132	https://doi.org/10.4103/2278-9596.117132	PROPN
ajlm-939	219	2	chalya	chalya	PROPN
ajlm-939	219	3	pl	pl	PROPN
ajlm-939	219	4	,	,	PUNCT
ajlm-939	219	5	mbunda	mbunda	NOUN
ajlm-939	219	6	f	f	X
ajlm-939	219	7	,	,	PUNCT
ajlm-939	219	8	rambau	rambau	VERB
ajlm-939	219	9	pf	pf	PROPN
ajlm-939	219	10	,	,	PUNCT
ajlm-939	219	11	et	et	PROPN
ajlm-939	219	12	al	al	PROPN
ajlm-939	219	13	.	.	PUNCT
ajlm-939	220	1	kaposi	kaposi	PROPN
ajlm-939	220	2	’s	’s	PART
ajlm-939	220	3	sarcoma	sarcoma	NOUN
ajlm-939	220	4	:	:	PUNCT
ajlm-939	220	5	a	a	DET
ajlm-939	220	6	10	10	NUM
ajlm-939	220	7	-	-	PUNCT
ajlm-939	220	8	year	year	NOUN
ajlm-939	220	9	experience	experience	NOUN
ajlm-939	220	10	with	with	ADP
ajlm-939	220	11	248	248	NUM
ajlm-939	220	12	patients	patient	NOUN
ajlm-939	220	13	at	at	ADP
ajlm-939	220	14	a	a	DET
ajlm-939	220	15	single	single	ADJ
ajlm-939	220	16	tertiary	tertiary	ADJ
ajlm-939	220	17	care	care	NOUN
ajlm-939	220	18	hospital	hospital	NOUN
ajlm-939	220	19	in	in	ADP
ajlm-939	220	20	tanzania	tanzania	PROPN
ajlm-939	220	21	.	.	PUNCT
ajlm-939	221	1	bmc	bmc	ADJ
ajlm-939	221	2	res	re	NOUN
ajlm-939	221	3	notes	note	NOUN
ajlm-939	221	4	.	.	PUNCT
ajlm-939	222	1	2015;8(1):440	2015;8(1):440	X
ajlm-939	222	2	.	.	PUNCT
ajlm-939	223	1	https://doi.org/10.1186/s13104-015-1348-9	https://doi.org/10.1186/s13104-015-1348-9	PROPN
ajlm-939	223	2	biryahwaho	biryahwaho	PROPN
ajlm-939	223	3	b	b	X
ajlm-939	223	4	,	,	PUNCT
ajlm-939	223	5	dollard	dollard	PROPN
ajlm-939	223	6	sc	sc	PROPN
ajlm-939	223	7	,	,	PUNCT
ajlm-939	223	8	pfeiffer	pfeiffer	PROPN
ajlm-939	223	9	rm	rm	PROPN
ajlm-939	223	10	,	,	PUNCT
ajlm-939	223	11	et	et	PROPN
ajlm-939	223	12	al	al	PROPN
ajlm-939	223	13	.	.	PROPN
ajlm-939	223	14	sex	sex	NOUN
ajlm-939	223	15	and	and	CCONJ
ajlm-939	223	16	geographic	geographic	ADJ
ajlm-939	223	17	patterns	pattern	NOUN
ajlm-939	223	18	of	of	ADP
ajlm-939	223	19	human	human	ADJ
ajlm-939	223	20	herpesvirus	herpesvirus	NOUN
ajlm-939	223	21	8	8	NUM
ajlm-939	223	22	infection	infection	NOUN
ajlm-939	223	23	in	in	ADP
ajlm-939	223	24	a	a	DET
ajlm-939	223	25	nationally	nationally	ADV
ajlm-939	223	26	representative	representative	ADJ
ajlm-939	223	27	population	population	NOUN
ajlm-939	223	28	-	-	PUNCT
ajlm-939	223	29	based	base	VERB
ajlm-939	223	30	sample	sample	NOUN
ajlm-939	223	31	in	in	ADP
ajlm-939	223	32	uganda	uganda	PROPN
ajlm-939	223	33	.	.	PUNCT
ajlm-939	224	1	j	j	PROPN
ajlm-939	224	2	infect	infect	VERB
ajlm-939	224	3	dis	dis	PROPN
ajlm-939	224	4	.	.	PUNCT
ajlm-939	225	1	2010;202(9):1347–1353	2010;202(9):1347–1353	NUM
ajlm-939	225	2	.	.	X
ajlm-939	225	3	https://doi.org/10.1086/656525	https://doi.org/10.1086/656525	PROPN
ajlm-939	225	4	ngalamika	ngalamika	PROPN
ajlm-939	225	5	o	o	PROPN
ajlm-939	225	6	,	,	PUNCT
ajlm-939	225	7	minhas	minhas	PROPN
ajlm-939	225	8	v	v	NOUN
ajlm-939	225	9	,	,	PUNCT
ajlm-939	225	10	wood	wood	PROPN
ajlm-939	225	11	c.	c.	PROPN
ajlm-939	225	12	kaposi	kaposi	PROPN
ajlm-939	225	13	’s	’s	PART
ajlm-939	225	14	sarcoma	sarcoma	NOUN
ajlm-939	225	15	at	at	ADP
ajlm-939	225	16	the	the	DET
ajlm-939	225	17	university	university	NOUN
ajlm-939	225	18	teaching	teaching	NOUN
ajlm-939	225	19	hospital	hospital	NOUN
ajlm-939	225	20	,	,	PUNCT
ajlm-939	225	21	lusaka	lusaka	PROPN
ajlm-939	225	22	,	,	PUNCT
ajlm-939	225	23	zambia	zambia	PROPN
ajlm-939	225	24	in	in	ADP
ajlm-939	225	25	the	the	DET
ajlm-939	225	26	antiretroviral	antiretroviral	ADJ
ajlm-939	225	27	therapy	therapy	NOUN
ajlm-939	225	28	era	era	NOUN
ajlm-939	225	29	.	.	PUNCT
ajlm-939	226	1	int	int	NOUN
ajlm-939	226	2	j	j	PROPN
ajlm-939	226	3	cancer	cancer	NOUN
ajlm-939	226	4	.	.	PUNCT
ajlm-939	227	1	2015;136(5):1241	2015;136(5):1241	NUM
ajlm-939	227	2	.	.	PUNCT
ajlm-939	228	1	https://doi.org/10.1002/ijc.29184	https://doi.org/10.1002/ijc.29184	VERB
ajlm-939	228	2	tukei	tukei	VERB
ajlm-939	228	3	vj	vj	INTJ
ajlm-939	228	4	,	,	PUNCT
ajlm-939	228	5	kekitiinwa	kekitiinwa	PROPN
ajlm-939	228	6	a	a	PRON
ajlm-939	228	7	,	,	PUNCT
ajlm-939	228	8	beasley	beasley	PROPN
ajlm-939	228	9	rp	rp	PROPN
ajlm-939	228	10	.	.	PUNCT
ajlm-939	229	1	prevalence	prevalence	NOUN
ajlm-939	229	2	and	and	CCONJ
ajlm-939	229	3	outcome	outcome	NOUN
ajlm-939	229	4	of	of	ADP
ajlm-939	229	5	hiv	hiv	PROPN
ajlm-939	229	6	-	-	PUNCT
ajlm-939	229	7	associated	associate	VERB
ajlm-939	229	8	malignancies	malignancy	NOUN
ajlm-939	229	9	among	among	ADP
ajlm-939	229	10	children	child	NOUN
ajlm-939	229	11	.	.	PUNCT
ajlm-939	230	1	aids	aids	PROPN
ajlm-939	230	2	.	.	PUNCT
ajlm-939	231	1	2011;25(14):1789–1793	2011;25(14):1789–1793	NUM
ajlm-939	231	2	.	.	PUNCT
ajlm-939	231	3	https://doi.org/10.1097/qad.0b013e3283498115	https://doi.org/10.1097/qad.0b013e3283498115	PROPN
ajlm-939	231	4	begré	begré	PROPN
ajlm-939	231	5	l	l	PROPN
ajlm-939	231	6	,	,	PUNCT
ajlm-939	231	7	rohner	rohner	NOUN
ajlm-939	231	8	e	e	NOUN
ajlm-939	231	9	,	,	PUNCT
ajlm-939	231	10	mbulaiteye	mbulaiteye	NOUN
ajlm-939	231	11	sm	sm	PROPN
ajlm-939	231	12	,	,	PUNCT
ajlm-939	231	13	egger	egger	NOUN
ajlm-939	231	14	m	m	PROPN
ajlm-939	231	15	,	,	PUNCT
ajlm-939	231	16	bohlius	bohlius	PROPN
ajlm-939	231	17	j.	j.	PROPN
ajlm-939	231	18	is	be	AUX
ajlm-939	231	19	human	human	ADJ
ajlm-939	231	20	herpesvirus	herpesvirus	NOUN
ajlm-939	231	21	8	8	NUM
ajlm-939	231	22	infection	infection	NOUN
ajlm-939	231	23	more	more	ADV
ajlm-939	231	24	common	common	ADJ
ajlm-939	231	25	in	in	ADP
ajlm-939	231	26	men	man	NOUN
ajlm-939	231	27	than	than	ADP
ajlm-939	231	28	in	in	ADP
ajlm-939	231	29	women	woman	NOUN
ajlm-939	231	30	?	?	PUNCT
ajlm-939	232	1	systematic	systematic	ADJ
ajlm-939	232	2	review	review	NOUN
ajlm-939	232	3	and	and	CCONJ
ajlm-939	232	4	meta	meta	ADJ
ajlm-939	232	5	-	-	PUNCT
ajlm-939	232	6	analysis	analysis	NOUN
ajlm-939	232	7	.	.	PUNCT
ajlm-939	233	1	int	int	NOUN
ajlm-939	233	2	j	j	PROPN
ajlm-939	233	3	cancer	cancer	NOUN
ajlm-939	233	4	.	.	PUNCT
ajlm-939	234	1	2016;139(4):776–783	2016;139(4):776–783	X
ajlm-939	234	2	.	.	PUNCT
ajlm-939	235	1	https://doi.org/10.1002/ijc.30129	https://doi.org/10.1002/ijc.30129	PROPN
ajlm-939	235	2	national	national	PROPN
ajlm-939	235	3	cancer	cancer	PROPN
ajlm-939	235	4	control	control	PROPN
ajlm-939	235	5	strategy	strategy	NOUN
ajlm-939	235	6	.	.	PUNCT
ajlm-939	236	1	ministry	ministry	PROPN
ajlm-939	236	2	of	of	ADP
ajlm-939	236	3	health	health	PROPN
ajlm-939	236	4	,	,	PUNCT
ajlm-939	236	5	kenya	kenya	PROPN
ajlm-939	236	6	.	.	PUNCT
ajlm-939	237	1	strategy	strategy	NOUN
ajlm-939	237	2	2017	2017	NUM
ajlm-939	237	3	–	–	PUNCT
ajlm-939	237	4	2022	2022	NUM
ajlm-939	237	5	nairobi	nairobi	PROPN
ajlm-939	237	6	.	.	PUNCT
ajlm-939	237	7	2017	2017	NUM
ajlm-939	237	8	.	.	PUNCT
ajlm-939	238	1	achenbach	achenbach	PROPN
ajlm-939	238	2	cj	cj	PROPN
ajlm-939	238	3	,	,	PUNCT
ajlm-939	238	4	harrington	harrington	PROPN
ajlm-939	238	5	rd	rd	PROPN
ajlm-939	238	6	,	,	PUNCT
ajlm-939	238	7	dhanireddy	dhanireddy	PROPN
ajlm-939	238	8	s	s	PROPN
ajlm-939	238	9	,	,	PUNCT
ajlm-939	238	10	crane	crane	NOUN
ajlm-939	238	11	hm	hm	NOUN
ajlm-939	238	12	,	,	PUNCT
ajlm-939	238	13	casper	casper	PROPN
ajlm-939	238	14	c	c	PROPN
ajlm-939	238	15	,	,	PUNCT
ajlm-939	238	16	kitahata	kitahata	NOUN
ajlm-939	238	17	mm	mm	PROPN
ajlm-939	238	18	.	.	PUNCT
ajlm-939	239	1	paradoxical	paradoxical	ADJ
ajlm-939	239	2	immune	immune	ADJ
ajlm-939	239	3	reconstitution	reconstitution	NOUN
ajlm-939	239	4	inflammatory	inflammatory	ADJ
ajlm-939	239	5	syndrome	syndrome	NOUN
ajlm-939	239	6	in	in	ADP
ajlm-939	239	7	hiv	hiv	PROPN
ajlm-939	239	8	-	-	PUNCT
ajlm-939	239	9	infected	infect	VERB
ajlm-939	239	10	patients	patient	NOUN
ajlm-939	239	11	treated	treat	VERB
ajlm-939	239	12	with	with	ADP
ajlm-939	239	13	combination	combination	NOUN
ajlm-939	239	14	antiretroviral	antiretroviral	ADJ
ajlm-939	239	15	therapy	therapy	NOUN
ajlm-939	239	16	after	after	ADP
ajlm-939	239	17	aids	aids	NOUN
ajlm-939	239	18	-	-	PUNCT
ajlm-939	239	19	defining	define	VERB
ajlm-939	239	20	opportunistic	opportunistic	ADJ
ajlm-939	239	21	infection	infection	NOUN
ajlm-939	239	22	.	.	PUNCT
ajlm-939	240	1	clin	clin	PROPN
ajlm-939	240	2	infect	infect	PROPN
ajlm-939	240	3	dis	dis	PROPN
ajlm-939	240	4	.	.	PUNCT
ajlm-939	241	1	2011;54(3):424–433	2011;54(3):424–433	X
ajlm-939	241	2	.	.	PUNCT
ajlm-939	242	1	https://doi.org/10.1093/cid/cir802	https://doi.org/10.1093/cid/cir802	PROPN
ajlm-939	242	2	letang	letang	PROPN
ajlm-939	242	3	e	e	PROPN
ajlm-939	242	4	,	,	PUNCT
ajlm-939	242	5	lewis	lewis	PROPN
ajlm-939	242	6	jj	jj	PROPN
ajlm-939	242	7	,	,	PUNCT
ajlm-939	242	8	bower	bower	PROPN
ajlm-939	242	9	m	m	PROPN
ajlm-939	242	10	,	,	PUNCT
ajlm-939	242	11	et	et	PROPN
ajlm-939	242	12	al	al	PROPN
ajlm-939	242	13	.	.	PROPN
ajlm-939	242	14	immune	immune	ADJ
ajlm-939	242	15	reconstitution	reconstitution	NOUN
ajlm-939	242	16	inflammatory	inflammatory	ADJ
ajlm-939	242	17	syndrome	syndrome	NOUN
ajlm-939	242	18	associated	associate	VERB
ajlm-939	242	19	with	with	ADP
ajlm-939	242	20	kaposi	kaposi	PROPN
ajlm-939	242	21	sarcoma	sarcoma	PROPN
ajlm-939	242	22	:	:	PUNCT
ajlm-939	242	23	higher	high	ADJ
ajlm-939	242	24	incidence	incidence	NOUN
ajlm-939	242	25	and	and	CCONJ
ajlm-939	242	26	mortality	mortality	NOUN
ajlm-939	242	27	in	in	ADP
ajlm-939	242	28	africa	africa	PROPN
ajlm-939	242	29	than	than	ADP
ajlm-939	242	30	in	in	ADP
ajlm-939	242	31	the	the	DET
ajlm-939	242	32	uk	uk	PROPN
ajlm-939	242	33	.	.	PROPN
ajlm-939	242	34	aids	aids	PROPN
ajlm-939	242	35	.	.	PUNCT
ajlm-939	243	1	2013;27(10):1603–1613	2013;27(10):1603–1613	NUM
ajlm-939	243	2	.	.	PUNCT
ajlm-939	243	3	https://doi.org/10.1097/qad.0b013e328360a5a1	https://doi.org/10.1097/qad.0b013e328360a5a1	PROPN
ajlm-939	243	4	kowalkowski	kowalkowski	PROPN
ajlm-939	243	5	ma	ma	PROPN
ajlm-939	243	6	,	,	PUNCT
ajlm-939	243	7	kramer	kramer	PROPN
ajlm-939	243	8	jr	jr	PROPN
ajlm-939	243	9	,	,	PUNCT
ajlm-939	243	10	richardson	richardson	PROPN
ajlm-939	243	11	pr	pr	PROPN
ajlm-939	243	12	,	,	PUNCT
ajlm-939	243	13	suteria	suteria	PROPN
ajlm-939	243	14	i	i	PROPN
ajlm-939	243	15	,	,	PUNCT
ajlm-939	243	16	chiao	chiao	PROPN
ajlm-939	243	17	ey	ey	PROPN
ajlm-939	243	18	.	.	PROPN
ajlm-939	243	19	use	use	NOUN
ajlm-939	243	20	of	of	ADP
ajlm-939	243	21	boosted	boost	VERB
ajlm-939	243	22	protease	protease	NOUN
ajlm-939	243	23	inhibitors	inhibitor	NOUN
ajlm-939	243	24	reduces	reduce	VERB
ajlm-939	243	25	kaposi	kaposi	PROPN
ajlm-939	243	26	sarcoma	sarcoma	NOUN
ajlm-939	243	27	incidence	incidence	NOUN
ajlm-939	243	28	among	among	ADP
ajlm-939	243	29	male	male	ADJ
ajlm-939	243	30	veterans	veteran	NOUN
ajlm-939	243	31	with	with	ADP
ajlm-939	243	32	hiv	hiv	PROPN
ajlm-939	243	33	infection	infection	NOUN
ajlm-939	243	34	.	.	PUNCT
ajlm-939	244	1	clin	clin	PROPN
ajlm-939	244	2	infect	infect	PROPN
ajlm-939	244	3	dis	dis	PROPN
ajlm-939	244	4	.	.	PUNCT
ajlm-939	245	1	2015;60(9):1405–1414	2015;60(9):1405–1414	NUM
ajlm-939	245	2	.	.	PUNCT
ajlm-939	246	1	https://doi.org/10.1093/cid/civ012	https://doi.org/10.1093/cid/civ012	PROPN
ajlm-939	246	2	borok	borok	VERB
ajlm-939	246	3	m	m	PROPN
ajlm-939	246	4	,	,	PUNCT
ajlm-939	246	5	fiorillo	fiorillo	VERB
ajlm-939	246	6	s	s	PROPN
ajlm-939	246	7	,	,	PUNCT
ajlm-939	246	8	gudza	gudza	PROPN
ajlm-939	246	9	i	i	PROPN
ajlm-939	246	10	,	,	PUNCT
ajlm-939	246	11	et	et	PROPN
ajlm-939	246	12	al	al	PROPN
ajlm-939	246	13	.	.	PUNCT
ajlm-939	246	14	evaluation	evaluation	NOUN
ajlm-939	246	15	of	of	ADP
ajlm-939	246	16	plasma	plasma	NOUN
ajlm-939	246	17	human	human	ADJ
ajlm-939	246	18	herpesvirus	herpesvirus	NOUN
ajlm-939	246	19	8	8	NUM
ajlm-939	246	20	dna	dna	NOUN
ajlm-939	246	21	as	as	ADP
ajlm-939	246	22	a	a	DET
ajlm-939	246	23	marker	marker	NOUN
ajlm-939	246	24	of	of	ADP
ajlm-939	246	25	clinical	clinical	ADJ
ajlm-939	246	26	outcomes	outcome	NOUN
ajlm-939	246	27	during	during	ADP
ajlm-939	246	28	antiretroviral	antiretroviral	ADJ
ajlm-939	246	29	therapy	therapy	NOUN
ajlm-939	246	30	for	for	ADP
ajlm-939	246	31	aids	aids	PROPN
ajlm-939	246	32	-	-	PUNCT
ajlm-939	246	33	related	relate	VERB
ajlm-939	246	34	kaposi	kaposi	PROPN
ajlm-939	246	35	sarcoma	sarcoma	NOUN
ajlm-939	246	36	in	in	ADP
ajlm-939	246	37	zimbabwe	zimbabwe	PROPN
ajlm-939	246	38	.	.	PUNCT
ajlm-939	247	1	clin	clin	PROPN
ajlm-939	247	2	infect	infect	PROPN
ajlm-939	247	3	dis	dis	PROPN
ajlm-939	247	4	.	.	PUNCT
ajlm-939	248	1	2010;51(3):342–349	2010;51(3):342–349	X
ajlm-939	248	2	.	.	PUNCT
ajlm-939	249	1	https://doi.org/10.1086/654800	https://doi.org/10.1086/654800	PROPN
ajlm-939	249	2	mosam	mosam	NOUN
ajlm-939	249	3	a	a	PRON
ajlm-939	249	4	,	,	PUNCT
ajlm-939	249	5	shaik	shaik	PROPN
ajlm-939	249	6	f	f	PROPN
ajlm-939	249	7	,	,	PUNCT
ajlm-939	249	8	uldrick	uldrick	PROPN
ajlm-939	249	9	ts	ts	PROPN
ajlm-939	249	10	,	,	PUNCT
ajlm-939	249	11	et	et	PROPN
ajlm-939	249	12	al	al	PROPN
ajlm-939	249	13	.	.	PUNCT
ajlm-939	250	1	a	a	DET
ajlm-939	250	2	randomized	randomized	ADJ
ajlm-939	250	3	controlled	control	VERB
ajlm-939	250	4	trial	trial	NOUN
ajlm-939	250	5	of	of	ADP
ajlm-939	250	6	highly	highly	ADV
ajlm-939	250	7	active	active	ADJ
ajlm-939	250	8	antiretroviral	antiretroviral	ADJ
ajlm-939	250	9	therapy	therapy	NOUN
ajlm-939	250	10	ver	ver	PROPN
ajlm-939	250	11	-	-	PUNCT
ajlm-939	250	12	sus	sus	PROPN
ajlm-939	250	13	highly	highly	ADV
ajlm-939	250	14	active	active	ADJ
ajlm-939	250	15	antiretroviral	antiretroviral	ADJ
ajlm-939	250	16	therapy	therapy	NOUN
ajlm-939	250	17	and	and	CCONJ
ajlm-939	250	18	chemotherapy	chemotherapy	NOUN
ajlm-939	250	19	in	in	ADP
ajlm-939	250	20	therapy	therapy	NOUN
ajlm-939	250	21	-	-	PUNCT
ajlm-939	250	22	naive	naive	ADJ
ajlm-939	250	23	patients	patient	NOUN
ajlm-939	250	24	with	with	ADP
ajlm-939	250	25	hiv	hiv	PROPN
ajlm-939	250	26	-	-	PUNCT
ajlm-939	250	27	associated	associate	VERB
ajlm-939	250	28	kaposi	kaposi	PROPN
ajlm-939	250	29	sarcoma	sarcoma	NOUN
ajlm-939	250	30	in	in	ADP
ajlm-939	250	31	south	south	PROPN
ajlm-939	250	32	africa	africa	PROPN
ajlm-939	250	33	.	.	PUNCT
ajlm-939	251	1	j	j	PROPN
ajlm-939	251	2	acquir	acquir	PROPN
ajlm-939	251	3	immune	immune	VERB
ajlm-939	251	4	defic	defic	ADJ
ajlm-939	251	5	syndr	syndr	NOUN
ajlm-939	251	6	.	.	PUNCT
ajlm-939	252	1	2012;60(2):150–157	2012;60(2):150–157	X
ajlm-939	252	2	.	.	PUNCT
ajlm-939	253	1	https://doi.org/10.1097/qai.0b013e318251aedd	https://doi.org/10.1097/qai.0b013e318251aedd	PROPN
ajlm-939	253	2	gbabe	gbabe	PROPN
ajlm-939	253	3	of	of	ADP
ajlm-939	253	4	,	,	PUNCT
ajlm-939	253	5	okwundu	okwundu	PROPN
ajlm-939	253	6	ci	ci	PROPN
ajlm-939	253	7	,	,	PUNCT
ajlm-939	253	8	dedicoat	dedicoat	PROPN
ajlm-939	253	9	m	m	PROPN
ajlm-939	253	10	,	,	PUNCT
ajlm-939	253	11	freeman	freeman	PROPN
ajlm-939	253	12	ee	ee	PROPN
ajlm-939	253	13	.	.	PROPN
ajlm-939	254	1	treatment	treatment	NOUN
ajlm-939	254	2	of	of	ADP
ajlm-939	254	3	severe	severe	ADJ
ajlm-939	254	4	or	or	CCONJ
ajlm-939	254	5	progressive	progressive	ADJ
ajlm-939	254	6	kaposi	kaposi	PROPN
ajlm-939	254	7	’s	’s	PART
ajlm-939	254	8	sarcoma	sarcoma	NOUN
ajlm-939	254	9	in	in	ADP
ajlm-939	254	10	hiv	hiv	PROPN
ajlm-939	254	11	-	-	PUNCT
ajlm-939	254	12	infected	infect	VERB
ajlm-939	254	13	adults	adult	NOUN
ajlm-939	254	14	.	.	PUNCT
ajlm-939	255	1	cochrane	cochrane	NOUN
ajlm-939	255	2	database	database	PROPN
ajlm-939	255	3	syst	syst	PROPN
ajlm-939	255	4	rev	rev	PROPN
ajlm-939	255	5	.	.	PUNCT
ajlm-939	256	1	2014;(9);cd003256	2014;(9);cd003256	NUM
ajlm-939	256	2	.	.	PUNCT
ajlm-939	257	1	https://doi.org/10.1002/14651858.cd003256.pub2	https://doi.org/10.1002/14651858.cd003256.pub2	PROPN
ajlm-939	257	2	krown	krown	PROPN
ajlm-939	257	3	se	se	PROPN
ajlm-939	257	4	,	,	PUNCT
ajlm-939	257	5	roy	roy	PROPN
ajlm-939	257	6	d	d	PROPN
ajlm-939	257	7	,	,	PUNCT
ajlm-939	257	8	lee	lee	PROPN
ajlm-939	257	9	jy	jy	PROPN
ajlm-939	257	10	,	,	PUNCT
ajlm-939	257	11	et	et	PROPN
ajlm-939	257	12	al	al	PROPN
ajlm-939	257	13	.	.	PROPN
ajlm-939	257	14	rapamycin	rapamycin	PROPN
ajlm-939	257	15	with	with	ADP
ajlm-939	257	16	antiretroviral	antiretroviral	ADJ
ajlm-939	257	17	therapy	therapy	NOUN
ajlm-939	257	18	in	in	ADP
ajlm-939	257	19	aids	aids	PROPN
ajlm-939	257	20	-	-	PUNCT
ajlm-939	257	21	associated	associate	VERB
ajlm-939	257	22	kaposi	kaposi	PROPN
ajlm-939	257	23	sarcoma	sarcoma	PROPN
ajlm-939	257	24	:	:	PUNCT
ajlm-939	257	25	an	an	DET
ajlm-939	257	26	aids	aids	PROPN
ajlm-939	257	27	malignancy	malignancy	NOUN
ajlm-939	257	28	consortium	consortium	NOUN
ajlm-939	257	29	study	study	NOUN
ajlm-939	257	30	.	.	PUNCT
ajlm-939	258	1	j	j	PROPN
ajlm-939	258	2	acquir	acquir	PROPN
ajlm-939	258	3	immune	immune	VERB
ajlm-939	258	4	defic	defic	ADJ
ajlm-939	258	5	syndr	syndr	NOUN
ajlm-939	258	6	.	.	PUNCT
ajlm-939	259	1	2012;59(5):447	2012;59(5):447	NUM
ajlm-939	259	2	.	.	PUNCT
ajlm-939	260	1	https://doi.org/10.1097/qai.0b013e31823e7884	https://doi.org/10.1097/qai.0b013e31823e7884	PROPN
ajlm-939	260	2	krell	krell	PROPN
ajlm-939	260	3	j	j	PROPN
ajlm-939	260	4	,	,	PUNCT
ajlm-939	260	5	stebbing	stebbe	VERB
ajlm-939	260	6	j.	j.	PROPN
ajlm-939	260	7	broader	broad	ADJ
ajlm-939	260	8	implications	implication	NOUN
ajlm-939	260	9	of	of	ADP
ajlm-939	260	10	a	a	DET
ajlm-939	260	11	stage	stage	NOUN
ajlm-939	260	12	-	-	PUNCT
ajlm-939	260	13	guided	guide	VERB
ajlm-939	260	14	stratified	stratified	ADJ
ajlm-939	260	15	therapeutic	therapeutic	ADJ
ajlm-939	260	16	approach	approach	NOUN
ajlm-939	260	17	for	for	ADP
ajlm-939	260	18	aids	aid	NOUN
ajlm-939	260	19	-	-	PUNCT
ajlm-939	260	20	related	relate	VERB
ajlm-939	260	21	kaposi	kaposi	PROPN
ajlm-939	260	22	’s	’s	PART
ajlm-939	260	23	sarcoma	sarcoma	NOUN
ajlm-939	260	24	.	.	PUNCT
ajlm-939	261	1	j	j	PROPN
ajlm-939	261	2	clin	clin	PROPN
ajlm-939	261	3	oncol	oncol	PROPN
ajlm-939	261	4	.	.	PUNCT
ajlm-939	262	1	2014;32(5):373	2014;32(5):373	NOUN
ajlm-939	262	2	.	.	PUNCT
ajlm-939	263	1	https://doi.org/10.1200/jco.2013.53.7126	https://doi.org/10.1200/jco.2013.53.7126	NOUN
ajlm-939	263	2	chinula	chinula	PROPN
ajlm-939	263	3	l	l	PROPN
ajlm-939	263	4	,	,	PUNCT
ajlm-939	263	5	moses	moses	PROPN
ajlm-939	263	6	a	a	PRON
ajlm-939	263	7	,	,	PUNCT
ajlm-939	263	8	gopal	gopal	PROPN
ajlm-939	263	9	s.	s.	PROPN
ajlm-939	263	10	hiv	hiv	PROPN
ajlm-939	263	11	-	-	PUNCT
ajlm-939	263	12	associated	associate	VERB
ajlm-939	263	13	malignancies	malignancy	NOUN
ajlm-939	263	14	in	in	ADP
ajlm-939	263	15	sub	sub	ADJ
ajlm-939	263	16	-	-	ADJ
ajlm-939	263	17	saharan	saharan	ADJ
ajlm-939	263	18	africa	africa	PROPN
ajlm-939	263	19	:	:	PUNCT
ajlm-939	263	20	progress	progress	NOUN
ajlm-939	263	21	,	,	PUNCT
ajlm-939	263	22	challenges	challenge	NOUN
ajlm-939	263	23	,	,	PUNCT
ajlm-939	263	24	op	op	NOUN
ajlm-939	263	25	-	-	PUNCT
ajlm-939	263	26	portunities	portunitie	NOUN
ajlm-939	263	27	.	.	PUNCT
ajlm-939	264	1	curr	curr	PROPN
ajlm-939	264	2	opin	opin	PROPN
ajlm-939	264	3	hiv	hiv	PROPN
ajlm-939	264	4	aids	aids	PROPN
ajlm-939	264	5	.	.	PUNCT
ajlm-939	265	1	2017;12(1):89	2017;12(1):89	X
ajlm-939	265	2	.	.	PUNCT
ajlm-939	265	3	https://doi.org/10.1097/coh.0000000000000329	https://doi.org/10.1097/coh.0000000000000329	PROPN
ajlm-939	265	4	vaishnani	vaishnani	PROPN
ajlm-939	265	5	jb	jb	PROPN
ajlm-939	265	6	,	,	PUNCT
ajlm-939	265	7	bosamiya	bosamiya	PROPN
ajlm-939	265	8	ss	ss	PROPN
ajlm-939	265	9	,	,	PUNCT
ajlm-939	265	10	momin	momin	NOUN
ajlm-939	265	11	am	be	AUX
ajlm-939	265	12	.	.	PUNCT
ajlm-939	266	1	kaposi	kaposi	PROPN
ajlm-939	266	2	’s	’s	PART
ajlm-939	266	3	sarcoma	sarcoma	NOUN
ajlm-939	266	4	:	:	PUNCT
ajlm-939	266	5	a	a	DET
ajlm-939	266	6	presenting	present	VERB
ajlm-939	266	7	sign	sign	NOUN
ajlm-939	266	8	of	of	ADP
ajlm-939	266	9	hiv	hiv	PROPN
ajlm-939	266	10	.	.	PUNCT
ajlm-939	267	1	indian	indian	PROPN
ajlm-939	267	2	j	j	PROPN
ajlm-939	267	3	der	der	PROPN
ajlm-939	267	4	-	-	PUNCT
ajlm-939	267	5	matol	matol	NOUN
ajlm-939	267	6	venereol	venereol	ADJ
ajlm-939	267	7	leprol	leprol	NOUN
ajlm-939	267	8	.	.	PUNCT
ajlm-939	268	1	2010;76(2):215	2010;76(2):215	X
ajlm-939	268	2	.	.	PUNCT
ajlm-939	269	1	https://doi.org/10.4103/0378-6323.60542	https://doi.org/10.4103/0378-6323.60542	PROPN
ajlm-939	270	1	fulciniti	fulciniti	NOUN
ajlm-939	270	2	f	f	PROPN
ajlm-939	270	3	,	,	PUNCT
ajlm-939	270	4	de	de	PROPN
ajlm-939	270	5	chiara	chiara	X
ajlm-939	270	6	a	a	DET
ajlm-939	270	7	,	,	PUNCT
ajlm-939	270	8	apice	apice	NOUN
ajlm-939	270	9	g	g	NOUN
ajlm-939	270	10	,	,	PUNCT
ajlm-939	270	11	et	et	PROPN
ajlm-939	270	12	al	al	PROPN
ajlm-939	270	13	.	.	PUNCT
ajlm-939	270	14	fine	fine	ADJ
ajlm-939	270	15	-	-	PUNCT
ajlm-939	270	16	needle	needle	NOUN
ajlm-939	270	17	cytology	cytology	NOUN
ajlm-939	270	18	of	of	ADP
ajlm-939	270	19	kaposi	kaposi	PROPN
ajlm-939	270	20	’s	’s	PART
ajlm-939	270	21	sarcoma	sarcoma	NOUN
ajlm-939	270	22	in	in	ADP
ajlm-939	270	23	an	an	DET
ajlm-939	270	24	intramammarylymphnode	intramammarylymphnode	NOUN
ajlm-939	270	25	:	:	PUNCT
ajlm-939	270	26	report	report	NOUN
ajlm-939	270	27	of	of	ADP
ajlm-939	270	28	one	one	NUM
ajlm-939	270	29	case	case	NOUN
ajlm-939	270	30	.	.	PUNCT
ajlm-939	271	1	diagn	diagn	ADJ
ajlm-939	271	2	cytopathol	cytopathol	NOUN
ajlm-939	271	3	.	.	PUNCT
ajlm-939	272	1	2012;40(s2):e149	2012;40(s2):e149	ADV
ajlm-939	272	2	–	–	PUNCT
ajlm-939	272	3	e152	e152	PROPN
ajlm-939	272	4	.	.	PUNCT
ajlm-939	273	1	https://doi.org/10.1002/dc.21783	https://doi.org/10.1002/dc.21783	PROPN
ajlm-939	273	2	ouyang	ouyang	PROPN
ajlm-939	273	3	x	x	PROPN
ajlm-939	273	4	,	,	PUNCT
ajlm-939	273	5	zeng	zeng	PROPN
ajlm-939	273	6	y	y	PROPN
ajlm-939	273	7	,	,	PUNCT
ajlm-939	273	8	fu	fu	PROPN
ajlm-939	273	9	b	b	PROPN
ajlm-939	273	10	,	,	PUNCT
ajlm-939	273	11	et	et	PROPN
ajlm-939	273	12	al	al	PROPN
ajlm-939	273	13	.	.	PROPN
ajlm-939	274	1	genotypic	genotypic	NOUN
ajlm-939	274	2	analysis	analysis	NOUN
ajlm-939	274	3	of	of	ADP
ajlm-939	274	4	kaposi	kaposi	PROPN
ajlm-939	274	5	’s	’s	PART
ajlm-939	274	6	sarcoma	sarcoma	NOUN
ajlm-939	274	7	-	-	PUNCT
ajlm-939	274	8	associated	associate	VERB
ajlm-939	274	9	herpesvirus	herpesvirus	NOUN
ajlm-939	274	10	from	from	ADP
ajlm-939	274	11	patients	patient	NOUN
ajlm-939	274	12	with	with	ADP
ajlm-939	274	13	kaposi	kaposi	PROPN
ajlm-939	274	14	’s	’s	PART
ajlm-939	274	15	sarcoma	sarcoma	NOUN
ajlm-939	274	16	in	in	ADP
ajlm-939	274	17	xinjiang	xinjiang	PROPN
ajlm-939	274	18	,	,	PUNCT
ajlm-939	274	19	china	china	PROPN
ajlm-939	274	20	.	.	PUNCT
ajlm-939	275	1	viruses	virus	NOUN
ajlm-939	275	2	.	.	PUNCT
ajlm-939	276	1	2014;6(12):4800–4810	2014;6(12):4800–4810	NOUN
ajlm-939	276	2	.	.	PUNCT
ajlm-939	277	1	https://doi.org/10.3390/v6124800	https://doi.org/10.3390/v6124800	PROPN
ajlm-939	278	1	van	van	PROPN
ajlm-939	278	2	bogaert	bogaert	PROPN
ajlm-939	278	3	lj	lj	PROPN
ajlm-939	278	4	.	.	PUNCT
ajlm-939	278	5	clinicopathological	clinicopathological	ADJ
ajlm-939	278	6	proficiency	proficiency	NOUN
ajlm-939	278	7	in	in	ADP
ajlm-939	278	8	the	the	DET
ajlm-939	278	9	diagnosis	diagnosis	NOUN
ajlm-939	278	10	of	of	ADP
ajlm-939	278	11	kaposi	kaposi	PROPN
ajlm-939	278	12	’s	’s	PART
ajlm-939	278	13	sarcoma	sarcoma	NOUN
ajlm-939	278	14	.	.	PUNCT
ajlm-939	279	1	isrn	isrn	PROPN
ajlm-939	279	2	aids	aids	PROPN
ajlm-939	279	3	.	.	PUNCT
ajlm-939	280	1	2012(5	2012(5	NOUN
ajlm-939	280	2	)	)	PUNCT
ajlm-939	280	3	;	;	PUNCT
ajlm-939	281	1	article	article	NOUN
ajlm-939	281	2	#	#	SYM
ajlm-939	281	3	565463	565463	NUM
ajlm-939	281	4	,	,	PUNCT
ajlm-939	281	5	7	7	NUM
ajlm-939	281	6	pages	page	NOUN
ajlm-939	281	7	doi:10.5402/2012/565463	doi:10.5402/2012/565463	PROPN